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A B S T R A C T
Defects within the DNA damage response (DDR) pathways are com-
mon in human malignancies. This is especially true in high-grade
serous ovarian cancer (HGSOC) where defects within the Homolo-
gous Recombination (HR) pathway may be present in up to 50% of
tumours. Oncolytic adenovirus is a potential novel therapy for hu-
man malignancies. These viruses infect malignant cells and multiply
selectively within them causing cell death and release of mature viri-
ons. Here, I have investigated the role of the DDR in determining
the efficacy of the E1A-CR2 deleted adenovirus type 5 (Ad5) vector,
dl922-947, in ovarian cancer.
I show that infection with dl922-947 stimulates a robust DDR within
the host cell, which the virus manipulates in order to ensure optimal
viral replication. In a panel of HGSOC cell lines, the extent of over-
replication of genomic DNA and the degree of genomic damage fol-
lowing infection with dl922-947 was shown to correlate closely with
viral efficacy. Functional HR, however, promoted viral DNA replica-
tion and augmented overall anti-cancer efficacy. Mechanistically, both
BRCA2 and RAD51 localised to viral replication centres within the
infected cell nucleus. RAD51 co-localisation was also demonstrated
in cells with defective HR and occurred independently of BRCA2.
In addition, a direct interaction was identified between RAD51 and
adenovirus E2 DNA binding protein. Using functional assays of HR
competence, I show that Ad5 infection does not alter cellular ability
to repair DNA double-strand break damage via HR. These data sug-
gest that oncolytic adenoviral therapy may be most clinically relevant
in tumours with intact HR function.
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Using a high-throughput siRNA DNA repair screen, potential novel
targets have been identified that can increase the efficacy of dl922-947
(for example: NONO) and also result in increased resistance (RPA).
These results highlight the complex interplay between adenovirus
and host cell. Further understanding of these pathways is vital to
increase efficacy, develop biomarkers and improve patient selection
into clinical trials for these therapies.
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Part I
I N T R O D U C T I O N
1
I N T R O D U C T I O N
1.1 ovarian cancer
Ovarian cancer is the most lethal gynaecological malignancy. It is
the eighth most common type of cancer and the seventh most com-
mon cause of cancer-related death in women worldwide (5th among
women in Western countries) (Jemal et al., 2011). Although patient
prognosis has improved for many solid cancers, survival for women
with ovarian cancer has changed little since the introduction of plat-
inum based chemotherapy over 30 years ago (Lowe et al., 2013; Cole-
man et al., 2011). Many women present with advanced disease with
only 27% of women with distant disease surviving 5 years post diag-
nosis (Jemal et al., 2010). There is clearly a need for new and more
effective therapies.
1.1.1 Epidemiology and genetics
The age-standardised incidence of developing ovarian cancer is ap-
proximately 9.4 per 100 000 population in developed areas and 5
per 100 000 populations elsewhere (Jemal et al., 2011; Soerjomataram
et al., 2012). In the UK, 7000 women develop ovarian cancer and
4200 die from the disease each year (Jelovac and Armstrong, 2011).
Age and genetics are the most well established risk factors for ovar-
ian cancer. It most commonly occurs in peri- or post-menopausal
women, with the median age of diagnosis being 63 years, although
some hereditary tumours are often diagnosed approximately 10 years
earlier (Boyd et al., 2000).
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The lifetime risk of developing ovarian cancer is <2% for the aver-
age woman and 4-5% among women with a single family member
with the disease (Lowe et al., 2013). Germ line genetic mutation syn-
dromes are a major cause of increased risk of epithelial ovarian cancer.
Approximately 10-12% of all ovarian cancers are familial and most of
these are linked to mutations in the breast and ovarian cancer sus-
ceptibility genes, BRCA1 or BRCA2. These genes are involved in the
repair of deoxyribonucleic acid (DNA) double strand breaks (DSB)
(Venkitaraman, 2009). The lifetime risk of developing ovarian can-
cer is 12-25% in women with a BRCA2 mutation and 35-60% among
women with BRCA1 mutations (Antoniou et al., 2003; King et al.,
2003). More recently, mutations in further genes have also been impli-
cated in increasing ovarian cancer risk including RAD51C, RAD51D
and BRCA1 Interacting Protein C-Terminal Helicase 1 (BRIP1) (Pen-
nington and Swisher, 2012). For women with germline BRCA1 or
BRCA2 mutations, prophylactic oophorectomy has been shown to be
associated with a 90% reduction in the risk of ovarian cancer (Rebbeck
et al., 2002). However a small percentage of women may develop dis-
seminated peritoneal disease (Piver et al., 1993). Other hereditary can-
cer syndromes that increase ovarian cancer risk include Lynch syn-
drome where mutations are found in DNA mismatch repair (MMR)
genes. This syndrome has been estimated to increase risk of ovar-
ian cancer by up to 20% but the risk depends on the gene involved
(Bonadona et al., 2011). These mutations are found to be present in
less than 1% of ovarian cancers and are more common in endometri-
oid and clear cell subtypes.
Although genetic factors have the most significant impact on ovar-
ian cancer risk, epidemiological studies have also shown that the risk
of developing ovarian cancer is proportional to the number of life-
time ovulations (Titus-Ernstoff et al., 2001; Jelovac and Armstrong,
2011). Factors that increase ovulations and/or oestrogen exposure,
such as nulliparity, early menarche, late menopause and the use of
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hormone replacement therapy, all increase the risk of ovarian can-
cer (Titus-Ernstoff et al., 2001; Morch et al., 2009; Salehi et al., 2008).
Conversely, factors associated with suppression of ovulations such as
increasing numbers of full term pregnancies, longer duration of lac-
tation and oral contraception use are associated with decreased risk
(Titus-Ernstoff et al., 2001; Hinkula et al., 2006). Tubal ligation and
hysterectomy have also been shown to decrease the risk (Hankinson
et al., 1993; Van Gorp et al., 2004). There are some studies that sug-
gest that chronic inflammation in the reproductive tract is involved in
ovarian cancer development (reviewed in Knutson et al. (2015)). These
studies suggest that inflammation as a result of incessant rounds of
ovulation lead to oncogenic events. This is supported by the associ-
ation of the inflammatory conditions endometriosis and polycystic
ovaries with ovarian cancer (Chittenden et al., 2009; Munksgaard and
Blaakaer, 2012).
1.1.2 Pathology and molecular characteristics of epithelial ovarian cancer
Epithelial ovarian cancer is not a single disease but is composed of a
diverse group of tumours that can be classified based on morpholog-
ical and molecular genetic features (Kurman and McConnell, 2010).
High grade serous, low grade serous, endometrioid, clear-cell and
mucinous ovarian cancers are the five most common histotypes (Fig-
ure 1.1). These different subtypes have distinct clinical characteristics
and are characterised by different molecular abnormalities. It was pre-
viously thought that these tumours arose from ovarian tissue. How-
ever, pathological and molecular studies have recently provided a dif-
ferent view of epithelial ovarian cancer and the majority of invasive
tumours are now thought to arise from non-ovarian tissues. Although
the actual contribution of the ovary to the spectrum of epithelial can-
cers is still debated, it is now apparent that the different histotypes
should be considered distinct diseases originating from different cell
1.1 ovarian cancer 31
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trials, presented in abstract form only, suggest 
improvements in progression-free survival 
when bevacizumab is given as concurrent or 
maintenance therapy. However, despite the 
presumed stability of the tumour endothe-
lium, resistance to anti-VEGF agents has 
rapidly emerged. Understanding resistance 
pathways and developing predictors of patient 
response are crucial for better exploiting  
anti-angiogenic therapies54,55.
A spontaneous antitumour immune 
response in the form of tumour-reactive 
T cells and/or antibodies has been dem-
onstrated in some patients with ovarian 
cancer56,57. The increased infiltration of 
lymphocytes in tumour islets predicts 
significantly longer survival in ovarian 
cancer58. Conversely, the detection of high 
numbers of T regulatory cells, which medi-
ate immune suppression, predicts poor 
patient survival59,60. The presence of addi-
tional immunosuppressive cell subtypes, 
such as B7-H4-expressing tumour macro-
phages61, has also been correlated with 
poor outcome.
Complex networks of inflammatory 
cytokines and chemokines62 regulate com-
munication between malignant cells and 
supporting stroma in ovarian cancer. These 
cytokines and their intracellular signal-
ling pathways can make malignant cells 
resistant to apoptosis, can facilitate the eva-
sion of tumour immunity and can promote 
angiogenesis. Tumour cells typically trigger 
inflammatory cytokine networks as a means 
of escaping immune recognition in spite of 
surrounding inflammation63,64. In experimen-
tal animal models, targeting these key inflam-
matory cytokines and chemokines has been 
shown to abrogate these processes that are key 
to the progression of ovarian cancer62,65.
The association of intratumoural T cells 
with increased survival, and T regulatory 
cells with worse survival, indicates that 
ovarian cancers could respond to immune 
therapy. Pilot studies indicate that therapies 
that capitalize on pre-existing antitumour 
immune responses can be successful in 
ovarian cancer. For example, objective 
responses and/or prolonged survival have 
been seen with immune checkpoint block-
ade using an antibody against cytotoxic 
T lymphocyte protein 4 (CTLA4)66,67, and 
Phase II studies are currently underway. 
The understanding that some conven-
tional chemotherapy drugs also have 
immunomodulatory activity offers new 
opportunities for designing combinatorial 
approaches for women with ovarian cancer 
whose tumours exhibit pre-existing anti-
tumour immunity in terms of high levels of 
intraepithelial tumour-infiltrating lympho-
cytes. In addition, trials targeting inflam-
matory cytokines68,69 are currently in early 
stages, but they can offer important biologi-
cal lessons for clinicians.
There needs to be rapid development 
of further Phase II/III studies that focus 
on agents targeting key pathways in the 
tumour microenvironment that not only 
assess their efficacy alongside established 
cytotoxic regimes, but that also aim to 
establish the optimal use of these agents for 
maintenance therapy.
Tumour adaptation and resistance
Improved understanding of clonal diversity 
in tumours prior to treatment and mecha-
nisms of tumour adaptation and the acqui-
sition of resistance following treatment 
are essential if more durable responses to 
therapy are to be achieved. Many women 
respond well to first-line treatment, but 
frequently relapse with chemotherapy-
resistant disease. Evolutionary models of 
clonal selection may explain drug resist-
ance in cancer. In acute lymphocytic leu-
kaemia and chronic myeloid leukaemia, 
point mutations that confer resistance to 
imatinib exist at low prevalence before 
treatment and can become highly enriched 
during relapse70,71. Autopsy studies on 
advanced pancreatic cancer have shown 
profound genetic heterogeneity, with 52% 
of mutations being present in subclonal 
populations72,73. Whether this paradigm 
can explain resistance in ovarian cancer, 
and in particular whether heterogeneity is 
associated with primary platinum resist-
ance, needs further investigation. With 
advances in next-generation sequencing 
we now have the tools to investigate clonal 
diversity84,85 and to start inferring the evo-
lutionary changes that may contribute to 
resistance.
Figure 2 | The origins of ovarian cancer. Ovarian cancer is a collective term for invasive cancers that 
are derived from different tissues. Most invasive mucinous ovarian cancers are metastases to the ovary, 
often from the gastrointestinal tract, including the colon, appendix or stomach. Endometrioid and 
clear cell ovarian cancers are derived from endometriosis, which in turn is associated with retrograde 
menstruation from the endometrium. High-grade serous ovarian cancers are derived from the surface 
of the ovary and/or the distal fallopian tube; the relative contribution that the two sites make to these 
tumours remains unclear. Benign and low-malignant potential (borderline) tumours are not shown. 
Such tumours are thought to be of ovarian origin, however, the originating cells are not defined and 
their derivation may be revised in the future. Histological images courtesy of R. Drapkin, Dana-Farber 
Cancer Institute, USA, and C. Crum, Brigham and Women’s Hospital, USA. 
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Figure 1.1: The origins of ovarian cancer. Ovarian cancer is not a single
disease. It consists of a diverse group of tumours with differ-
ent origins and distinct pathological and molecular features. Im-
age sh ws five sub yp s of ovarian c ncer with their likely site
of origin and lists k y molecular features. I age ad pted from
V ugh et al. (2011).
types (Vaughan et l., 2011). Key features of he m in subtyp s of
ovarian cancer are outlined below.
1.1.3 Low grade serous ovarian cancer
Low grade invasive tumours are thought to arise from the ovary al-
though their initiating cell is unknown. This subtype accounts for
around 4% of ovarian cancers. It shows a much more indolent be-
haviour compared to high grade tumours and most studies show
poor response rates to chemotherapy (Gershenson et al., 2009; Malpica
et al., 2004). In addition, low grade serous cancers are not precursor
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lesions for high grade serous cancers, as they have a distinct range of
molecular events (Bowtell, 2010). Unlike high grade serous cancers,
low grade serous ovarian cancer is generally TP53 and BRCA wild-
type and chromosomally stable (Singer et al., 2005; Gilks and Prat,
2009; Kuo et al., 2009). Mutations are often found in phosphatidyl-
inositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA),
B-Raf proto-oncogene, serine/threonine kinase (BRAF) and Kirsten
rat sarcoma viral oncogene homolog (KRAS) (Singer et al., 2003).
1.1.4 Mucinous carcinomas
Mucinous ovarian cancers account for 3-4% of ovarian cancers and are
often diagnosed at an early stage when they are confined to the ovary.
KRAS mutations are common and HER2 amplification has been re-
ported in 18-35% of cancers (Gilks, 2010; Chao et al., 2014). Most in-
vasive mucinous ovarian cancers are believed to represent metastases
to the ovary from other cancer types including gastrointestinal tu-
mours, in particular appendiceal cancers (Lee and Young, 2003; Kele-
men and Kobel, 2011). The ability to distinguish mucinous ovarian
cancers from those from the gastrointestinal tract has improved with
the development of immunohistochemistry for the cytokeratins CK7
and CK20 (Jayson et al., 2014) and therefore the incidence of true mu-
cinous ovarian cancers appears to have fallen. Studies have shown
poor response rates to chemotherapy and a poorer prognosis com-
pared to high grade serous cancers in patients with advanced stage
mucinous cancers (Pignata et al., 2008; Bamias et al., 2010).
1.1.5 Clear cell and endometrioid ovarian cancers
Clear cell and endometrioid carcinomas each account for approxi-
mately 10% of ovarian cancers. They bear frequent mutations in the
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tumour suppressor gene, AT-rich interaction domain 1A (ARID1A),
a chromatin remodelling gene, and about a third of clear cell ovar-
ian cancers also have PIK3CA mutations (Kuo et al., 2009; Wiegand
et al., 2010). Pathological and epidemiological data have associated
endometrioid and clear cell ovarian cancer with endometriosis. This
association has been strengthened by identification of high-frequency
somatic mutations in ARID1A in adjacent endometriotic and precan-
cerous lesions (Wiegand et al., 2010). Ovarian clear cell cancers have
expression phenotypes similar to renal cell cancers (Anglesio et al.,
2011) and this may impact treatment choices for this group of pa-
tients (for example the use of tyrosine kinase inhibitors frequently
used in renal cell cancers) .
1.1.6 Molecular characteristics of high grade serous ovarian cancers
Most patients with epithelial ovarian cancer have high grade serous
ovarian cancer (HGSOC), a disease that has now been shown to be
characterised by specific molecular events (Figure 1.2). By examining
focal premalignant lesions and carcinoma in situ in the fallopian tubes
of women with germ-line BRCA1/2 mutations who were undergoing
prophylactic risk-reducing surgery, the secretory cells of the distal
fallopian tubes are the likely progenitor of HGSOC (Lee et al., 2007;
Levanon et al., 2008). In addition, disseminated peritoneal cancers are
histologically similar and share molecular findings to HGSOC (Birrer,
2010).
The Cancer Genome Atlas (TGCA) project analysed mRNA expres-
sion, miRNA expression, promoter hypermethylation and DNA copy
number in 489 HGSOCs and the DNA sequences of exons from cod-
ing genes in 316 of these tumours (TGCA, 2011). This revealed that
HGSOC is characterised by TP53 mutations in almost all tumours
(96%), confirming earlier data (Ahmed et al., 2010). TP53 mutations
have been found to be present in the distal, fimbriated end of the fal-
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TCGA, Nature (2011) 474:609; Martins et al Genome Biol. (2014) 15:526; ICGC – unpublished data;  
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Figure 1.2: Molecular characteristics of HGSOC. The majority have a TP53
mutation and approximately 50% have mutations affecting the
HR pathways. Image created by Prof I. McNeish, data from
(TGCA, 2011; Etemadmoghadam et al., 2009; Patch et al., 2015)
lopian tube and these areas, known as tubal intraepithelial carcinoma
(TIC), are the probable precursors of many HGSOC (Crum et al., 2007;
Lee et al., 2007; Folkins et al., 2008). TP53 mutation is therefore both
an early and necessary event for the development of HGSOC (Bowtell,
2010).
Beyond TP53 mutations, the TGCA project revealed the importance
of the homologous recombination (HR) pathway (discussed in detail
below). This pathway is responsible for the repair of DNA double
stand breaks (DSBs) and key components of this pathway are BRCA1
and BRCA2. It was shown that 20% of HGSOC have germ-line or so-
matic mutations in BRCA1/2, the majority of which are frame-shift
insertions or deletions (Rebbeck et al., 2015). Promoter hypermethy-
lation resulting in loss of BRCA1 (but not BRCA2) expression was
seen in 11% of tumours and appears to be mutually exclusive of
BRCA1/2 mutations. (TGCA, 2011; Baldwin et al., 2000). Genomic
alterations were seen in other HR genes including RAD51C, Ataxia
Telangiectasia and RAD3-related protein/Ataxia Telangiectasia Mu-
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tated (ATR/ATM) and mutations of the Fanconi anaemia genes. Over-
all pathway analysis suggests that the HR pathway is defective in
about half of tumours (TGCA, 2011) (Figure 1.2) HGSOC with de-
fects within the HR pathway may represent a subset of tumours
with a more favourable prognosis as they respond better to cytotoxic
chemotherapy and may be candidates for more targeted treatment.
This is discussed in more detail below.
The molecular characteristics of the HR competent tumours are less
well defined. Approximately 30% of this group have amplification
of Cyclin E1 (CCNE1) (Etemadmoghadam et al., 2013; Ciriello et al.,
2013; TGCA, 2011). Cyclin E1 forms a complex with, and regulates,
CDK2 to facilitate G1/S progression of the cell cycle (Siu et al., 2012).
A further study looking at chemo-resistant ovarian cancers confirmed
that CCNE1 amplification is confined to HR competent tumours as it
appeared to be exclusive of BRCA1/2 mutation (Patch et al., 2015).
Further classification of HGSOC has been investigated by the use
of gene expression analysis. Microarray gene expression profiling of
300 HGSOCs as part of the Australian Ovarian Cancer Study iden-
tified distinct molecular subtypes (C1/mesenchymal, C2/immune,
C4/differentiated, C5/proliferative) linked with clinical and patho-
logical features (Tothill et al., 2008). Further studies have confirmed
distinct gene expression patterns which partially overlap with those
found by Tothill et al (Tothill et al., 2008) including TGCA and the
prognostic gene expression profile ’Classification of Ovarian Cancer’
(CLOVAR) (Verhaak et al., 2013; Helland et al., 2011). Although it is
currently not clear what is driving these gene expression profiles, spe-
cific subtypes may respond to particular treatments. Currently, how-
ever, this classification has not been applied to clinical care.
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1.1.7 Ovarian cancer and genomic instability
One of the most striking features of HGSOC is that it is characterised
by considerable genomic instability (Ciriello et al., 2013), with fre-
quent DNA gains and losses resulting in loss of heterozygosity (LOH),
aneuploidy and intra-tumour heterogeneity. Structural change is an
important mechanism for the loss or inactivation of tumour suppres-
sor genes in HGSOC (TGCA, 2011). For example, gene breakage com-
monly inactivates the tumour suppressors Neurofibromin 1 (NF1),
retinoblastoma protein (pRB), RAD51B and phosphatase and tensin
homolog (PTEN) (Patch et al., 2015).
There is a complex relationship between genomic instability and
prognosis. Studies have shown that genomic instability has been asso-
ciated with a poorer prognosis in many tumours (Carter et al., 2006).
However, in HGSOC (and basal-like breast cancer), which show ex-
treme level of genomic instability, a high level of LOH was associated
with a better prognosis and low platinum chemotherapy resistance
rates (Wang et al., 2012; Baumbusch et al., 2013). In contrast to plat-
inum chemotherapy, ovarian cancer with a gene expression signature
reflecting higher chromosomal instability (CIN70) showed resistance
to taxanes in a trial of taxane monotherapy (Swanton et al., 2009).
Widespread chromosomal changes that are seen in HGSOC are
likely a result of mutations in TP53 along with BRCA1 or BRCA2
(Bowtell, 2010). Basal like breast cancers, the most common subtype
arising in women with BRCA mutation, also show widespread copy
number changes (Natrajan et al., 2009) and they also have a high fre-
quency of TP53 mutation (Manie et al., 2009; Holstege et al., 2009).
Deletion of BRCA1 or BRCA2 in cell lines has been shown to result
in significant chromosomal instability and aneuploidy (Patel et al.,
1998; Xu et al., 1999). In addition, mutations in a variety of DNA re-
pair genes in addition to BRCA1 and 2 result in genomic instability
syndromes with heightened risk of developing cancer (for example
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Bloom’s syndrome, xeroderma pigmentosum, Neijmegen breakage
syndrome and Fanconi anaemia), reviewed in (Martin et al., 2010).
Defects within these DNA repair pathways, which normally main-
tain the integrity of the genome, result in genomic instability and
are thought to promote tumorigenesis through accumulation of mu-
tations in tumour suppressor genes and oncogenes (Charames and
Bapat, 2003). It is proposed that DNA copy number change as a re-
sult of BRCA and TP53 mutation is a vital step in the development of
HGSOC (Bowtell, 2010).
1.1.8 The spread of ovarian cancer and the tumour microenvironment
HGSOC spreads either by direct extension from the primary tumour
or when malignant cells shed from the ovarian/fallopian tube surface.
Peritoneal fluid then facilitates their spread throughout the peritoneal
cavity. Tumour deposits can therefore be found across all peritoneal
surfaces and in draining lymph nodes, and frequently the develop-
ment of increased peritoneal fluid (ascites) occurs. This ascitic fluid is
rich in immune cells and inflammatory cytokines. In contrast, blood-
borne dissemination to extra-abdominal sites is uncommon (Lengyel,
2010).
The immune microenvironment and immune cells in ovarian can-
cer disease play an important part in disease prognosis. The balance
between the tumour promoting effects of the tumour evading the im-
mune system verses the immune system mediating an anti-tumour
response is complex (Figure 1.3). An understanding of this complex
interplay is opening up potential avenues of new immune therapies
in ovarian cancer.
T cell infiltration into ovarian tumours has been associated with im-
proved survival (Zhang et al., 2003a). CD8 cytotoxic T lymphocytes
(CTL) are thought to be the main mediators of anti-tumour responses.
These cells recognise antigens displayed on major histocompatibil-















Figure 1.3: The immune microenvironment in ovarian cancer. Simplified di-
agram showing the balance between tumour suppressive factors
and tumour promoting factors in ovarian cancer. The balance
favours ovarian cancer progression. Figure adapted from Knut-
son et al. (2015).
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ity complex (MHC) class I expressed on ovarian cancer cells. It has
been shown that patients with higher CD8+ T cells have improved
survival compared to those without infiltrating T cells (55 months
vs 26 months) (Sato et al., 2005). The role of CD4 helper T cells is
less clear. Some studies have shown similar outcomes among patients
with and without CD4+ staining in tumours while others have shown
increased CD4 cells is associated with improved survival. High levels
of interleukin-17 (IL-17) in ascites has been shown to be associated
with improved survival suggesting that a subset of CD4 helper cells
may have a role in eradicating tumour (reviewed in Knutson et al.
(2015)).
Other specific subsets of potential anti-tumour effectors have been
studied. Antibody responses to ovarian cancer are a common obser-
vation, suggesting a role for B cells (Knutson et al., 2015). Studies,
however, evaluating whether B cell infiltration is associated with im-
proved survival show mixed results. Some have suggested that these
cells are involved in modulating CTL recruitment or activity (Milne
et al., 2009). Recently published data has shown that the presence
of antibody producing plasma cells are associated with the most
prognostically favourable CD8+ tumour infiltrating lymphocyte re-
sponses in HGSOC (Kroeger et al., 2016). It is suggested that the
co-localisation of B and T cells within tertiary lymphoid structures
facilitates their antitumour responses (Kroeger et al., 2016). Natural
killer (NK) cells are also found in the immune microenvironment.
Nearly all ovarian cancers express NK ligands (MICA, MICB and
ULBP2) (Li et al., 2009a). However, increased numbers of NK cells
in peritoneal and pleural effusions have been associated with poor
prognosis (Dong et al., 2006).
Immune evasion in ovarian tumours involves a complex collection
of immune factors that suppress the generation of the anti-tumour
response (Knutson et al., 2015). Immune suppression is mediated by
factors released from the tumour or by a variety of suppressor or reg-
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ulatory cells. The role of CD4+ regulatory T cells (Tregs) in ovarian
tumours has been well documented. These cells are a T cell subpop-
ulation that functions to suppress the immune response through re-
lease of immune suppressive mediators such as transforming growth
factor b (TGFb) and Interleukin-10 (IL10). They also prevent T cell re-
sponses through cytokine dependent or cell contact-dependent mech-
anisms (Knutson et al., 2015). Tumours with increased numbers of
Tregs have a poor prognosis (Li et al., 2005; Preston et al., 2013) .
Multiple regulatory cells, including macrophages and dendritic cells
(DCs) are dervived from the myeloid arm of the immune system. In-
filtration of tumours with macrophages of the M2 phenotype is char-
acterised by immune suppression and is tumour promoting (Ko and
Naora, 2014). Human ovarian cancers have been shown to recruit a
subset of DCs that induce T cells to release large amounts of IL-10
preventing local T cell activation (Wei et al., 2005). In addition, de-
pletion of DCs has been shown to delay ovarian cancer progression
in a murine model (Huarte et al., 2008). Tumour cells also express a
variety of molecules that directly block the immune response. These
include programmed death ligand 1 (PD-L1) (Hamanishi et al., 2007),
Cancer antigen 125 (Ca125 also known as MUC16) (Patankar et al.,
2005) and indoleamine 2,3-dioxygenase (IDO) (Inaba et al., 2009).
The role of the inflammatory cytokine network has also been as-
sessed. The ’tumour necrosis factor (TNF) network’, consisting of
TNFa, chemokine (C-X-C motif) ligand 12 (CXCL12) and interleukin
6 (IL-6), has paracrine actions on angiogenesis, infiltration of myeloid
cells and NOTCH signalling in ovarian cancer (Kulbe et al., 2012).
High levels of IL-6 in the serum of ovarian cancer patients have been
associated with shorter survival (Plante et al., 1994; Coward et al.,
2011). IL-6 is also associated with the generation of thrombocytosis
that is associated with shortened survival (Stone et al., 2012).
An understanding of this complex relationship between the tumour
and the immune system is important in the development of new treat-
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ments and particularly novel treatments such as oncolytic viral ther-
apy as they have a complex interaction with the immune system that
is discussed in more detail below.
1.1.9 Current treatment of Ovarian Cancer
1.1.9.1 Surgery
Currently epithelial ovarian cancer is treated as a single disease en-
tity. The mainstay of treatment, in both early and advanced ovarian
cancer, is surgery. Data from retrospective studies show that minimal
residual disease following surgery is associated with improved out-
come (Chi et al., 2009; du Bois et al., 2009). There is some debate over
whether this association is causal or due to the fact that resectable
tumours may be less aggressive or more responsive to chemotherapy
(Schorge et al., 2010). Nevertheless, the aim of surgery is therefore for
complete removal of all cancer tissue (optimal debulking) (du Bois
et al., 2009).
In cases where optimal debulking is not possible, neoadjuvant (pre-
operative) chemotherapy is an option (Chi et al., 2009). Interval de-
bulking can then be considered after 3 cycles of treatment. This strat-
egy is supported by large randomised trials that show non-inferiority
in survival and reduced surgical morbidity when compared to up-
front surgery in advanced ovarian cancer (Hou et al., 2007; Vergote
et al., 2010; Kehoe et al., 2015; Fagotti et al., 2016).
1.1.9.2 Chemotherapy
early stage disease There have been several randomised con-
trolled trials looking at the role of platinum based chemotherapy fol-
lowing surgery in early stage disease. A recent meta analysis of these
trials has concluded that the addition of adjuvant chemotherapy in
early stage disease (The International Federation of Gynecology and
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Obstetrics (FIGO) stage I/IIa) improves both progression free sur-
vival (PFS) and overall survival (OS) (Lawrie et al., 2015). It is un-
clear whether this benefit is confined to women with intermediate
and high-risk disease and the role of chemotherapy in those with low
risk disease (stage Ia/ grade 1 disease) is currently debated (Lawrie
et al., 2015).
advanced disease Platinum based chemotherapy treatment has
been the standard of care in ovarian cancer for around 40 years. Cur-
rently, standard chemotherapy consists of a combination of paclitaxel
(175mg/m2) and carboplatin (area under the curve (AUC) 5-6), both
administered intravenously every 3 weeks (Ozols et al., 2003). This
has been the standard of treatment for more than 15 years, and clin-
ical trials adding a third conventional chemotherapy drug have been
shown not to improve PFS or OS in these patients (Bookman et al.,
2009). The combination of cisplatin and paclitaxel is equally effective
but more toxic. There is no evidence to suggest that more than 6 cy-
cles result in better outcome (Bookman et al., 2009).
A number of recent trials are now beginning to influence first line
treatment of advanced ovarian cancer. Large randomised trials in-
hibiting angiogenesis with bevacizumab (a monoclonal antibody tar-
geting vascular endothelial growth factor, VEGF) (GOG218 and ICON-
7) or pazopanib (a VEGF receptor tyrosine kinase inhibitor (VEGF
RTKi)) have shown improved PFS (Burger et al., 2011; Perren et al.,
2011; du Bois et al., 2014). Fractionating paclitaxel into a dose dense
weekly regime has also shown an improvement in PFS and OS and
it has been suggested that this regime should be standard of care
(Katsumata et al., 2013). Two further trials (ICON8 and GOG262) are
currently evaluating the role of dose dense weekly paclitaxel together
with bevacizumab (Suh et al., 2014).
Since ovarian cancer is often confined within the abdomen, the
role of intraperitoneal treatment in ovarian cancer has been investi-
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gated. A catheter is placed into the peritoneal cavity and remains in
place for the duration of therapy. A ‘turning protocol’ can be used in
which the patient spends 1.5 to 2 hours lying in different positions to
maximise exposure of peritoneal surfaces to the drugs (Alberts et al.,
2006). A phase III trial comparing intraperitoneal (IP) and intravenous
cisplatin and paclitaxel therapy with intravenous paclitaxel and cis-
platin showed an improvement in both PFS and OS in the group that
received IP treatment (Armstrong et al., 2006). Toxicities were higher
in the IP group and as a result the IP regime was only deliverable
in 42% of patients. Despite the potential for this approach to deliver
higher concentrations of cytotoxic treatment to the tumour, general
uptake has been poor and more tolerable regimes are needed (Jayson
et al., 2014).
1.1.9.3 Recurrent disease
Despite optimal upfront surgery and administration of chemotherapy,
approximately 70% of patients will relapse in the first 3 years and the
median PFS is around 18 months. Detection of relapse could be by the
rising serum tumour marker, CA125 level (Meyer and Rustin, 2000),
the development of symptoms or by imaging. A rising of CA125 lev-
els can often predate symptoms; however, early intervention on the
basis of a rising CA125 alone without the presence of symptoms did
not improve survival and reduced quality of life in these patients
(Rustin et al., 2010).
The choice of chemotherapy regime for relapsed disease is largely
dictated by the interval from the last cycle of platinum based chemo-
therapy to the point of development of disease (Eisenhauer et al.,
1997). For those patients with a late relapse (more than 6 months af-
ter chemotherapy), carboplatin combination is the treatment of choice.
Randomised trials have shown that options for platinum sensitive re-
currence include the combination of carboplatin with paclitaxel (Par-
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mar et al., 2003), gemcitabine (Pfisterer et al., 2006) or liposomal dox-
orubicin (Pujade-Lauraine et al., 2010).
Chemotherapy resistance is a major problem and treatment for
platinum resistant (progressing within 6 months of platinum based
chemotherapy) or platinum refractory (progressing during or within
4 weeks of platinum chemotherapy) patients are limited and progno-
sis is poor. Options include chemotherapy with paclitaxel (Thigpen
et al., 1994), topotecan (Bookman et al., 1998), liposomal doxorubicin
(PLD) (Gordon et al., 2000) and gemcitabine (Markman et al., 2003).
Overall response rates are poor and median PFS is 3-4 months (Ushi-
jima, 2010).
The angiogenesis inhibitor, bevacizumab, has shown to improve
PFS of recurrent ovarian cancer in two randomised phase III trials
(Aghajanian et al., 2012; Pujade-Lauraine E, 2012). An improvement
in OS was, however, not seen and this may be due to cross- over
and further lines of treatment at progression. Currently the addition
of bevacizumab in recurrent disease is not standard of care. Other
angiogenesis inhibitors such as cediranib, vandetanib and aflibercept
are being assessed in ovarian cancer but currently their efficacy is yet
to be determined.
Currently the options for patients with relapsed disease and espe-
cially those with platinum refractory disease are limited, and there
is a need for newer treatments. A variety of chemotherapeutic agents
and novel targeted drugs are currently being developed and evalu-
ated in ovarian cancer. Although a number of newer chemotherapy
agents have been assessed in platinum resistant ovarian cancer (eg.
Ixabepilone) the response rates have been poor and none have been
incorporated into the standard of care (Mantia-Smaldone et al., 2011).
With the increasing understanding of the molecular basis of ovar-
ian cancer, trials have focused on a variety of molecularly targeted
treatments. One focus has been to exploit the overexpression of the
folate receptora (Konner et al., 2010; Lorusso et al., 2012) and large
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randomised trials are underway. Targeting CA125 has also been in-
vestigated but unfortunately trials with the anti-CA125 antibody, ore-
govamab have been negative (Berek et al., 2009).
Immune therapies are currently receiving a great deal of attention
in the treatment of cancer and these also starting to be investigated
in ovarian cancer. As discussed in more detail earlier, the immune
microenvironment has been shown to be important in the biology
of ovarian cancer, the status of T-cell infiltration in the immune mi-
croenvironment (Zhang et al., 2003a, 2015), along with reduced ex-
pression of the programmed cell death ligand-1 (PD-L1) (Hamanishi
et al., 2007; Maine et al., 2014) are associated with improved progno-
sis. Based on this rationale, clinical trials are currently underway with
immune checkpoint inhibitors (anti-PD-L1/PD-1, anti anti-cytotoxic
T-lymphocyte-associated protein 4 (anti-CTLA4)) (e.g. NCT02608684,
NCT02440425, NCT02537444).
What is now clear is that ovarian cancer is a heterogeneous disease
and for treatments to be effective they need to be developed and tar-
geted towards appropriately selected patients. The knowledge that
the DNA repair pathway, HR, is frequently compromised in ovarian
cancer has lead to the development of treatments targeted to this par-
ticular group of patients. The role of poly(ADP)ribose polymerase
(PARP) inhibitors in ovarian cancer demonstrates the importance of
defects within this pathway and this is discussed in more detail below.
Given the importance of HR in HGSOC, the next section will discuss
this DNA repair pathway with a particular focus on how knowledge
of defects within the DDR is now influencing therapy.
1.2 the homologous recombination pathway and the dna
damage response
The DNA damage response (DDR) is vitally important for maintain-
ing the integrity of the genome (Friedberg et al., 2006). The genome is
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Figure 1.4: The molecular and physiological consequences of the DDR.
Adapted from Harper and Elledge (2007).
constantly exposed to endogenous and exogenous genotoxins. Unless
repaired by an error-free process, DNA damage can result in muta-
tions and altered cellular behaviour. Consequently, cells respond to
DNA damage by activating a number of interconnecting pathways.
These pathways not only involve the DNA repair process itself but
also integrate with regulatory pathways such as cell cycle control and
apoptosis. This is summarised in Figure 1.4. Together, these pathways
ensure that mutated DNA is not duplicated, and therefore ensure the
lesion is repaired, or if damage is too great, trigger cell death (Harper
and Elledge, 2007).
A human cell undergoes tens of thousands of DNA lesions per
day (Hoeijmakers, 2009; Jackson and Bartek, 2009). These lesions can
block replication and transcription, and if they are not repaired or
repaired incorrectly, can lead to mutation or cell death. Different
forms of DNA damage evoke different repair mechanisms and sig-
nalling pathways (Jackson and Bartek, 2009). In human cells there
are five major repair pathways (shown in Figure 1.5). The most com-
mon form of DNA damage is single strand breaks (SSBs), which
are repaired by the base excision repair (BER) pathway (Caldecott,
2014). The nucleotide excision repair (NER) pathway deals with mod-
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by elongating RNA polymerase; and global-genome NER, in which 
the lesion is detected not as part of a blocked transcription process but 
because it disrupts base pairing and distorts the DNA helix. Although 
these processes detect lesions using different mechanisms, they repair 
them in a similar way: DNA surrounding the lesion is excised and then 
replaced using the normal DNA replication machinery. Excision repair 
cross-complementing protein 1 (ERCC1) is key to this excision step. 
The major mechanisms that cope with DSBs are homologous 
recombination9 and non-homologous end joining (NHEJ)10. Homol-
ogous recombination acts mainly in the S and G2 phases of the cell 
cycle and is a conservative process in that it tends to restore the original 
DNA sequence to the site of damage. Part of the DNA sequence around 
the DSB is removed (known as resection) and the DNA sequence on 
a homologous sister chromatid is used as a template for the synthesis 
of new DNA at the DSB site. Crucial proteins involved in mediating 
homologous recombination include those encoded by the BRCA1, 
BRCA2, RAD51 and PALB2 genes. In contrast to homologous recom-
bination, NHEJ occurs throughout the cell cycle. Rather than using a 
homologous DNA sequence to guide DNA repair, NHEJ mediates repair 
by directly ligating the ends of a DSB together. Sometimes this process 
can cause the deletion or mutation of DNA sequences at or around the 
DSB site. Therefore, compared with homologous recombination, NHEJ, 
although mechanistically simpler, can often be mutagenic.
 Mismatch repair11 is crucial to the DDR. It deals primarily with dNTP 
misincorporation and formation of ‘insertion and deletion’ loops that 
form during DNA replication. These errors cause base ‘mismatches’ in 
the DNA sequence (that is, non-Watson-Crick base pairing) that distort 
the helical structure of DNA and so are recognized as DNA lesions. The 
recognition of this distortion triggers a procession of events resulting in 
the excision of newly synthesized DNA encompassing the mismatch site 
and the resynthesis of DNA in its place. Key to the process of mismatch 
repair are proteins encoded by the mutS and mutL homologue genes, 
such as MSH2 and MLH1. 
Finally, translesion synthesis and template switching allow DNA to 
continue to replicate in the presence of DNA lesions that would oth-
erwise halt the process. Translesion synthesis and template switching 
are therefore usually considered to be part of the DDR. In translesion 
synthesis, relatively high-fidelity DNA replication polymerases are tran-
siently replaced with low-fidelity ‘translesion’ polymerases that are able 
to synthesize DNA using a template strand encompassing a DNA lesion. 
Once the replication fork passes the site of the lesion, the low-fidelity 
DNA polymerases are normally replaced with the usual high-fidelity 
enzyme, which allows DNA synthesis to continue as normal. In template 
switching, the DNA lesion is bypassed at the replication fork by simply 
leaving a gap in DNA synthesis opposite the lesion. After the lesion 
has passed the replication fork, the single-strand gap is repaired using 
template DNA on a sister chromatid, similar to the process used during 
homologous recombination.
Although sometimes considered distinct from the DDR, the 
mechanisms that control the integrity of telomeric DNA at the end of 
each human chromosome also act as a barrier against genomic instabil-
ity and mutation12. Rather than being an exposed DNA double-helix 
structure at the end of the chromosome, telomeric DNA comprises 
a series of guanine-rich, repetitive DNA sequences. These enable the 
telomeric DNA to be bound in a loop-like structure with a series of 
proteins (telomere repeat binding factor 1 and 2 (TERF1 and TERF2), 
protection of telomeres 1 (POT1), TERF1-interacting nuclear factor 
2 (TINF2)) that form a shelterin complex. This ‘capping’ structure 
prevents the otherwise exposed ends of different chromosomes from 
becoming fused together (a process known as end–end fusion) by the 
DDR. In most somatic cells, the length of telomeric DNA is reduced 
at each cell cycle, a process termed telomere attrition. Eventually, tel-
omeres reach a crucial length that precludes the formation of an effec-
tive shelterin complex. In normal cells, this failure in telomere capping 
induces a p53-mediated response that results in cellular senescence, a 
mechanism that ultimately prevents unlimited cell proliferation. When 
the p53 response is abrogated, end–end fusions occur, which leads to 
the formation of chromosomes with two centromeres. At mitosis, each 
centromere in a dicentric chromosome attaches to an opposite spindle 
pole. The physical stress of opposing forces during chromosome segre-
gation shears dicentric chromosomes, resulting in broken chromosome 
ends. This process is an ideal substrate for the chromosome translo-
cation, focal DNA amplification and deletion events that potentially 

















































Figure 1 | A panoply of DNA repair mechanisms 
maintains genomic stability. DNA is continually 
exposed to a series of insults that cause a range of 
lesions, from single-strand breaks (SSBs) to base 
alkylation events. The choice of repair mechanism 
is largely defined by the type of lesion, but factors 
such as the stage of the cell cycle also have a role. 
Key proteins involved in each DDR mechanism, 
the tumour types usually characterized by DDR 
defects and the drugs that target these defects are 
shown. BER, base excision repair; NER, nucleotide 
excision repair; NHEJ, non-homologous end-
joining. Figure modified, with permission, from  
ref. 72.
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Figure 1.5: Illustration of the five main pathways involved in repair of DNA
damage. DNA is continuously exposed to a variety of forms of
DNA damage. Different forms of DNA damage trigger different
repair pathways and signalling mechani ms. Ad pted from Lord
and Ashworth (2012)
ified nucl oti es that distort the structure of the DNA double helix.
This pathway deals with ultaviolet (UV)–induced damage and also
plays a role in dealing with the damage induced by platinum agents
(O’Connor, 2015). The mismatch repair (MMR) pathway is involved
in repairing replication errors, including mismatch base-pairing as
well as nucleotide insertions and deletions (Jiricny, 2006).
The most genotoxic lesions are DNA double strand breaks (DSBs).
A single nrepaired DSB can lead to aneuploidy, genetic aberrations
or cell d ath. DSBs can be generated by a number of sources, includ-
ing genotoxic chem ca s (for xa ple chemotherap utics) and ion-
izing radiati . In additi n, ma y other types of DNA lesions im-
ped replication fork progression, leading to replication fork c llapse
and DSBs (Krejci et al., 2012). There are two main pathways that re-
pair these lesions: HR and classical non-homologous end joining (C-
NHEJ). In addition, other error prone DSB repair pathways, namely
alternative-NHEJ (alt-NHEJ) and single-strand annealing (SSA), have
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recently been shown to operate in many different conditions and
contribute to genome rearrangements and oncogenic transformation
(Ceccaldi et al., 2016).
1.2.1 Signalling DSB damage
Following a DSB, proteins are rapidly recruited to the DSB and hi-
stone modifications take place. At least four, partially independent,
sensors detect DSBs: PARP, Ku70/80, MRN complex (MRE11/ RAD50
/ NBS1) and, the if end processing occurs, replication protein A (RPA).
Ku localises within seconds to DSBs where it loads and activates
DNA dependent protein kinase (DNA-PK) to initiate C-NHEJ. PARP1/
2 act to promote alt-NHEJ, which functions as a back-up pathway of
C-NHEJ. DSB resection and formation of 3’ssDNA ends results in
RPA accumulation and activation of the ATR pathway leading to SSA
or HR (Ciccia and Elledge, 2010). The MRN complex is the major
DSB sensor and recruits and activates ATM. MRE11 has endonucle-
ase and exonuclease activity important for the initial steps of DNA
end resection that is essential for HR (Williams et al., 2007).
Once DSB have been detected, key proteins that mediate the DDR
include proteins of the phosphatidylinositol 3-kinase-like protein ki-
nase (PIKKs) family – ATM and ATR (Ciccia and Elledge, 2010). ATM
and ATR coordinate a wide number of cellular processes through
phosphorylation of a large number of mediator proteins. ATM is ac-
tivated by DSBs created by DNA damaging agents (like irradiation).
ATR, together with ATRIP, is activated following recruitment to RPA-
coated ssDNA regions particularly at stalled replication forks (Cim-
prich and Cortez, 2008). These proteins initially amplify the DDR by
acting as recruiters of ATM/ATR substrates (Zhou and Elledge, 2000).
Effector proteins of the DDR are then either directly phosphorylated
by ATM/ATR or by kinases such as checkpoint kinase 1 and 2 (CHK1
and CHK2) (Ciccia and Elledge, 2010). As a result, ATM and ATR co-
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ordinate a wide variety of cellular activities in response to DNA dam-
age including modulating the cell cycle and apoptosis (Figure 1.6).
ATM and ATR promote DSB repair in part through phosphoryla-
tion dependent recruitment of DDR factors to the sites of DNA dam-
age (Ciccia and Elledge, 2010). A critical aspect of the process involves
rapid phosphorylation of Ser139 on histone H2AX, a variant of H2A,
by ATM. This promotes chromatin binding of mediator of damage
checkpoint 1 (MDC1); MDC1 interacts with MRE11, tethering MRN
and also ATM at the DSB (Shibata and Jeggo, 2014). The DDR sig-
nal is amplified as ATM extends the region of phosphorylated H2AX
(gH2AX) (Harper and Elledge, 2007). Formation of extensive gH2AX
is important for sustaining the DDR. In addition, gH2AX recruits
chromatin remodelling enzymes that stabilise DDR factors at the site
of DSBs (Ciccia and Elledge, 2010).
MDC1 phosphorylation and recruitment to gH2AX initiates a ubiq-
uitin cascade at sites of DNA damage. Recruitment of the ubiquitin
ligase, ring finger protein 168 (RNF168) by MDC1 mediates the forma-
tion of p53-binding protein 1 (53BP1) foci at damaged chromatin, pro-
moting C-NHEJ. 53BP1 has recently been shown to be an important
regulator of the cellular response to DSB (Panier and Boulton, 2014).
53BP1 also binds to the RAD50 component of MRN (Shibata and
Jeggo, 2014). Additional proteins, including BRCA1, RAP80, Abraxas
and BRCC36, assemble at DSBs and some of these are cell cycle depen-
dent, being more abundant in G2/S phase (Shibata and Jeggo, 2014).
BRCA1 is required to relieve the barrier that 53BP1 poses to resection,
thereby promoting homologous recombination (Bunting et al., 2010).
Together, this plethora of factors meditating phosphorylation, ubiqui-
tination, sumoylation and acetylation, carefully regulate the repair of
the DSB and play an important role in determining the most appro-
priate pathway to repair the damage (Ciccia and Elledge, 2010). The
different pathways involved to repair DSBs are discussed below, with
a focus on HR.
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Figure 1.6: Signalling DNA damage to cell cycle checkpoints. ATM is acti-
vated by DSBs and triggers the G1 checkpoint by phosphorylat-
ing CHK2 and p53. ATM and ATR are activated by resected DSBs
and stalled replication forks. This results in phosphorylation of
CHK1 and activates the intra-S phase and G2 checkpoints. CHK1
also phosphorylates and inactivates CDC25 to inhibit cell cycle
progression through suppression of CDK activity (Curtin, 2012).
There is also cross talk between the pathways and dashed arrows
show secondary targets. (Figure adapted from Curtin (2012))
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1.2.2 Repair of DSBs: Classical NHEJ
Of the four known pathways that repair DSBs, the C-NHEJ path-
way represents the major DSB repair pathway in mammalian cells,
a feature demonstrated by the dramatic radiosensitivity shown by
defective mutants (Jeggo and Lavin, 2009). NHEJ ligates DSBs with
minimal end-processing. The DSB is repaired by blunt end ligation
independent of sequence homology. It is not error free but is active in
all phases of the cell cycle, predominating in G0 and G1 (Branzei and
Foiani, 2008).
NHEJ is initiated by sequence independent binding of the hetero-
dimeric Ku70/80 protein to the double strand ends. This is achieved
through the Ku’s ring structure, which enables Ku to loop onto the
DNA end. DNA-bound Ku recruits the catalytic component of the
DNA–dependent protein kinase catalytic (DNA-PK) complex DNA-
PKcs, activating the kinase activity (Shibata and Jeggo, 2014). Au-
tophosphorylation of DNA-PKcs regulates end-processing together
with artemis nuclease, polynucleotide kinase 3’ phosphatase (PNKP)
and polymerases (including poll and polµ) (Radhakrishnan et al.,
2014). Once DNA ends have been processed, they are covalently joined
by DNA ligase IV, which exists in a complex with X-ray repair cross-
complementing protein 4 (XRCC4). XRCC4 is required for stabilisa-
tion of DNA Ligase IV and stimulates its activity (Grawunder et al.,
1997). XRCC4 also interacts with XLF (XRCC4-like factor), which is
required to repair a subset of breaks involving mismatched or non-
cohesive ends (Ahnesorg et al., 2006; Tsai et al., 2007).
The abundance of Ku 70 and DNA-PKcs together with Ku’s capac-
ity to bind double-stranded DNA ends make C-NHEJ an important
mechanism of DSB repair (Shibata and Jeggo, 2014). Despite the po-
tential for mutagenicity of C-NHEJ, its fast kinetics means that it plays
a role in protecting genomic integrity by suppressing chromosomal
translocations (Difilippantonio et al., 2000).
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1.2.3 Alt-NHEJ and SSA
Recent studies have shown that, following end resection, DSB can
be repaired by two error-prone end-joining pathways, Alt-NHEJ and
SSA (Ceccaldi et al., 2016). Alt-NHEJ occurs in various cellular con-
ditions but the mechanistic details of the pathway remain unclear
(Ceccaldi et al., 2016). Alt-NHEJ predominantly occurs when NHEJ
is compromised by the loss of Ku or ligase IV. This pathway requires
end resection by CtBP-interacting protein (CtIP) and uses DNA lig-
ase I or III, XRCC1 and PARP1 (Ceccaldi et al., 2016). The process
involves two ssDNA re-joining events using microhomology to tether
the ends. It has harmful consequences on genomic integrity due to
the possibility of joining DSBs on different chromosomes thus gener-
ating chromosomal translocations and deletions (Deriano and Roth,
2013). SSA can occur when end resection reveals flanking homolo-
gous sequences and it involves reannealing of RPA coated ssDNA by
the RAD52 protein. It therefore mediates end joining between inter-
spersed nucleotide repeats in the genome resulting in deletion of the
intervening sequences (Mehta and Haber, 2014) and subsequent loss
of genetic information (Ceccaldi et al., 2016).
1.2.4 Homologous recombination
In contrast to NHEJ, HR exploits the use of an undamaged homol-
ogous template to restore any lost sequence information (Shibata
and Jeggo, 2014). It functions in the S and G2 phases of the cell
cycle when an intact sister chromatid is available. The central reac-
tion of HR is homology search and DNA strand invasion mediated
by RAD51 (Shibata and Jeggo, 2014). There are three phases of HR:
pre-synapsis, synapsis and post-synapsis, and RAD51 is involved in
all stages (Sung et al., 2003). The presence of DSBs is signalled by



























Figure 1.7: Representation of the key factors involved in repair of DSBs by
HR. In response to DSBs, sensors (light blue) detect the damage,
and signalling mediators recruit or activate effectors that repair
the damage through RAD51 mediated process. Figure adapted
from Roy et al. (2012).
the factors such as gH2AX (described in more detail Section 1.2.1)
and HR is initiated by CtIP/MRE11-dependent resection of double-
stranded DNA ends. The extension of the resection is highly regu-
lated and involves the repositioning of 53BP1 via a BRCA1-dependent
process (Bunting et al., 2010). The resulting single-stranded 3’ tails
generated by resection are rapidly bound by RPA. In the presynap-
sis phase, RAD51 displaces RPA and is loaded onto ssDNA. The re-
sulting RAD51-ssDNA filament (the presynaptic filament) mediates
homology search (Krejci et al., 2012) (Figure 1.7).
During synapsis, RAD51 facilitates the formation of a physical con-
nection between the invading DNA substrate and the homologous
DNA template, leading to the generation of heteroduplex DNA (D-
loop). At this point, RAD51-dsDNA filaments are formed by accom-
modating both the invading and donor ssDNA strands within the
filament. Finally, during post synapsis, RAD51 dissociates from the
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dsDNA to expose the 3’-OH end, which is required for DNA synthe-
sis (Krejci et al., 2012).
At least three different routes can be used once DNA synthesis is
initiated. In double strand break repair (DSBR), the second end of
DSB can be used to stabilise the D–loop structure, leading to the gen-
eration of a double Holliday junction (dHJ) (Krejci et al., 2012). The
dHJ is subsequently resolved by enzyme complexes such as BLM in
complex with topoisomerase IIIa (Wu and Hickson, 2003) or GEN1
to produce crossover or noncrossover products (Krejci et al., 2012;
Ip et al., 2008). Alternatively, the invading strand can be displaced
from the D loop after DNA synthesis and then anneal with its com-
plementary strand. This is known as the synthesis-dependent strand-
annealing mode of HR (SDSA) (Krejci et al., 2012). In break-induced
replication (BIR), the D-loop structure can assemble into a replica-
tion fork and copy the entire chromosome arm to result in loss of
heterozygosity (Li and Heyer, 2008) (Figure 1.8).
1.2.5 Regulation of HR
There are multiple regulatory mechanisms that control HR at many
points along the pathway. One level of regulation occurs between
RAD51 and RPA complex. RPA has a higher affinity for ssDNA and
has been shown to arrive at DSB sites prior to RAD51 (Krejci et al.,
2012). The presence of RPA blocks RAD51 binding and therefore
needs to be removed for HR to take place. Once RAD51 is loaded
onto ssDNA, however, RPA has also been shown to promote recom-
bination by protecting DNA ends from resection and removing sec-
ondary structures formed on ssDNA that could impede RAD51 fila-
ment formation (Sung et al., 2003).
Recombination mediators are proteins that can overcome the in-
hibitory effect of RPA on RAD51. These mediators can facilitate RAD51
loading onto ssDNA, increase intrinsic stability of RAD51 presynap-
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Figure 1.8: Models for the repair of DSBs by HR. DNA DSBs are resected to
generate 3’ ends followed by the formation of RAD51 filaments
that invade the homologous strand to form a D loop structure.
After priming DNA synthesis, three pathways can be followed.
In the DSBR pathway, the second end is captured and a dHJ is
formed. Resolution of the dHJs can generate cross over or non
crossover products. In the SDSA, pathway the newly extended
strand is displaced, followed by pairing with the other 3’ single
stranded tail and DNA synthesis completes the repair. The third
pathway, BIR, can act when the second end is absent. The D-loop
intermediate turns into a replication fork capable of both lagging
and leading strand synthesis. Figure adapted from Krejci et al.
(2012).
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tic filament and prevent RAD51 from being removed by factors such
as helicases. Mediators include RAD52, RAD51B, RAD51C, and X-ray
repair cross-complementing protein 2/3 (XRCC2/3) but the most im-
portant mediator in mammalian cells is BRCA2 (Ceccaldi et al., 2016).
1.2.5.1 BRCA2
BRCA2 is the main mediator of RAD51 nucleofilament formation and
strand exchange. BRCA2 contains a DNA binding domain that binds
to ssDNA and dsDNA and interacts with RAD51 through a series
of eight evolutionary conserved motifs, the BRC repeats (Roy et al.,
2012). The repeats have subtle differences and bind RAD51 with vary-
ing affinity by mimicking the structure of RAD51 monomers (Pelle-
grini et al., 2002). The BRC repeats facilitate the recruitment of RAD51
to ssDNA, and also accelerate the displacement of RPA by RAD51,
and facilitate RAD51 filament formation on ssDNA by maintaining
the active ATP-bound form of RAD51 on ssDNA (Roy et al., 2012;
Carreira et al., 2009). In addition to the BRC domains, BRCA2 also
interacts with RAD51 through its C-terminal part, but this region can
only interact with RAD51 in the nucleoprotein filament form and in
a cell cycle dependent fashion (Krejci et al., 2012).
The primary function of BRCA2 is to promote HR repair (Roy et al.,
2012). BRCA2 deficient cells are defective in recruiting RAD51 to sites
of DSBs and in repairing DSBs by HR (Yuan et al., 1999). Recently
work has also shown that BRCA2 may also have a second role in
protecting replication forks by preventing degradation of the nascent
strand at stalled replication forks (Schlacher et al., 2011).
Partner and localizer of BRCA2 (PALB2) interacts with the N-termi-
nus of BRCA2 and plays a role in HR by regulating BRCA2 and pos-
sibly affecting RAD51 function (Krejci et al., 2012). Germline muta-
tions in PALB2 in breast and ovarian cancer patients lead to loss of
BRCA2-PALB2 binding and BRCA2 function in HR (Xia et al., 2006).
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In addition both PALB2 and BRCA2 have been shown to influence
cell cycle checkpoints (Menzel et al., 2011).
Further regulators of BRCA2 function include deleted in split hand/
split foot protein 1 (DSS1), which has been shown to facilitate BRCA2
in RAD51-ssDNA filament formation (Krejci et al., 2012). P53 has also
been shown to interact with multiple regions of BRCA2 and suppress
HR (Rajagopalan et al., 2010).
1.2.5.2 BRCA1
BRCA1 interacts with tumour suppressors, DNA repair proteins and
cell cycle regulators has multiple functions that link DNA damage
sensing and DDR effectors. (Roy et al., 2012). BRCA1 contains an
amino-terminal RING domain that has E3 ubiquitin ligase activity
and a BRCA1 C Terminus (BRCT) domain that facilitates phospho-
protein binding. Mutations in the RING and BRCT domain have been
linked to the development of ovarian cancer (Friedman et al., 1994).
BRCA1 is directly involved in HR through a number of interac-
tions. BRCA1 binds to DSBs through its association with abraxas
which in turn binds to ubiquitylated histones at DNA DSBs through
RAP80 (Roy et al., 2012). BRCA1 is involved in end resection of DSBs
through the interaction with CtIP and the MRN complex. BRCA1 also
promotes HR (and inhibits NHEJ) by removing 53BP1 from DSBs
(Bunting et al., 2010). BRCA1 is also required for RAD51 recruitment
to the sites of DSBs through its interactions with PALB2 and BRCA2
(Roy et al., 2012).
BRCA1 has an important role in cell cycle checkpoint activation.
The BRCA1-BRCA1-associated RING domain protein (BARD1) com-
plex is involved in the activation of G1/S, S-phase and the G2/M
checkpoints. The G1/S checkpoint requires phosphorylation of BRCA1
by ATR or ATM, which facilitates phosphorylation of p53 on S15.
P53-S15 phosphorylation is necessary for transcriptional induction of
the CDK inhibitor p21 and G1/S checkpoint activation (Roy et al.,
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2012). The exact mechanism of BRCA1 control of the S and G2/M
checkpoint is less well characterised (Roy et al., 2012). The BRCA1-
BRIP1-DNA topoisomerase 2-binding protein 1 (TOPBP1) complex
appears to be necessary for S phase checkpoint activation in response
to stalled or collapsed replication forks. The G2/M checkpoint control
involves the BRCA1-abraxas–RAP80 complex (Roy et al., 2012). These
roles of BRCA1 in the cell cycle along with HR may account for the
increased severity of genomic instability found in BRCA1 deficient
tumours relative to BRCA2-deficient tumours (Roy et al., 2012).
1.2.6 Negative regulators of HR
There are a number of factors that negatively regulate RAD51 and
consequently HR. Several mammalian helicases including the RecQ
helicase and Proliferating Cell Nuclear Antigen (PCNA)-interacting
factor (PARI) have been shown to dismantle RAD51 nucleofilaments
(Ceccaldi et al., 2016). The polymerase polu has been shown to act
at the presynaptic step as an anti recombinase. These factors have
been shown also to promote error-prone repair pathways (such as
alt-NHEJ and SSA).
Even after RAD51 nucleofilament formation, HR can be modu-
lated at the level of strand exchange (Ceccaldi et al., 2016). D-loop
displacement by specific DNA helicases prevents cross over events
and can inhibit HR (Ceccaldi et al., 2016). After strand exchange,
RAD51 needs to be removed from dsDNA to allow for the down-
stream steps of strand extension, junction resolution and chromatin
assembly. ATM regulates these last steps of HR possibly through
RAD54 activation. The HELQ helicase removes RAD51 from dsDNA
and promotes strand exchange in an ATP-dependent manner (Ward
et al., 2010).
HR is therefore a tightly controlled process and RAD51 is central
to all aspects of the process.
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1.2.7 Repair of DSBs: Pathway choice
There are multiple mechanisms that control DSB pathway choice and
it is an area of ongoing research. HR only functions after DNA repli-
cation in the late S/G2 phase of the cell cycle and therefore the cell
cycle phase plays a crucial role in pathway choice decision (Shibata
and Jeggo, 2014) (summarised in Figure 1.9).
Since three of the DSB pathways require end resection, it is likely
that the control of end resection dictates pathway choice and repair
outcome (Symington and Gautier, 2011). C-NHEJ will repair DSBs
unless end-resection occurs (Kakarougkas and Jeggo, 2014). ATM pro-
motes end resection by recruiting and phosphorylating all members
of the MRN complex, which subsequently leads to ATM-dependent
phosphorylation of other HR components including BRCA1, CtIP,
EXO1 and Bloom syndrome protein (BLM), (Ceccaldi et al., 2016).
MRE11 and CtIP carry out the initial phase of end resection followed
by a more extensive resection mediated by helicases and exonucle-
ases (including DNA2, BLM, CtIP and EXO1). This commits the cells
to HR or SSA (Ceccaldi et al., 2016).
One mechanism underlying the regulation of HR is the control of
resection by cyclin-dependent kinases (CDKs) (Aylon et al., 2004). In
the S/G2 phases of the cell cycle, end resection is stimulated by CDKs
through phosphorylation of multiple substrates. For example, CDK-
phosphorylation of CtIP favours the CtIP-BRCA1 interaction in G2/S
phase and therefore promotes HR. In addition, CDK dependent phos-
phorylation of EXO1 promotes end resection and thus HR (Ceccaldi
et al., 2016). Conversely, impairment of EXO1 phosphorylation atten-
uates resection, cell survival and HR but greatly increases NHEJ upon
DNA damage (Ceccaldi et al., 2016).
The balance between 53BP1 and BRCA1 also modulates end resec-
tion and therefore pathway choice. In the G1 phase of the cell cy-
cle, 53BP1 proteins localise to DSB, inhibit BRCA1 recruitment, block












Figure 1.9: Cell cycle regulation of DNA end resection and DNA repair
pathway choice. The cell cycle controls the competition between
C-NHEJ and HR. Extensive end resection is stimulated in the
S/G2 phase of the cell cycle. This is controlled by CDK activ-
ity which mediates phosphorylation of multiple substrates such
as components of the MRN complex and CtIP. In G1 phase of
the cell cycle, 53BP1 foci localise to DSBs, inhibit BRCA1 recruit-
ment, block DNA end resection and therefore promote C-NHEJ.
In the S and G2 phase of the cell cycle, ATM kinase, which phos-
phorylates members of the MRN complex, BRCA1, CtIP or BLM,
favours the three resection-dependent pathways (HR/SSA/Alt-
NHEJ). Adapted from Ceccaldi et al. (2016)
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end resection and favour C-NHEJ (Panier and Boulton, 2014). Loss-
of-function mutations in factors that control end resection, such as
53BP1, result in reduced C-NHEJ and restored DNA end resection.
This results in HR activity and induces PARP inhibitor resistance in
BRCA1-deficient cells (Bunting et al., 2010).
Although it has been assumed that HR plays the major role in re-
pair of DSBs in G2, recent work has suggested that the situation may
be more complex. Cells lacking NHEJ proteins such as DNA ligase IV,
display a marked G2 phase repair defect and conversely cells defec-
tive in HR only show a subtle G2 repair defect (Shibata et al., 2011).
It has therefore been suggested that NHEJ initially attempts to repair
in G2, but if re-joining is delayed then resection and HR repair occur
(Kakarougkas and Jeggo, 2014). Factors influencing the switch from
NHEJ to HR include the heterochromatic status and the complexity
of DNA damage (Kakarougkas and Jeggo, 2014).
1.2.8 HR defects and cancer
HR has a key role in repair of DNA lesions and preventing inappro-
priate recombination that could otherwise lead to oncogenic trans-
formation. It is therefore not surprising that mutations of the genes
involved in the HR pathway can predispose of a variety of cancers.
Mutations in BRCA1 and 2 increase the risk of ovarian cancer (as dis-
cussed earlier) but also lead to increased risk of breast cancer. BRCA2
mutations also increase the risk of prostate (Edwards et al., 2003) and
pancreatic cancer (Carnevale and Ashworth, 2015).
Mutations of other RAD51 mediators including RAD51C, RAD54B,
RAD51B along with PALB2 have also been shown to increase the risk
of breast, pancreatic and ovarian cancer (reviewed in Krejci et al.
(2012)). Although mutations in RAD51 have not been linked to any
disease, many cancer cell lines show evidence of elevated levels of
RAD51 (Raderschall et al., 2002). It is postulated that high levels
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of RAD51 may lead to uncontrolled HR and destabilisation of the
genome in the early events in carcinogenesis (Richardson et al., 2004).
An alternative view is that high levels of RAD51 maintain the genome
during tumourigenesis (Krejci et al., 2012; Schild and Wiese, 2010).
1.2.9 Therapeutic targeting of the DDR
Knowledge of the DDR in tumours is influencing treatment choice.
Deregulation of the pathways involved not only affects responses to
DNA-damaging chemotherapy but can be a targeted for therapeutic
intervention (Curtin, 2012). Loss of elements of one DNA repair path-
way may be compensated for by increased activity of other elements
or pathways. The resulting upregulation of these other DNA repair
pathways can cause resistance to DNA damage chemotherapy or ra-
diotherapy (Curtin, 2012). Specific inhibitors of these up-regulated
pathways have the potential to sensitize cells to these therapies. In
addition, tumour cells may be ‘addicted’ to compensatory DDR path-
ways for survival. Exploiting this dependence and using the concept
of synthetic lethality has resulted in the development of DNA repair
inhibitors (Curtin, 2012). These principles have been applied to the
HR pathway in ovarian cancer.
1.2.10 Targeting the HR pathway in ovarian cancer
1.2.10.1 Response to chemotherapy
Tumours with HR defects are sensitive to cross-linking agents such
as carboplatin and cisplatin (Clauson et al., 2013). This is highlighted
in ovarian cancer where large studies have shown that BRCA-mutated
ovarian cancer demonstrate superior response to platinum chemother-
apy and longer platinum-free durations than wild-type BRCA ovar-
ian cancer patients, with BRCA2 mutation carriers having the best
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prognosis (Tan and Kaye, 2015; Yang et al., 2011; Bolton et al., 2012).
Post-treatment secondary mutations that result in gain of function
of BRCA1 and BRCA2 restoring the function of HR are associated
with platinum resistance (Sakai et al., 2008; Swisher et al., 2008). It is,
however, unclear which functions of BRCA1/2 proteins are required
for therapy resistance and which BRCA1/2 genotypes are more likely
to undergo reversion mutations. It is also unclear whether certain
BRCA1/2 mutations result in differing sensitivities to platinum.
Although the improved response to platinum agents in BRCA-mu-
tated ovarian cancer has been well documented, there are only limited
clinical data as to whether BRCA-mutated cancers also have improved
response to other chemotherapy agents. Two retrospective studies on
patient outcomes following the topoisomerase IIa inhibitor, pegylated
liposomal doxorubicin (PLD), have demonstrated improved response
rates and PFS when compared with patients with non-BRCA mutated
cancers (Adams et al., 2011; Safra et al., 2011). Treatment of BRCA-
mutated cancers with topotecan, a topoisomerase I inhibitor, how-
ever, showed no differences in PFS compared to non BRCA-mutated
cancers (Safra et al., 2011). There is also some data to suggest that pa-
tients with BRCA deficiency have increased sensitivity to other DNA
damaging agents such as mitomycin C (induces DNA cross links)
and melphalan (alkalyating agent that induces inter-and intra-strand
DNA cross links) (Tan and Kaye, 2015). The data on the use of taxanes
(microtubule-interfering drugs) are conflicting. There are a number of
preclinical and clinical studies that suggest that mutations in BRCA1
and 2 may confer resistance to taxanes (Tagliaferri et al., 2009; Tan
et al., 2013). However, benefit has been seen with the use of pacli-
taxel in BRCA-mutated cancers (Tan et al., 2013) and therefore they
continue to have a therapeutic role.
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1.2.10.2 PARP inhibitors
A promising approach for targeting the HR pathway is the exploita-
tion of dysregulated DDR through a synthetic lethal approach. This
is illustrated by the use of poly(ADP)ribose polymerase (PARP) in-
hibitors in HR defective tumours. The best-documented role of the
PARP enzymes is their role in the repair of DNA single strand breaks
(SSB) in the base-excision repair/single strand break repair (BER/
SSBR) pathway. PARP enzymes catalyse the transfer of adenosine
diphosphate (ADP)-ribose moieties from cellular NAD+ forming ADP-
ribose polymers (Dianov and Hubscher, 2013). By inhibiting repair of
SSBs, PARP inhibition results in accumulation of these lesions. The
unrepaired SSBs can be converted to double strand breaks (DSBs) at
replication forks (Boulton et al., 1999). In cells with defective HR path-
ways (for example, BRCA1 and BRCA2 mutant cancers), these DSBs
accumulate and cannot be repaired resulting in cell death (McCabe
et al., 2006). However, PARP inhibition is not toxic in cells with func-
tioning HR pathways (McCabe et al., 2006; Bryant et al., 2005). This is
the concept of synthetic lethality where cell death only occurs when
there is loss of two genes (or pathways) but loss of each gene inde-
pendently does not affect cell survival (Figure 1.10). PARP inhibitors
should therefore be synthetically lethal in patients with cancers that
have defective HR function (Fong et al., 2009), and as discussed ear-
lier, this could be in up to 50% of HGSOCs.
Recent reports have challenged this view of the mechanism of ac-
tion of PARP inhibitors and have proposed alternative mechanisms
of synthetic lethality (reviewed in De Lorenzo et al. (2013)). For ex-
ample, it is now known that PARP inhibitors can be toxic to cells by
trapping PARP1 and 2 at the sites of DNA damage. These trapped
complexes obstruct replication forks, which require the HR pathway
to be resolved (Murai et al., 2012). Several studies also suggest a role
of non-homologous end joining (NHEJ) in PARP inhibitor induced
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Figure 1.10: Synthetic lethality. A: Loss of gene A alone, such a mutation
in the DDR, is compatible with cell survival. B: loss of gene B
alone is compatible with cell survival. C: loss of gene A and
gene B causes cell death.
killing (Patel et al., 2011). An understanding of the contribution of
these different mechanisms to PARP inhibitor sensitivity will help in
determining their use in a clinical setting. Despite the possible incom-
plete understanding of the mechanism of action of PARP inhibitors,
these drugs have showed promising results in clinical trials.
The activity of PARP inhibitors has been assessed in phase I and
II trials in showing PARP inhibitors have shown activity in BRCA
mutated ovarian cancer (Gelmon et al., 2011; Kaye et al., 2012; Le-
dermann et al., 2012; Kaufman et al., 2015a; Domchek et al., 2016).
Activity has also been seen in sporadic BRCA non-mutated cancers
(Gelmon et al., 2011). However, this was associated with platinum
sensitivity suggesting that these patients had defects within the HR
pathway and highlighting the need for a marker for HR function.
Several PARP inhibitors are currently being investigated, the most
studied of which is olaparib. The pivotal phase II study investigated
olaparib maintenance therapy in platinum sensitive recurrent cancer
(study 19) which demonstrated improved PFS compared to placebo
(4.8 months vs 8.4 months for patients treated with olaparib) with the
largest benefit seen in the BRCA mutated groups. (Ledermann et al.,
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2012). A further trial of olaparib given with paclitaxel and carboplatin
followed by a period of olaparib maintance compared to chemother-
apy alone also led to a significant improvement in PFS (12.2 months
in the olaraprib maintainance group compared to 9.6 months in those
given chemotherapy alone) (Oza et al., 2015).
Two other PARP inhibitors, niraparib and rucaparib, have been
shown to have activity in ovarian cancer (Sandhu et al., 2013; Mc-
Neish et al., 2015). Phase III trials maintenance trials (NOVA study
for niraparib and ARIEL3 study of rucaparib) are currently underway
in platinum sensitive disease. Both trials include cohorts of patients
with BRCA mutations and ARIEL3 is stratified by homologous recom-
bination defects determined on tumour biopsies. The results of these
and other trials are awaited.
The optimal timing of the use of PARP inhibitors is debated, in
particular whether PARP inhibitor or bevacizumab should be used at
first relapse (Tan and Kaye, 2015). It is hoped that further clinical trials
will help in answering this question. A further question surrounding
PARP inhibitor use is whether development of resistance to PARP
inhibitors might also confer resistance to other chemotherapy agents
and therefore compromise benefit to subsequent chemotherapy. The
significance of this remains to be determined (Tan and Kaye, 2015).
Knowledge about the molecular basis of ovarian cancer is therefore
beginning to influence treatment options in BRCA-mutated cancer.
There are, however, several important questions that remain. Firstly,
there are other mechanisms that result in HR deficiency in ovarian
cancer and should these HR defective patients be considered as hav-
ing a similar phenotype to BRCA1/2 mutated cancers and therefore be
treated similarly. If this is the case it raises the question of how should
these HR defective cancers be identified. A number of approaches
have been taken to address this problem, including gene expression
profiles (Konstantinopoulos et al., 2010) and the use of a functional
HR assay measuring RAD51 foci that predicts sensitivity to PARP
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inhibitors (Naipal et al., 2014; Mukhopadhyay et al., 2010). In addi-
tion, given that the potential effects of the mechanisms of BRCA1/2
inactivation may influence clinical phenotype, should patients also
be stratified according to their underlying mutation when consider-
ing treatment options?
1.2.10.3 Inhibitors of the HR pathway
The sensitivity of HR defective tumours to chemotherapy provides
the rationale for the development of HR inhibitors. Specific inhibi-
tion of the HR pathway has proved technically difficult. Mirin is an
inhibitor of MRE11 endonuclease function and therefore inhibits HR
function but it is non-specific, also inhibiting NHEJ. RAD51 inhibitors
are in development (Curtin, 2012). The HR pathway has also been tar-
geted by ATM inhibitors. Studies have shown that the ATM inhibitor,
KU55933, sensitizes cells to IR and topoisomerase inhibitors (Hickson
et al., 2004). Recently ATR inhibitors have been identified and have
been shown to sensitize cells to a variety of DNA damaging agent
(Charrier et al., 2011; Reaper et al., 2011).
When developing new treatments for ovarian cancer it is therefore
important to consider the DDR. Manipulation of the DDR may of-
fer ways of improving treatment efficacy and also may be important
in patient stratification and selecting patients who would most ben-
efit from the therapy. There is a significant unmet clinical need for
treatments targeting HR competent tumours. These patients, espe-
cially those with platinum resistant disease, have a poor prognosis
and have limited therapeutic options (Bolton et al., 2012). This thesis
addresses the role of the DDR in the efficacy of oncolytic viruses, a
novel therapy for ovarian cancer.
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1.3 oncolytic viruses
Oncolytic viruses represent a novel class of anti-cancer agent for the
treatment of cancer. Interest in the use of viruses as possible agents
for tumour destruction has been present for over a hundred years.
The idea was derived from reports that following an infectious dis-
ease, patients with cancer (often leukaemia) occasionally had periods
of clinical remission (reviewed in Kelly and Russell (2007)). The use
of viruses to treat cancer then began to take hold in the 1950s when
tissue culture systems were developed (Russell et al., 2012). Cancer
patients at this time were treated with impure oncolytic virus prepa-
rations and, in some cases, patients were even inoculated with viruses
from previous patients (Larson et al., 2015). The majority of viruses
were usually destroyed by the host immune system but sometimes
the infection took hold and the tumours responded. This usually
occurred in immunocompromised individuals, although frequently
they subsequently became unwell when the infection spread to nor-
mal tissues (Kelly and Russell, 2007; Russell et al., 2012). Unfortu-
nately, enthusiasm for viral gene therapy waned as any anti-tumour
effects were short lived and new chemotherapy agents were being
developed.
More recently, however, as knowledge of viral biology and mecha-
nisms of oncogenesis has accumulated, there has been a development
of more rationally designed, tumour specific viruses that have entered
clinical trials. Several different oncolytic viruses, from 10 different
virus families, have been identified to date and entered clinical trials
including herpesvirus, reovirus, polio virus, parvovirus and vaccinia
along with adenovirus (Russell et al., 2012). Different viruses have
differing structures, lifecycles, tropisms and toxicities and each may
possess several advantages as well as disadvantages for use as an on-
colytic viral therapy. In addition, to enhance efficacy, these oncolytic
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viruses may be ‘armed’ with additional therapeutic genes that can
drive systemic anti-tumour immune responses. (Russell et al., 2012).
This thesis focuses on replication-selective Adenovirus based on
human serotype 5 of group C. Adenoviruses replicate very efficiently
in human cells and are well characterised. In addition, human aden-
oviruses are associated with relatively mild respiratory illnesses, their
genomes can be easily manipulated and they can be purified to a high
titre, making them an attractive vector for oncolytic viral therapy (Ale-
many et al., 2000).
1.3.1 The development of oncolytic adenoviral vectors
Early adenoviral vectors were designed to deliver transgenes, and
thus had complete E1 deletions in order to prevent replication (Robert-
Guroff, 2007). The transgenes inserted into the deleted region in-
cluded tumour suppressor genes, antisense oligonucleotides to block
oncogene expression, prodrug activating genes and antiangiogenic
factors. Although preclinical results were encouraging, therapeutic
benefit in clinical trials was minimal and thought to be due to the in-
ability of these non-replicating viruses to access every malignant cell
(Robert-Guroff, 2007).
More recent adenoviral gene therapy have used replicating viruses.
This harnesses the property of adenovirus to infect cells, multiply
within them, cause death and infect neighbouring cells. One method
to achieve tumour selectivity uses the principal that viral replication
and oncogenesis both require inactivation of the same proteins. This
has resulted in the development of viral mutants deleted in parts
of their genome that are not required for replication within tumour
cells with specific genetic defects. (Wong et al., 2010). These viruses
should not replicate in normal cells that do not have the tumour asso-
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Figure 1.11: Tumour specific killing by oncolytic adenovirus. Replication-
competent oncolytic adenoviruses specifically replicate within,
and lyse tumour cells releasing mature virions that can then
spread throughout a tumor. Image taken from Choi and Yun
(2013).




Human adenoviruses comprise a large family of 51 different serotypes
originally classified on the basis of their ability to be neutralised by
specific animal antisera. These can be further subdivided into six sub-
groups (A-F) based on their sequence homology and ability to ag-
glutinate red blood cells (Flint et al., 2004). The adenovirus genome
is contained within a capsid that has a characteristic icosahedral ap-
pearance. The capsid is comprised of three major proteins: hexon (II),
penton base (III), and a knobbed fibre (IV) along with a number of
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penton bases and extended fibres on the 12 fivefold apices.
Other so-called ‘minor’ components: IIIa, VI, VIII and IX
are also associated with the capsid (Vellinga et al., 2005).
There are six other structural components situated in the
virus core, five are associated with the double stranded DNA
genome [V, VII, Mu, IVa2 and the terminal protein (TP)],
the remaining component is the 23K virion protease which
plays a vital role in the assembly of the virion (see below).
Most of the detailed structural analyses have been carried
out using human serotypes, although a recent study of
canine adenovirus 2 has indicated that, while the basic
features are retained, the capsid of the canine virus is much
smoother and the fibre is more complex (Schoehn et al.,
2008). A recent structural analysis of an atadenovirus by
cryo-electron microscopy has indicated that there are some
differences from mastadenoviruses in capsid topology, but
the main characteristic adenovirus morphology is retained
(Pantelic et al., 2008). A more detailed description of these
structural proteins is given below as a forerunner for
consideration of their role in infection.
Hexon
The hexon capsomere is a pseudo-hexagonal trimer situated
on the 20 facets of the icosahedral capsid created by
threefold repetition of two b-barrels at the base of each
hexon molecule. The pseudo-hexagonal base allows close
alignment within the facets and there are three tower
regions that are presented to the exterior. There are 240
hexons in the capsid. Because of their different environ-
ments there are four kinds of hexon – designated H1, H2,
H3 and H4 (Burnett, 1985). Sixty H1 hexons associate
with the pentons at the 12 apices and are also termed
peripentonal hexons (Fig. 2a). The remaining hexons are
designated ‘groups of nine’ or GONs on the 20 faces of the
icosahedron and are further defined as H2 (on the twofold
axes), H3 (on the threefold axes) and the remaining ones as
H4 (Fig. 2a).
The size of the hexon molecule can vary with the serotype –
the largest described is from Ad2 and comprises 967 aa. Up
to nine hypervariable regions, determined by comparative
sequence analysis of serotypes, are present in each hexon
molecule. These are situated at the top of the molecule and
six can be resolved as a-helical rods in the 6 Å structure
(Saban et al., 2006). These relate to the type-specific
antigens of the hexon and at least one of them constitutes
the major part of the virus-neutralizing activity (Crawford-
Miksza & Schnurr, 1996; Pichla-Gollon et al., 2006; Roberts
et al., 2006; Rux et al., 2003; Takeuchi et al., 1999) (Fig. 3a).
The base of each hexon molecule has one loop and two
eight-stranded ‘jelly rolls’ which provide the means for
interacting with neighbouring capsomeres, probably via
charged residues in interacting loops. There must be
considerable flexibility in these interactions given the
differing environments of the H1 to H4 hexons. The N
and C termini lie beneath the base and do not seem to take
part in interactions with other hexons.
Penton
The penton capsomere is a covalent complex of two
proteins – the homopentameric penton base and the
homotrimeric fibre protein protruding from the 12 vertices
of the icosahedron (Fig. 1). The fibre has three distinct
regions: tail, shaft and knob.
The penton base monomer in Ad2 comprises 471 aa and
its pentameric structure (Fig. 3b) has been determined to
3.3 Å (0.33 nm; Zubieta et al., 2005) and consists of two
domains: the lower one with the typical jelly roll of two
four-stranded anti-parallel b-sheets forming a b-barrel, and
the upper one with irregular folds formed by two insertions
arising from the lower jelly roll strands. The first insertion
contains the RGD loop (discussed later) and the other a
loop which is variable between serotypes. Pentamerization
can occur, providing stability by the burying of hydro-
phobic surfaces. A pore occurs along the fivefold axis of the
pentamer and the top narrow part is predominantly
hydrophobic. The b-barrels from the surrounding peri-
Fig. 1. Structure of adenovirus. A schematic depiction of the
structure based on cryo-electron microscopy and crystallography.
The locations of the capsid and minor components are reasonably
well defined and are not to scale. The disposition of the core proteins
and the virus DNA is largely conjectural. The symbols for IIIa and VIII
are based on the structures defined by Saban et al. (2006).
W. C. Russell
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Figure 1.12: Structure of adenovirus. A schematic depiction of the structure
based on electron microscopy and crystallography. Taken from
Russell (2009)
other minor proteins (VI, VII, IX, IIIa and IVa2). There are 240 hexons
on the faces and edges of the capsid with 12 pentons on the apices.
Extended fibres aris from each pe ton base located at the 12 vertices
of the capsid. E ch fibre terminates at a distal kn b that binds the
virus to the cell surface receptor on the host cell (Russell, 2000, 2009)
(Figure 1.12).
1.4.2 Adenoviral DNA
Linear, double-stranded adenoviral DNA is 35-36 Kb long and is
tightly wrapped around viral proteins V and VII in the adenoviral
core. Terminal proteins (TP) are covalently attached to the 5’ ends
and the adenoviral genome is flanked by inverted terminal repeats
(ITR), which contain sequences that serve as the origin of replication.
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Coxsackie-Adenovirus Receptor (CAR) for all groups 
beside B, which uses CD46 [7, 8]. Internalization, 
via clathrin-dependent endocytosis, is mediated by a 
secondary interaction of the RGD motif on the penton base 
with αv integrins on the cell surface [9]. While endosomal 
escape is known to be dependent on the acidity of the 
microenvironment, the molecular steps that govern viral 
escape remain to be elucidated. Once in the cytoplasm, 
virion trafficking is guided by dynein along microtubules, 
which docks to the nuclear pore complex where viral 
DNA enters the nucleus [10, 11]. All of the steps including 
viral attachment and intracellular escape, as well as DNA 
transcription, take only 10 minutes [12]. 
the InterleukIn-1/InflAmmAtory 
PAthwAy
The complexity of the innate immune response is 
matched only by the diversity of experimental designs 
that are used to investigate it. Different routes of delivery, 
conditions, time points and targets make this complicated 
system even more difficult to understand, which includes 
high levels of redundancy and cell-type specificity [12, 
13]. Thus, understanding how all of these seemingly 
different responses and measurable variables are related 
is required.
In this review, we offer a more structured approach 
to understanding the innate immune response as a result 
of adenoviral entry by dissecting the major pathways 
involved. Of the many independent receptors in innate 
immunity, two stand out: the interferon α receptor (IFN-
AR) and interleukin-1 receptor (IL-1R) The downstream 
effectors of IFN-AR and IL-1R diverge to block viral 
replication using different signal transduction pathways. 
While the IFN response acts in an autocrine/paracrine 
fashion to contain and destroy the virus from within the 
cell, the interleukin pathway recruits a pro-inflammatory 
infiltrate to eliminate the pathogen. 
The quick nature of the inflammatory responses 
suggests that an early recognition of the virus activates 
an immature form of IL-1 which resides in the cytosol. 
But the maximum inflammatory response relies on a fully-
functioning IL-1R [12, 14] and a number of protein kinases 
induced upon infection (Figure 1). These protein kinases, 
JNK, ERK1/2 and p38 MAPK, are also downstream 
effectors of non-specific stress response pathways [15]. 
The earliest sensor to be activated upon viral 
infection appears to be triggered by the adenoviral fiber 
binding with the CAR [16]. While the downstream 
signaling of CAR has yet to be elucidated, recent work 
has shown that CAR promotes the clustering of junctional 
adhesion molecule-like protein (JAML) and activation of 
phosphoinositide 3-kinase (P13K) [17]. Irrespective of 
the possible effectors involved [18], adenovirus binding 
to CAR induces downstream signaling of ERK1/2, JNK 
and MAPK, followed by NF-κB activation (Figure 2) and 
the up-regulation of chemokines. 
Current dogma supports the hypothesis that the 
earliest event inducing innate immunity is the interaction 
of the RGD motif with αv integrins, especially B3 [12]. 
Furthermore, the downstream signaling of αv integrins 
induces NF-κB activation and subsequently increases 
IL-1 expression, which has been reviewed elsewhere 
[19]. Importantly, the intensity of this response depends 
on endosomal viral escape and the presence of foreign 
figure 1: Adenovirus structure and transcription regions. 
A) Adenovirus capsid is composed of three major and four minor 
proteins. The three major proteins plus protein IX form the outer 
surface. Reproduced with permission [5] B) The double stranded 
DNA adenoviral linear genome is covalently linked at its ends to 
terminal proteins via inverted terminal repeats (ITRs). The first viral 
transcription unit to be expressed is E1A that activates the other early 
adenovirus transcripts (E1B, E2, E3 and E4). Late gene transcription 
(L1-L5) is activated after the onset of DNA replication and is under 




Fig. 1.2 Schematic diagram of human adenoviral genome  
Orange arrows represent early and delayed early genes and blue arrows represent late genes. MLP is 











1.3 S phase induction (E1A)                              
Once inside the cell, the immediate priority for adenoviruses is to promote 
replication of their DNA. Only host cell proteins are needed for E1A expression 
(Evans, 2002) and therefore it is the first adenoviral protein to be expressed after 
viral DNA has been transported to the nucleus along host cell microtubules 
(Nemerow, 2002). E1A contains three regions, CR1, CR2 and CR3, that are 
conserved across all adenoviral serotypes (Gallimore and Turnell, 2001). Alternative 
splicing of the E1A RNA transcript results in the production of two mRNAs, 13S and 
12S (Evans, 2002; Gallimore and Turnell, 2001). The 13S gene product contains 289 
amino acids, whilst that of the 12S mRNA contains only 243. The 12S and 13S 
proteins share CR1 and CR2, whilst CR3 is encoded in the additional capacity of 13S 
mRNA (fig. 1.6). It is predominantly through these three domains that E1A binds to 
cellular proteins, including retinoblastoma protein (pRb), most of which regulate 
transcription (Evans, 2002; Shenk, 2001).  
 
Retinoblastoma protein is a tumour suppressor protein and the first identified 
member of a family of rela ed protein  that includes p107 and p130. These possess 
pocket domains that are essential for their common role in regulating cell transition 
into S phase (Felsani et al., 2006). Un- or hypo-phosphorylated pRb binds to and 
inhibits the E2F family of transcription factors (Shenk, 2001) (fig.1.3). In quiescent 
cells, cyclin E and its dependent kinase, Cdk2 are strongly suppressed by the Cdk 
inhibitors, p27Kip1 and p21cip1 (Sherr and McCormick, 2002). During the G1 phase of 





















Figure 1.13: Adenoviral DNA. The double stranded DNA adenoviral linear
genome is covalently linked at its ends to terminal proteins via
inverted terminal repeats (ITRs). The first viral transcription
unit to be expressed is E1A that activates the other early aden-
ovirus transcripts (E1B, E2, E3 and E4). Late gene transcription
(L1-L5) is activated after the onset of DNA replication and is un-
der the control of major late promoter (MLP). Arrows indicate
the direction of transcription.
The genes are grouped into transcriptional units: five early transcrip-
tion units amed E1A, E1B, E2, E3 a d E4, two delayed arly units,
IX and IVa2, and the major late transcription unit that produces five
groups of mRNA designated L1 to L5 (Shenk, 2001) (Figure 1.13).
All of these units are transcribed by cellular RNA polymerase II, the
early regions are transcribed before the late ones (Flint et al., 2004).
Each region is transcrib d to yield multipl mRNAs through the use
of alternative splicing and diff rential polyadenylation. There are also
two viral-associated (VA) RNAs, which play a role in regulating trans-
lation, transcribed from a polymerase III promoter (Thimmappaya
et al., 1982). Tr scription occurs fr b th the leftwa d a d right-
ward stand of the adenoviral chromosome (Flint et al., 2004).
With the exception of E4 region, transcription nits encode proteins
with similar functions. The early regions are involved with viral repli-
cation and late regions encode viral structural proteins such as hexon
and penton bases (McConnell and Imperiale, 2004). In addition to
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promoting the expression of key viral and cellular genes, early genes
also suppress the ability of the host cell to mount a viral response.
For example, early viral genes block host protein synthesis, inhibit
apoptosis, inhibit the DNA damage repair response and the immune
response. These effects facilitate the ultimate aim of successful repli-
cation and virion production (Weitzman and Ornelles, 2005) and is
discussed in more detail below. This interaction between the virus
and host is important when considering the development of an on-
colytic virus.
1.4.3 Adenoviral life cycle
The adenovirus infectious cycle can be divided into two phases. The
first ‘early’ phase consists of the entry of the virus into the host cell
and the passage of the viral genome to the nucleus followed by the
selective transcription and translation of the early genes (E1-E4). This
phase can take around 6-8 hours. The late phase leads to the assembly
within the nucleus of structural proteins and the maturation of the
infectious virus and takes around 4-6 hours (Russell, 2000).
1.4.4 Early phase: cell entry
The capsid fibre is the first component to interact with the host. Ade-
noviruses from groups A, C, D, E and F bind to host cells via an
interaction between the fibre and cell surface coxsackie adenovirus
receptors (CAR) (Bergelson et al., 1997). CAR is widely expressed on
human tissues, it is a member of the immunoglobulin family and
is involved in vivo in the formation of tight junctions (Coyne and
Bergelson, 2005). Most of the species B viruses bind to a ubiquitously
expressed, CD46. Members of the group D viruses can use the sialic
acid receptor (Russell, 2000).
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Binding to these initial receptors occurs along with the attachment
of the five arginine-glycine-aspartate (RGD) motifs on each penton
base to cell surface avb3 and avb5 integrins. This results in viral in-
ternalisation within clathrin-coated vesicles into endosomes for fur-
ther processing. This interaction with integrins also induces a variety
of cellular responses, for example activation of PI3K and Rho GT-
Pases (Li et al., 1998). These responses are important in altering the
cytoskeleton of the cell to facilitate internalisation. Following perme-
abilisation of the vesicles, the virus is released into the cytoplasm
where the viral capsid is disrupted (Stewart et al., 1997). The viral
genome, associated with core protein VII, is then transported via cel-
lular dynein and microtubules to the nuclear pore whereby the aden-
ovirus particle disassembles (Leopold et al., 2000). Viral DNA is then
released which can enter the nucleus via the nuclear pore (Trotman
et al., 2001; Kelkar et al., 2004). Viral DNA can be detected within the
nucleus between 1 and 2 hours after infection (Matthews and Russell,
1998). Once inside the nucleus the genome is targeted to the nuclear
matrix (Russell, 2000).
1.4.4.1 Oncolytic adenovirus and enhancing entry into host cells
There is evidence that CAR expression on malignant cells is variable.
Low CAR expression could therefore affect the efficient infection of
tumours by group C adenoviral vectors (Akiyama et al., 2004). To ad-
dress this problem, modifications have been made to the adenoviral
fibre protein. D24-RGD, has a RGD peptide motif inserted into the
fibre, which allows the virus to bind to cell surface integrins rather
than just CAR(Jiang et al., 2009). In models of glioma, this mutant
showed imporved infectivity and cytotoxicity when compared with
D24 in both low and high CAR-expressing cell lines (Jiang et al., 2009,
2003). A phase I clinical trial of D24-RGD in patients with recurrent
ovarian cancer demonstrated overall safety and potential anti-tumour
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efficacy with stable disease seen in 71% of patients after 1 month
(Kimball et al., 2010).
A further approach to increase infection involves creating an ade-
novirus containing a chimeric fiber with the knob domain of Ad3 in
the Ad5 capsid (Kanerva et al., 2002). This virus was found to infect
ovarian cancer cell lines more efficiently than Ad5. In addition, in as-
citic fluid samples from four patients with ovarian cancer, infection
by Ad5/3 was greater than that of Ad5 (Kanerva et al., 2002).
1.4.5 Early phase: S phase induction
Once inside the cell, the priority for adenoviruses is to promote repli-
cation of their DNA. The proteins encoded by early region 1A (E1A)
of human adenovirus type 5 (Ad5) activate viral transcription and
reprogram cellular gene expression in the infected cell which pro-
vides the optimal environment for viral replication (Flint and Shenk,
1989). E1A is the first adenoviral protein to be expressed after viral
DNA has been transported to the nucleus (Flint and Shenk, 1997).
Only host proteins are required for E1A expression. It is transcribed
by cellular RNA polymerase, and following alternative splicing and
export of the mRNAs to the cytoplasm, it is synthesised by cellu-
lar translation machinery. Ad5 E1A is expressed as two alternately
spliced isoforms, referred to as 12S and 13S, and shares four highly
conserved regions (CR1-CR4) with E1A proteins from other serotypes.
These proteins, which are extensively modified by phosphorylation,
are imported into the nucleus where they regulate transcription of
both cellular and viral genes.
E1A proteins bind to cellular proteins, most of which regulate host
cellular transcription (Flint and Shenk, 1997). One such protein is the
retinoblastoma protein (pRb). The tumour suppressor pRb is part of
the retinoblastoma family of proteins, which includes p107 and p130,
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E1A overrides cell cycle control
Figure 1.14: Cell cycle control and E1A. In G0-G1 phase of the cell cycle, hy-
pophosphorylated RB protein (pRB) forms a complex with the
transcription factors of the E2F family (E2F), which prevents
their ability to activate transcription. Phosphorylation of pRB
is controlled by cell cycle dependent cyclin/cyclin dependent
kinases (CDKs) and releases pRB from E2F resulting in S phase
progression. Infection by adenovirus overrides this control by
binding to pRB releasing E2F. Adapted from Frisch and Mym-
ryk (2002).
cent cells, un- or hypophosphorylated pRb binds to and inhibits the
E2F family of transcription factors, holding the cell in G1. In early
stages of adenoviral infection CR2 binds with high affinity to the
pRB pocket domain and subsequently, E1A CR1 displaces E2F from
pRB by binding with pRB at the E2F binding site. This overrides the
normal phosphorylation dependent regulation of the pRB-E2F tran-
scription by cyclin dependent kinases (CDKs) (Figure 1.14).
The release of E2F also transactivates genes (E1B, E2, E3 and E4)
necessary for DNA replication and S-phase entry. This stimulates the
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transcription of cellular genes that encode enzymes that make sub-
strates for DNA synthesis, therefore driving viral DNA replication.
The virus therefore bypasses the normal control of the cell cycle, facil-
itating preferential replication of the viral genome (Flint and Shenk,
1997).
In addition to RB, E1A interacts with an impressive collection of cel-
lular proteins. Figure 1.15 shows some of the cellular proteins bound
to the conserved regions of E1A (Frisch and Mymryk, 2002). Many
of these cellular proteins are critical regulators of gene expression,
cell signalling and cell cycling, and by altering their activity, the ade-
novirus prepares the host cell for maximal production of viral pro-
genies (Berk, 2005). For example, E1A CR3 activates transcription by
interacting with the MED23 subunit of the Mediator of transcription
complex (Boyer et al., 1999b). This stimulates pre-initation complex
(PIC) assembly (Cantin et al., 2003) and may also increase the rate
at which PICs initiate transcription. This results in an increase in the
rate of re-initiation at early viral promoters. CR1 binds to the cyclin
dependent kinase (CDK) inhibitors p21 (Chattopadhyay et al., 2001)
and p27 (Nomura et al., 1998), which prevents them from binding
and inhibiting CDK-cyclin complexes, and thus promotes cell cycling.
CR1 also influences transcription by binding several cellular protein
complexes involved in chromatin structure, including p300 (Barbeau
et al., 1992) and CBP (CREB-binding protein) (Arany et al., 1995) The
CR4 region of E1A also binds and inactivates the transcription co
repressor, CtIP (Frisch and Mymryk, 2002; Bruton et al., 2007).
1.4.5.1 E1A deletions and Oncolytic adenovirus: dl922-947
Based on the principle that both viral replication and oncogenesis
proceed due to inactivation of the same regulatory proteins, adenovi-
ral mutants have been developed targeting regions of the adenovi-
ral genome that are dispensable for replication in tumour cells. This
project focuses on the adenoviral mutant, dl922-947. dl922-947 has a
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Figure 1.15: E1A regions bind to a variety of cellular proteins to manipulate
cell signalling, cell cycling and gene expression to prepare the
host cell for the production of virus. Adapted from Berk (2005).
24 base pair deletion in the early region 1A (E1A) CR2 region between
amino acids 122 and 129 (Figure 1.16). As discussed, in wild type ade-
novirus, the CR2 region binds to retinoblastoma protein, dissociating
it from E2F and inducing S phase induction. dl922-947 should there-
fore not induce S phase induction and subsequent viral replication
in normal cells. However, the pRb pathway is disrupted in the major-
ity of cancers (Sherr and McCormick, 2002), including ovarian cancer
(D’Andrilli et al., 2004) therefore dl922-947 should replicate selectively
in pRb-deregulated malignant cells.
dl922-947 has shown to have activity in both ovarian (Lockley et al.,
2006) and non ovarian cell lines (Heise et al., 2000). It has shown
efficacy that exceeded that of wild-type adenovirus (Ad5 WT) and
ONYX-015. It has also shown activity when given by intraperitoneal
(IP) injection in a mouse model of ovarian cancer (Lockley et al., 2006).
In contrast, in growth arrested normal cells dl922-947 was signifi-
cantly less toxic than Ad5-WT (Heise et al., 2000). A similar aden-
ovirus, D24, with the same E1A deletion as dl922-947, has also been




Fig. 1.6 Diagram of deletion in dl922-947                            
 Numbers represent amino acids. 
 
 










The potency of dl922-947 in cancer cell lines was found to be greater than that of 
Ad5 WT and dl1520 (Heise et al., 2000). In contrast, dl922-947 was less efficient 
than Ad5 WT at inducing S phase in growth-arrested MVEC and SAEC and this 
correlated with a greatly reduced expression of dl922-947 viral hexon protein 
compared to Ad5 WT. dl922-947 replicated approximately 20 to 100 times less 
efficiently than Ad5 WT in growth-arrested MVEC and SAEC respectively. 
Although replication of dl922-947 did increase when these cells were actively 
proliferating, it remained significantly lower than in cancer cell lines. That 
replication of dl922-947 was more efficient than Ad5 WT in cancer cells such as 
C33A and HLaC was reflected in its ability to lyse these and other cancer cell lines 
10 to 1000 times more effectively than dl1520 or dl1101 and 2-8 times more 
effectively than Ad5 WT. The in vivo potency of dl922-947 was also promising 
following both IT and IV injection. In both cases, the survival advantage with dl922-
947 was comparable to that with Ad5 WT, both viruses increasing median survival 
and complete response rates compared to dl1520. When mice bearing SC MDA-MB-
231 xenografts with lung and lymph node metastases were treated with IV dl922-
947, none of the mice had evidence of metastases at the time of sacrifice. This 
compared to 57% and 37% in those treated with dl1520 and Ad5 WT respectively 
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Figure 1.16: The adenoviral mutant, dl922-947. dl922-947 has a 24 base pair
deletion in the early region 1A (E1A) CR2 region between
amino acids 122 and 129. The diagram represents the two Ad5
E1A isoforms (12S and 13S) showing the location of the dele-
tion.
phase, replicating in and lysing several glioma cell lines and shows
activity in vivo in a mouse model (Fueyo et al., 2000).
1.4.6 Viral replication
Following S phase induction, preferential replication of the adenovi-
ral genome occurs. Adenovirus replicates very efficiently in human
cells, a property that makes it an attractive and frequently used vector
for gene therapy. Up to 106 new DNA molecules can be synthesised
within 48 hours after infection. This efficiency is achieved through a
mechanism that requires three viral proteins and at least three cellu-
lar proteins (De Jong and Van der Vliet, 1999). The E2 region encodes
proteins necessary for replication of the viral genome. These are the
pre-terminal protein, pTP, the 72-kDa single-stranded DNA-binding
protein, DBP, and DNA polymerase (pol) (de Jong et al., 2003). Cel-
lular proteins are, however, needed for efficient replication. These in-
clude nuclear factors (NF) I, NFII (a topoisomerase) and Oct-1. Ade-
noviral DNA replication is initiated by a protein priming mechanism
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involving the viral pTP, which is covalently attached to the 5’ end of
the genomic DNA, together with NF1 and Oct-1. Viral DNA is syn-
thesised by the E2b DNA polymerase (De Jong and Van der Vliet,
1999). DBP is required for viral DNA replication and also regulates
transcription and translation of viral genes during the late stages of
infection (Kruijer et al., 1983).
1.4.7 Inhibition of apoptosis by adenovirus
The expression of E1A alone results in short lived proliferation prior
to cell death by apoptosis (Rao et al., 1992). E1A causes stabilisation
of p53 (Lowe and Ruley, 1993) due to a variety of mechanisms (Gal-
limore and Turnell, 2001) including the inhibition of MDM2 (a p53
inhibitor) and proteosome modification by E1A CR1 (Zhang et al.,
2004). The response to stabilisation of p53 as a result of E1A includes
cell cycle arrest in G1 through activation of the CDK inhibitor, p21
or cell death via the intrinsic apoptotic pathway (Berk, 2005). p53 re-
sults in apoptosis by a complex series of mechanisms including acti-
vating cellular proapototic genes (such as BAX and BAK) (Berk, 2005).
BAX is also activated by the release of its binding partner MCL-1 (Cu-
conati et al., 2003). BAK and BAX cooperate to form pores in the outer
mitochondrial membrane. This causes the release of the proapototic
proteins, cytochrome C and Smac/DIABLO. This initiates apoptosis
through caspases and blocks the inhibitor of apoptosis proteins (IAPs)
(White, 2001). The viral genome must, therefore, prevent this p53 sta-
bilisation to inhibit apoptosis function to keep the cell alive for as
long as possible in order to allow maximal viral replication (White,
2001). This is achieved through E1B-19K and E1B-55K, the two main
proteins encoded by E1B (Berk, 2005) along with the E4 region prod-
uct E4orf6 (Querido et al., 2001; Ben-Israel and Kleinberger, 2002).
The apoptotic pathway is blocked in wild-type virus infected cells
by the binding of E1B-19K to both BAX and BAK, preventing them
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from co-oligomerising and forming pores in the outer mitochondrial
membrane (Cuconati et al., 2003). In adenoviral infected cells, E1B
55K is found in a complex with E4orf6 (Sarnow et al., 1984). In in-
fected cells, this complex is assembled with several cellular proteins
into ubiquitin ligase complex with elongins B and C, cullin5 (Cul5)
and RING-box 1 (Rbx-1) (Berk, 2005). P53 along with the MRN com-
plex (discussed in more detail below), are the two substrates for this
complex targeting these proteins for proteosomal degradation (Berk,
2005). It is interesting to note that in the case of Ad12, cullin 2 (Cul2)
rather than Cul5 is recruited to the E3 ligase (Blackford et al., 2008;
Forrester et al., 2011). The reason for these differences between aden-
oviral serotypes has not yet been determined.
1.4.7.1 E1B deleted oncolytic adenovirus
The first replication competent oncolytic virus to enter clinical tri-
als was ONYX-015 (dl1520). ONYX-015 was generated by deletion
of the viral E1B 55K gene, which results in a complete lack of E1B
55K expression (Bischoff et al., 1996). As discussed above, the E1B re-
gion of the viral genome has crucial p53 inhibitory functions. ONYX-
015 should therefore not be able to prevent p53-induced apoptosis of
normal cells, resulting in cell death of infected cells prior to comple-
tion of the viral replication cycle. Since over 50% of human cancers
have abnormalities of the p53 pathway (Sherr and McCormick, 2002),
E1B-55K should not be required for viral replication in many malig-
nant cells. This deletion should allow ONYX-015 to selectively kill
p53 deficient cancer cells without damaging normal cells (Bischoff
et al., 1996). However, results from clinical trials were disappointing:
although some tumour selection was seen, durable responses were
rare. In addition ONYX-015 was also shown to replicate in some p53
wild-type tumour cells (O’Shea et al., 2004). It is now known that E1B
55K has functions that are essential to viral replication, in particular
promoting export of late adenoviral mRNA in normal cells (O’Shea
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et al., 2004). The tumour selectivity is thought to be due to the expres-
sion of Y-Box Binding Factor-1 (YB1) which is expressed on tumour
cells but not on normal cells (O’Shea et al., 2004). YB1 substitutes for
the mRNA export function of E1B-55K only in tumours (but not all
tumours are positive for YB1). This initial incomplete understanding
of the virus may explain its lack of efficacy (Larson et al., 2015).
Despite this, phase I and II clinical studies showed that the toxicity
profile of ONYX 015 was promising and dose limiting toxicity was
rarely reached (even at the highest dose of 3x1011 pfu) (Kirn, 2001).
The most common side effects were short-lived ’flu’-like symptoms
(Larson et al., 2015). An oncolytic virus virtually identical to ONYX-
015 called H101 has been assessed in a phase III trial in 160 patients
with advanced head and neck squamous cancer. The patients were
randomised to chemotherapy with or without H101. Patients treated
with the virus with 5-FU/cisplatin had a 78.8% response rate, com-
pared to 39.6% in the chemotherapy alone group. Based on these re-
sults, H101 has been approved in China for treatment of head and
neck squamous cell cancer (Lu et al., 2004).
1.4.8 Adenoviruses and the immune response
Following adenoviral infection, rapid immune responses are induced
to protect the host from further infection. In general, this immune re-
sponse represents a major challenge when using adenoviral vectors
(Hendrickx et al., 2014) as it could result in both clearance of the virus
as well as inducing toxicity. However, this inflammatory response
may also increase the therapeutic potential of oncolytic viruses (Rus-
sell et al., 2012). These defence mechanisms are divided into innate
and adaptive, and their ultimate aim is destruction of virally infected
cells. With respect to the former, the nature of the innate response net-
work triggered by virus varies depending on receptor usage and cell
type, yielding a complex signalling cascade with diverse outcomes.
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Figure 1.17: The E3 region of the viral genome. Products of the viral E3 re-
gion function to inhibit aspects of the host immune response to
allow persistence of virally infected cells. Once viral replication
is complete the E3 protein ADP facilitates cell lysis .
Multiple genes within the virus are involved in ensuring that the
host cell does not recognise viral infection and therefore continues
to replicate the viral genome. For example, in addition to its action
on p53, E1B-55K interferes with the induction of IFN-inducible genes
(Chahal et al., 2013). The E1a proteins also inhibit activation of genes
induced by interferon and IL-6 (Ackrill et al., 1991; Takeda et al., 1994)
and therefore may reduce the effect of the inflammatory cytokines
and chemokines. Products of the viral E3 region also function to sub-
vert the host immune response and allow persistence of infected cells
(Lichtenstein et al., 2004). A summary of the function of the viral E3
region is shown in Figure 1.17.
One host response against viral infection is the presentation of anti-
gens by virally infected cells to cytotoxic T lymphocytes by major
histocompatibility complex class one (MHC I). The viral protein E3
gp19 down regulates MHC I. This reduces antigen presentation to
cytotoxic T-lymphocytes, thereby preventing T cell recognition of in-
fected cells (Burgert and Kvist, 1987). E3-gp19 also lowers the cell sur-
face levels of receptors for natural killer cells (McSharry et al., 2008).
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A major component of the host cell response to virus is lysis of
infected cells caused by inflammatory cytokines and CTLs binding to
death receptors (DRs). Proteins encoded by the E3 region also pro-
tect cells from the lytic effects of tumour necrosis factor-a (TNFa)
(Deryckere and Burgert, 1996). These proteins act to prevent the in-
duction of the extrinsic apoptotic pathways and possibly classical
TNFa induced necrosis by binding to death receptor signalling. For
example RIDa binds strongly to the Fas receptor and RIDb interacts
with TNF receptor type 1 (TNFR1). Once bound these death receptors
are internalised and targeted for lysosomal destruction. This prevents
the induction of apoptosis by TNFa and the Fas ligand on the surface
of CTLs (reviewed in Benedict (2003)). The inflammatory response is
also inhibited by E3 proteins by a number of mechanisms including
the interaction of 14.7K with NF-kB to prevent its binding to DNA
(Carmody et al., 2006).
Adenoviral E3 therefore protects infected cells from the host im-
mune system to allow viral replication and mature viral particles to
be produced. Spread of mature virions to adjacent cells requires cell
lysis and this is facilitated by a further E3 protein, the adenoviral
death protein (ADP) (Tollefson et al., 1996). The E3 genes are, how-
ever, dispensable for replication of virus in tissue culture and parts
of this viral region are commonly deleted in viral vectors including
dl922-947. A full assessment of the impact of this deletion is beyond
the scope of this project, however it is possible that the E3B deletion
may affect their therapeutic potency either by permitting premature
immune-mediated lysis of infected cells or by preventing release of
mature progeny by ADP.
1.4.8.1 Oncolytic adenovirus and the immune response
Treatment of patients with systemic adenoviral therapy results in
dose limiting inflammatory toxicities, which can be severe and in
some cases has resulted in death (Reid et al., 2002; Raper et al., 2003).
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These toxicities have understandably hindered the development of on-
colytic viruses. Liver toxicity as a result of oncolytic adenovirus is also
of particular concern. Ad5 is extensively sequestered by the liver by
macrophages (Kupffer cells), leading to acute transaminitis and vas-
cular damage (Shayakhmetov et al., 2005). In female nude mice with
human ovarian cancer IP xenografts treated with dl922-947, high lev-
els of ascitic cytokines were seen and marked hepatotoxicity occurred
(Lockley et al., 2006). In an attempt to modulate these side effects, in-
hibitors of TNFa were combined with the oncolytic virus. Although
improved viral efficacy was seen, liver toxicity still occurred (Salako
et al., 2011). More recently, in a murine ovarian cancer model, sys-
temic cytokines and hepatic toxicity have been shown to be reduced
by pharmacological inhibition of b3 integrin without compromising
efficacy (Browne et al., 2015).
Along with mediating toxicities to adenoviral vectors, the immune
system is also a barrier to delivery of virus. Neutralising antibod-
ies (nAbs) directed against the primary antigenic epitopes in the
three major capsid proteins target the systemically-delivered thera-
peutic vector for elimination, thus limiting therapeutic efficacy (Uusi-
Kerttula et al., 2015)). Administering the virus directly to the tumour
by intratumoral injection may partly overcome this problem (Turn-
bull et al., 2015). In ovarian cancer, IP injection of virus may be the
route of choice to maximize delivery of virus to the tumour. Further
approaches to limit antibody neutralisation is to coat the virus in
chemical conjugates (Fisher and Seymour, 2010) or encapsulate the
adenovirus into liposomes (Wan et al., 2013). To address the problem
of the prevalence of preexisting anti-Ad5 nAbs alternative serotypes
have been developed. ColoAd1 is a chimeric Ad3/Ad11p virus gen-
erated through forced evolution via recombination of a pool of Ads
from different serotypes on tumour cell lines (Di et al., 2014). Clin-
ical trials of this virus are now underway in both ovarian cancer
(NCT02028117) and other solid tumours.
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Although aspects of the immune system mediate toxicity to ade-
noviral vectors, it is also recognised that oncolytic viruses exert an
immunogenic, in addition to a directly cytotoxic, effect (Turnbull
et al., 2015; Kaufman et al., 2015b). The immune response to oncolytic
viruses is complex and could be innate, driven by cytokine release
causing migration of immune cells such as NK cells or adaptive via
a response to tumour associated antigens. Following oncolytic cell
death, tumour cells release tumour-associated antigens that serve to
promote an adaptive immune response that could mediate tumour
regression at distant sites that are not exposed to the virus. The re-
sponse to oncolytic viruses has the potential to overcome the immune
evasion seen in tumours. By altering the cytokines and immune cells
within the tumour microenvironment oncolytic viruses could pro-
mote immune recognition of tumour cells (Kaufman et al., 2015b).
To further stimulate an immune response and overcome the im-
mune evasion seen in tumours, there are a number of adenoviral
vectors in development that are armed with factors that stimulate
the immune response including GM-CSF (Cerullo et al., 2010), and
IL12 (Yang et al., 2012). In a trial of Ad5-D24-GMCSF in 20 patients,
2 patients had a complete response, 1 a minor response and 5 had
stable disease. Responses were frequently seen in both injected and
uninjected tumours (Cerullo et al., 2010). Combining oncolytic virus
with immune checkpoint inhibitors, for example, antibodies targeting
CTLA-4 and PD-1/PD-L1 may offer a further approach to enhance
therapeutic efficacy (Turnbull et al., 2015).
The importance of the immune system in oncolytic adenovirus
highlights the need for immunocompetent models. Murine cells do
not support productive replication of human adenovirus (Young et al.,
2012). This has been a significant barrier to the development of pre-
clinical models and more fully understanding how the immune sys-
tem contributes to adenoviral efficacy.
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1.4.9 The adenoviral E4 region
The E4 region produces transcripts for six proteins named after their
open reading frames: orf1, orf2, orf3, orf4, orf6 and orf6/7. These
proteins that play a role in DNA replication, transcription, apopto-
sis, host cell protein shut off, regulation of cell cycle signalling and
regulation of the DNA damage response (discussed in more detail
below)
In early stages of infection, E4orf6/7 binds to the displaced E2F
from pRb and E1A, and promotes viral DNA replication by stabilis-
ing the binding of E2F to the E2 promotor (Weitzman and Ornelles,
2005). The E4orf3 protein associates with the nuclear matrix and in-
duces the reorganisation of nuclear bodies into tract-like structures
(Doucas et al., 1996). These structures contain proteins implicated in
multiple cellular functions and it is thought that this reorganisation
is advantageous for viral replication (Russell 2000). E4orf3 has been
shown to bind E1B 55K, re-localising it to the nucleus and it also
has a role in regulating late viral gene expression (Weitzman and Or-
nelles, 2005). E4orf6 cooperates with E1B-55K and is involved in viral
replication, RNA processing, nucleo-cytoplasmic transport of late vi-
ral mRNA and the shut off of host protein synthesis (Gonzalez and
Flint, 2002; Russell, 2000). In addition, E4orf6 and E1B-55K together
with cellular factors (Cul5, elongin B and C) mediate polyubiquintiny-
lation and degradation of cellular targets including p53 and MRE11
(discussed below) (Harada et al., 2002). A summary of some of the
functions of the E4 regions is shown in Figure 1.18.
1.4.10 Adenovirus and the DNA damage response
The adenoviral genome mainly exists as monomers of dsDNA through-
out infection. At late stages of infection, amplification of this linear
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Figure 1.18: The E4 region of the viral genome. Schematic showing the six
proteins encoded by the E4 region of the viral genome and their
interaction with host proteins.
genome presents the cell with a huge number of free DNA ends
(Weitzman and Ornelles, 2005). The host cell responds to this chal-
lenge by activation of the DNA damage response (Weitzman and Or-
nelles, 2005). There is a complex interplay between the host cell’s
DDR and adenoviral infection. Infection by many viruses is sufficient
to trigger a DDR, activating some or all the repair pathways and this
has been seen as the host cell recognising viral DNA as its own dam-
aged DNA (Weitzman and Ornelles, 2005). This cellular response is
an obstacle to efficient viral replication and, therefore, viruses have a
complex series of mechanisms that, in turn, have evolved to combat
and inactivate the cellular damage response pathways.
During the first few hours after infection, the host cell responds to
adenovirus, possibly due to recognition of viral DNA or due to cellu-
lar stress, by activating various DNA damage response signals. These
include phosphorylation of H2AX, structural maintenance of chromo-
somes protein 1 (SMC1) and RPA32 (Turnell and Grand, 2012). Full
1.4 adenovirus 89
activation of the DSB machinery, however, only occurs in the absence
of the E4 region of the adenovirus (Stracker et al., 2002). Following
infection with a mutant adenovirus lacking the E4 region, activation
of MRE11 occurs (Carson et al., 2003) together with activation of the
ATM kinase (as demonstrated by autophosphorylation on S1981) and
many of the known substrates for ATM and ATR become phosphory-
lated (Weitzman and Ornelles, 2005). Proteins involved in the cellular
response to DNA damage are thought to be recruited to sites of DSB
in the host genome and appear as foci within the nucleus of infected
cells. Many of these proteins, including MRE11 and autophosphory-
lated ATM, are found to form foci surrounding viral replication cen-
ters (VRC) during infection with an E4 deleted virus (Carson et al.,
2003; Stracker et al., 2002).
The result of this activation of the DDR in an E4 mutant virus is
that viral DNA genomes are joined end to end to form high molec-
ular weight concatamers of viral DNA that cannot be packaged into
viral capsids (Weiden and Ginsberg, 1994). The junctions of the con-
catamers also have deletions (Weiden and Ginsberg, 1994), suggest-
ing that the ends of the Ad genomes are degraded or end-resected.
Since the origins of replication are located at the termini of the vi-
ral genome, this would inhibit viral replication. The ligation of viral
genomes into concatamers seen following infection with E4 mutant
virus is thought to be due to the function of the NHEJ pathway. This
is supported by the fact that the concatameric junctions had variable
sized deletions, with little or no sequence homology (Karen et al.,
2009a). In addition, concantamers are not formed in cells with mu-
tant DNA-PK (Boyer et al., 1999a) and ligase IV (Stracker et al., 2002)
following infection with an E4 mutant virus.
Together these observations imply that the viral genome is a sub-
strate for DNA repair processess and proteins from the E4 region
are necessary to block the DNA repair response. Mechanisms em-
ployed by the virus to inhibit NHEJ, and thus prevent concatamer for-
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mation, include proteosomal degradation of DNA Ligase IV (Baker
et al., 2007) whilst both E4-34kDa and E4-11kDa bind and inactivate
DNAPK, which is an essential kinase for NHEJ (Boyer et al., 1999a).
A major target of the virus following Ad5 infection is the MRN
complex (comprised of MRE11, RAD50 and NBS1) (Stracker et al.,
2002). In uninfected cells, the MRN complex is a sensor and central
player in the response to DSBs (Williams et al., 2007). The MRN com-
plex is inactivated by several mechanisms following Ad5 infection.
E1B-55K together with E4orf6 form an E3 ubiquitin ligase complex
with the cellular proteins Cul5, Rbx1 and elongins B and C and tar-
gets MRE11 (along with p53, and DNA-ligase IV) for proteosomal
degradation (Harada et al., 2002; Karen et al., 2009b). A second mech-
anism is the mislocalization of the MRN complex by E4-orf3 from the
nucleoplasm to promyelocytic leukaemia protein (PML)-containing
’nuclear tracks’ (Araujo et al., 2005; Stracker et al., 2005; Evans and
Hearing, 2005). This sequesters the MRN complex away from the
viral genomes, which are located in the VRC (Stracker et al., 2005;
Evans and Hearing, 2005). These VRCs do not co-localise with the
redistributed MRN proteins (Stracker et al., 2005).
E1B-55K and E4orf3 are also involved in re-localising MRE11 to cy-
toplasmic aggresomes (Araujo et al., 2005), resulting in degradation.
Degradation of the MRN complex has been shown to occur early
in infection, prior to the accumulation of viral DNA (Karen et al.,
2009b). E1B-55K/E4orf6–dependent degradation of MRN is sufficient
to prevent ATM activation (Carson et al., 2003). Inhibition of ATR sig-
nalling, such as CHK1 phosphorylation, occurs due to mislocalisation
of MRN by Ad5 E4orf3 prior to MRN degradation by E1B-55K/E4orf6
(Blackford et al., 2008). Adenoviral inhibition of MRE11 prevents both
the DDR signalling and the formation of viral genome concatamers
(Stracker et al., 2002; Carson et al., 2003).
Further proteins involved in the DNA damage response that have
been shown to be degraded include BLM (Orazio et al., 2011) and
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SPOC1 (a regulator of DNA damage response and chromatin struc-
ture (Mund et al., 2012; Schreiner et al., 2013). During adenoviral in-
fection, a number of DDR proteins are recruited to viral VRC. These
include RPA32, ATR, ATRIP, RAD9, DNA topoisomerase 2-binding
protein 1 (TOPBP1), RAD17 and heterogeneous nuclear ribonucleao-
protein U-Like 1(hnRNPUL1) (Blackford et al., 2008). It is unclear
whether re-localisation of these DDR proteins to VRC may alter or
inhibit their function (Weitzman and Ornelles, 2005) or whether their
presence facilitates viral replication. It has been shown that the E1B
55K associated protein, E1B-AP5, is required for the ATR-dependent
phosphorylation of RPA32 and it is postulated that RPA32 may aid
DNA elongation (Blackford et al., 2008).
Different adenoviral serotypes affect the host cell DNA damage re-
pair mechanisms differently. For example p53 is not degraded follow-
ing infection with Ad3, Ad7, Ad9 and Ad11 but shows a pronounced
increase in expression (Forrester et al., 2011). MRE11 is degraded in
Ad5, Ad4 and Ad12 infected cells but is not degraded by group B
and group D viruses (Forrester et al., 2011). In addition, the mecha-
nism of ATR inhibition also varies; Ad5 E4orf3 protein inhibits ATR
activation by re-localizing and immobilizing MRN subunits before
their targeted degradation by E1B-55K/E4orf6. In contrast to Ad5,
TOPBP1, an activator of ATR, is degraded by Ad12 and results in
inhibition of ATR signalling (Blackford et al., 2010). The reasons for
these differences await further investigation.
Adenoviruses, therefore, go to considerable lengths to disable the
DDR (summarised in Figure 1.19) yet some DDR proteins are re-
cruited to VRCs suggesting that they may be required for viral repli-
cation (Weitzman and Ornelles, 2005). Further investigation into the
DDR following viral infection may identify key components that could
shed further light into the lifecycle of adenovirus and importantly
could identify targets to enhance oncolytic viral efficacy. As discussed














































Figure 1.19: Regulation of the DDR by adenovirus type 5. Adenoviral genes
(E1B55K and E4orf6) promote degradation of p53, BLM, MRE11
and DNA Ligase IV. E4orf6 inactivates DNAPK by reducing
phosphorylation. Ad5 E4orf3 sequesters MRN to aggresomes
to inhibit MRN–dependent activation of ATR. Components of
the ATM and ATR pathways are recruited to VRC or PML-
containing nuclear tracks and aggresomes. Viral replication pro-
teins are shown in orange, cellular proteins in blue. Broken ar-
rows shown proteins recruited to VRCs, PML-tracks or aggre-
somes. Figure adapted from Turnell and Grand (2012).
cer and investigation into these pathways may also aid patient selec-
tion for future clinical trials of oncolytic adenoviruses.
1.4.11 Oncolytic adenoviruses summary and rationale for this project
Adenovirus replication ultimately results in death of the infected cell.
Although the mechanism of cell death and the pathways involved
are complex and yet to be fully elucidated (Baird et al., 2008), har-
nessing this cell killing in a tumour specific fashion is the goal of on-
colytic viral therapies. The oncolytic nature of adenoviruses reflects
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an intrinsic property of the cancer cell. Cancer cells arise from the
deregulation of multiple pathways that regulate cell growth and sur-
vival. Adenoviruses express genes that achieve these same changes
in the host cell during the course of infection. Consequently, due to
the intrinsic properties of cancer cells, viral replication can still occur
despite genetic manipulation of the virus and deletion of specific key
genes needed for viral replication in normal cells. Why some tumour
cells display acute sensitivity to viral cytotoxicity whereas other cells
are resistant is currently not know.
What is clear is that adenoviruses, including the E1A CR2 adenovi-
ral mutant dl922-947, interact with, and deregulate multiple cellular
processes. Investigation into these pathways will not only shed light
on adenoviral biology but could identify targets that could enhance
efficacy. It may also lead to the identification of patients who are most
likely to respond to oncolytic viral therapy.
The DDR is a key pathway that is deregulated by oncolytic viruses.
This pathway is also frequently abnormal in tumours, particularly
ovarian cancer. Previous work has shown that, following infection
with dl922-947, profound deregulation of the cell cycle is observed in
sensitive cells (Connell et al., 2011). This is associated with the pres-
ence of extensive genomic DNA damage. Inhibition of the ATR-Chk1
pathway promoted genomic DNA damage and over-replication in re-
sistant cells, which was accompanied by increased adenovirus toxicity
both in vitro and in vivo (Connell et al., 2011). It appears that virus-
induced host cell DNA damage signalling may be key determinants
of viral efficacy and understanding this further could identify the
factors which could promote viral efficacy. This is particularly impor-




1. To assess the role of DNA double strand break damage follow-
ing infection with the oncolytic adenovirus, dl922-947, in a panel
of ovarian cancer cell lines.
2. To assess the role of the homologous repair pathway in the effi-
cacy of dl922-947.
3. To assess the role of components of the DDR in their response to
the oncolytic adenovirus, dl922-947, through the use of a DNA
repair siRNA screen.
Part II
M AT E R I A L S A N D M E T H O D S
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M AT E R I A L S A N D M E T H O D S
2.1 cell lines
Cell lines were maintained at 37 C in a humidified atmosphere with
5% CO
2
. There were routinely passaged twice a week using 0.5%
trypsin in PBS (PAA Laboratories) to detach monolayers.
All cell lines were routinely tested for mycoplasma and human cell
lines underwent short tandem repeat profiling (LGC Standards) to
verify their authenticity. For long term storage, cells were pelleted
by centrifugation, and the cell pellet resuspended in 10% dimethyl
sulphoxide (DMSO) and 90% foetal bovine serum (FBS) (Biosera).
Cell were stored overnight at 80 C, and then transferred to liquid
nitrogen.
The human ovarian cancer cell line, SKOV3ip1, was provided by Dr
Janet Price (University of Texas-MD Anderson Cancer Center, Texas)
and SKOV3 cells were obtained from Cancer Research UK Cell Ser-
vices (Clare Hall, South Mimms, Hertfordshire, UK). TOV21G cells
were obtained from Prof F Balkwill (Centre for Cancer and Inflamma-
tion, BCI). OVCAR4 cells were obtained from Dr R. Camalier (NCI-
Frederick, MD, USA). IGROV1 cells were obtained from NCI. The
PE01 and PE04 cells were kindly provided by Dr Simon Langdon
(School of Molecular, Genetic and Population Health Sciences, Uni-
versity of Edinburgh, UK). UWB 1.289 and UWB 1.289 + BRCA1 cells
were obtained from ATCC.
Of these cell lines, IGROV1, PE01, PE04 and SKOV3 cells were
maintained in RPMI with 10% heat-inactivated FBS. The UWB 1.289
cells were maintained in 50% RPMI and 50% mammary epithelial
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growth medium (Medium 171 and mammary epithelial growth sup-
plement (MEGS), ThermoFisher Scientific) with 3% FBS and Penicillin
100 units/mL streptomycin 100 µg/mL (PAA laboratories). To main-
tain expression of BRCA1, UWB + BRCA1 cells were also cultured
with G418 (200 µg/ml) (Geneticin, ThermoFisher Scientific). The re-
mainder of the cell lines were cultured in DMEM with 10% FBS.
2.2 adenoviral mutants
The adenoviral 5 (Ad5) mutant dl922-947 is deleted in the region en-
coding amino acids 122-129 of the E1A CR2 domain. It also has a
745bp deletion in E3B between base pairs 30,005 and 30,750 that is
substituted for by a 642bp non-coding DNA fragment (Heise et al.,
2000). The adenoviral 5 mutant, dl309 has the same E3B deletion as
dl922-947 but has wild-type E1A. Wild type adenovirus 5 (Ad5WT)
and the E3B-deletion mutant dl309 were kindly provided by Dr. W.S.
Wold (St. Louis University, St. Louis, MO, USA). Ad5 GFP is deleted
in E1 and E3B and has green fluorescent protein (GFP) in the E1 po-
sition under control of the cytomegalovirus (CMV) promoter. Ad5
LM-X has a complete deletion of E1, it is therefore non-replicating,
and its E3 region is intact. The construction has been described previ-
ously (McNeish et al., 2001).
2.3 cell survival assays
2.3.1 MTT assay
Cell survival was measured using an MTT (3-(4,5-Dimthylthiazol-2-
yl)-2,5-17 diphenyltetrazolium bromide) (Sigma) assay. MTT assays
were performed in 24 well tissue culture plates and cells plated at
a density of 1 ⇥ 104   4 ⇥ 104 cells per well depending on the cell
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line used, in 1ml of complete medium. Cells were treated with virus
or drug 24 hours after plating and cell survival measured after 120
hours by adding 100 µl of a 5 mg/ml solution of MTT (final concen-
tration 500µg/ml) to each well. After 3 hours of incubation at 37oC
the medium was then aspirated and crystals dissolved in 100-500 µl
of DMSO depending on the colour intensity of the crystals. Plates
were read at 560 nm on a Wallac 1420 Multilabel counter plate reader
(PerkinElmer Life and Analytical Sciences). Cell survival was nor-
malised for background absorbance and expressed as a percentage
of untreated cells (100% survival).
2.3.2 Sulforhodamine B assay
Sulforhodamine B assays were performed in a 24 well plate. Cells
were seeded at a density of 1⇥ 104   4⇥ 104 cells per well depending
on the cell line used in 1 ml of complete medium. Cell survival was as-
sessed 72-120 hours following drug treatment by removing medium
and fixing cells in 100µl/well trichloroacetic acid for 1 hour at 40oC.
Cells were washed 3 times with water, allowed to air dry at room tem-
perature. They were then stained with 250 µl of 0.4% w/v sulphoro-
damine B in 1% acetic acid for 30 minutes at room temperature. Ex-
cess dye was removed by washing with 1% acetic acid, the plates air
dried and then the amount of incorporated dye within the cells was
dissolved in 1ml/well 10 mM tris base solution. Plates were read on
Wallac 1420 Multilabel counter plate reader (PerkinElmer Life and
Analytical Sciences). Cell survival was normalised for background
absorbance and expressed as a percentage of untreated cells (100%
survival).
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2.3.3 CellTitre-Glo
Cell viability was also measured using the ATP-based luminescent
CellTiter-Glo assay (Promega). The luciferase reaction for this assay
is shown by the following formula:
beetle luci f erin + ATP + O2 ! Oxyluci f erin
CellTiter-Glo reagent was diluted 1 in 4 in PBS prior to use. Cells
were cultured in a 96 well plate and cell survival measured 72-120 hours
following treatment with drug, siRNA or virus. The medium was re-
moved from the cells and 100 µl diluted CellTiter-Glo was added. The
plates were mixed for 2 mins using a plate shaker (Grant-bio) and in-
cubated for 10 mins at room temperature. Luminescence was read us-
ing a Wallac 1420 Multilabel counter plate reader (PerkinElmer Life
and Analytical Sciences). Luminescence data were expressed as a per-
centage of untreated cells (100% survival).
2.3.4 Analysis
Dose response curves were created using GraphPad Prism version 6
(GraphPad Software San Diego CA, USA). The IC50 (inhibitory con-
centration, 50%) was calculated from the equations of the sigmoidal
curves generated by GraphPad Prism software.
2.4 immunoblot blot analysis
2.4.1 Preparation of protein lysates
For preparation of whole protein lysates, cells were washed twice in
cold PBS and scraped into cold western lysis buffer (150 mM NaCl,
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50 mM Tris Base, 0.05% SDS and 1% TritonX-100) containing one pro-
tease and one phophatase inhibitor tablets (Roche) per 10 ml buffer.
Samples were put on ice for 10 min and sonicated for 10 seconds.
Samples were then centrifuged for 5 mins at 8000 rpm at 4oC and the
supernatant stored at -80oC.
2.4.2 Protein concentration evaluation
The protein concentration of cell lysates was measured using the Bio-
Rad assay. Dilutions of protein ranging from 0.1 mg/ml to 1.0 mg/ml
were made using bovine serum albumin (BSA) as positive, protein
standard controls. Reagent A’ was prepared by adding 20 µl Bio-Rad
reagent S to 1 ml Bio-Rad reagent A. 5 µl of each protein lysate sam-
ple was added per well of a 96 well plate in triplicate, with the pro-
tein standards added in triplicate plus a control well of 5 µl water.
To each 5 µl of sample, 25 µl of A’ and 200 µl Bio-Rad reagent B was
added and the plate incubated at room temperature for 5minutes. Ab-
sorbance was measured at 630 µm on Wallac 1420 Multilabel counter
plate reader. The absorbance of the protein standards was used to
construct a standard curve and the equation for this line was used to
calculate the protein concentrations of the cell lysates.
2.4.3 SDS polyacrylamide gel electrophoresis (SDS PAGE)
Samples were run on either a NuPAGE 4-12% Bis-Tris precast gel
(Invitrogen) or a poured 10% - 15% polyacrylamide gel (Table 2.1).
Resolving gels were poured as shown in (Table 2.1) and allowed to
set in a multiple gel caster system (Amersham Biosciences). Once set,
a stacking gel (Table 2.1) was poured on the top of the gel a comb
inserted to creat the wells and the gel set at room temperature.
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reagent 10% 15% stacking gel
water 4 ml 2.3 ml 3.4 ml
30% Proto- Gel (National Diagnostics) 3.3 ml 5 ml 0.83 ml
1.5MTris (pH 8.8) 2.5 ml 2.5 ml -
1M Tris (pH 6.8) - - 0.63 ml
10% SDS (Bio-Rad, Ca. USA) 0.1 ml 0.1 ml 0.05 ml
10% Ammonium persulphate (Sigma) 0.1 ml 0.1 ml 0.05 ml
TEMED 0.004 ml 0.004 ml 0.005 ml
Table 2.1: Components of SDS PAGE resolving (10% and 15%) and stacking
gels
Up to 30 µg of the protein lysates were mixed with 6x loading
buffer (375 mM Tri-HCL pH 6.8, 6% SDS, 48% Glycerol, 9% mercap-
toethanol and 0.03% Bromophenol Blue) and made up to a total of
24 µl with distilled water. Samples were boiled on a heating block at
95
 C for 5 mins, then transferred to ice and centrifuged briefly be-
fore loading. Electrophoresis took place at 120 V for 90-120 mins in
1⇥ running buffer diluted from a 10⇥ stock (30.2g Tris Base, 94 g
Glycine and 100 ml 10% SDS in 1 litre) or MOPS buffer (Invitrogen)
(for precast gels). Molecular weight rainbow markers (Amersham Bio-
sciences) were loaded alongside the protein samples to allow size
comparison of bands. Proteins were transferred onto nitrocellulose
membranes (GE Healthcare) using a semi-dry transfer system (Trans-
Blot, Bio-Rad) set at 20 V for 40 mins. After being soaked in transfer
buffer (39 nM Glycine, 48 mM Tris Base and 20% Methanol in 1 litre).
Membranes were blocked with a solution of 4% (w/v) skimmed milk
powder in 0.1% Tween 20 (Fluka Analytical) in PBS (PBS-T) for at
least 1 hour at room temperature.
The primary antibody was diluted in a 1.5% solution of BSA (Sigma)
in 0.1% PBS-T or 4% (w/v) non-fat milk and incubated for either
1 hour at room temperature or 4 C overnight on a gentle rocker
(Table 2.2). Primary antibody was removed by three washes with
0.1% PBS-T for 5, 10 and 15 mins. Secondary horseradish peroxidise
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antibody company dilution species
E1A Becton Dickinson (cat 554155) 1:1000 mouse
Ad5 Abcam (ab36851) 1:5000 goat
RAD51 Santa-Cruz (sc-8348) 1:500 rabbit
RAD51 Abcam (ab213) 1:500 mouse
MCM3 Abcam (ab97282) 1:1000 rabbit
Ku70 Santa Cruz (sc-1486) 1:1000 goat
MRE11 Cell signalling (4895) 1:500 rabbit
NONO Abcam (ab70335) 1:2000 rabbit
E2-DBP kind gift of Dr. David Ornelles 1:500 mouse
Anti-rabbit HRP Dako 1:1000 goat
Anti-goat HRP Dako 1:1000 rabbit
Anti-mouse HRP Dako 1:1000 rabbit
Table 2.2: Antibodies used for Immunoblot analysis
(HRP)-conjuated antibody (Table 2.2) was diluted at a concentration
of 1:1000 in a solution of 1.5% BSA in 0.1% PBS/Tween and incu-
bated with the membrane for one hour at room temperature. Three
washes with 0.1% PBS/Tween were repeated as before. The detection
of HRP-conjugated secondary antibodies was performed by ECL Plus
Western Blotting Detection Reagent (GE Healthcare) and visualised
by exposure of the member to Hyperfilm ECL (GE Healthcare) prior
to developing in a Curix 60 Developer (Agfa, Middlesex, UK).
2.5 co-immunoprecipitation
2⇥106 cells were infected with dl922-947 (MOI 10) and lysed 24 hours
later in 800 ml RIPA lysis buffer (with complete protease inhibitors,
Roche, Herts, UK). 35 ml Sepharose beads (Santa Cruz, CA, US) were
incubated with anti-RAD51 antibody (Santa Cruz, H-92, sc8349) or
control antibody (anti-HA, sigma H6908) for 1 hour at 4 C. Lysates
were then incubated with the IP matrix beads for 1 hour at room
temperature and washed with RIPA lysis buffer. SDS loading buffer
was added, samples boiled and proteins detected by Western blot as
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described in Section 2.4. Primary antibodies used: rabbit anti-Ad5 E2
DBP and anti-RAD51 (Abcam, ab213).
2.6 viral life cycle
2.6.1 Virus Infectivity assay
5 ⇥ 105 cells were plated in 6 cm plates. 24 hours later, cells were in-
fected with an E1 deleted adenovirus type 5 containing the green
fluorescent protein gene driven by the cytomegalovirus (CMV) im-
mediate early promoter (Ad GFP) or mock infected. 24 hours post
infection the cells were trypsinised, re-suspended in medium and
centrifuged for 5 mins in a centrifuge at 1500 rpm. The supernatant
was removed and the cell pellet re-suspended in 2 mls warm phos-
phate buffered saline (PBS) and centrifuged for 5 mins at 1500 rpm.
The supernatant was removed and the cells re-suspended in 400 µl
PBS. Samples were processed in a Florescence-activated cell sorting
(FACS) Caliber (Becton Dickinson, CA, USA). Infectivity was deter-
mined after 10,000 total events were recorded. The percentage of GFP
positive events was determined from the total count. All conditions




assay (tissue culture inhibitory dose 50%) is a limiting
dilution assay that enables the quantification of any infectious parti-
cles in the test sample. To quantify intracellular production of mature
viral particles, 2 ⇥ 105 cells were seeded in 6 well plates. Cells were
infected 24 hours later with dl922-947 at the stated MOI in serum free
medium and re-fed 2 hours later with serum containing medium. 24,
48 and 72 hours post infection, cells were washed twice with PBS and
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then scraped into 0.5 ml 0.1 M Tris pH 8.0, all time points were har-
vested in triplicate. The collected samples were freeze/thawed three
times and samples spun in a microfuge at 8000 rpm for 5 mins to pel-
let out the cell debris.
The quantity of replicating virus (measured in pfu/ml) was deter-
mined by titrating 10 fold serial dilutions of virus onto JH293 cells in a
96 well plate. JH293 cells were seeded in 96 well plates at 1⇥ 104 cells
per well in 200 µl medium per well. The test samples were prepared
by diluting in DMEM. Dilutions started at 10 3 for the 24 hour sam-
ple and 10 6 for the 48 and 72 hour sample. The samples were added
to the second row of the plate (22 µl) and serial dilutions within the
same plate were made by taking 10% of the volume of each well of
the second row (22 µl) and adding it to the third row and so on until
the final row. The top row of each plate was left uninfected.
The JH293 cells were scored for cytopathic effect (CPE) 10-12 days
later. The observed number of wells displaying CPE at each dilution
were counted and the TCID
50
calculated with the formula:
Log TCID50 = A   D (S   0.5)
where:
A = Log of the highest dilution showing CPE in more than 50% of
the wells
D = Log of the dilution factor.
S = summation of the proportion of positive wells in each row.
This gives a value for 22 µl of virus and the value is therefore





titre by 0.7 log compared to plaque assay, TCID50/ml is converted to
pfu/ml using the following formula:
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P f u/ml = 10n 0.7
Where: n = log TCID
50
/ml
This result is only valid if the lowest dilution gives greater than
50% CPE, and the highest dilution gives less than 50% CPE.
2.6.3 Extraction of viral DNA for qPCR for viral proteins
2x105 cells were plated and infected 24 hours later with dl922-947.
Cells were harvested at 24-72hours following infection. Cells were
washed twice in ice cold PBS and scraped into 500 µl PBS. Extraction
of viral DNA was performed using QIAmp DNA Blood Mini Kit (Qi-
agen). 20 µl of proteinase K (Qiagen) was added to 200 µl of virus,
followed by 200 µl of Buffer AL (supplied with the extraction kit) and
then incubated at56 C for 10 mins in a heat block. 200 µl of ethanol
was added to the sample and the mix was pulse-vortexed for 15 sec
and transferred to a QIAmp spin column in a 2 ml collection tube.
After centrifugation for 1 min at 8000 rpm, the QIAmp spin column
was transferred to a new collection tube. 500 µl of Buffer AW1 (sup-
plied) was added and the sample centrifuged again at 8000 rpm for
1 min. 500 µl of buffer AW2 (supplied) was added and the colum was
centrifuged at 1300 rpm for 3 mins, followed by another 1 mins after
transfer to a new collection tube. After placing the column in a sterile
Eppendorf tube, 40 µl of distilled H2O was added and the column
centrifuged at 8000 rpm for 1 min to elute the purified DNA. DNA
concentration was measured using a Nanodrop ND-1000 spectropho-
tometer and stored at -20 C.
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e1a Ad5
5’ primer sequence CCACCTACCCTTCACGAACTG GGTGGCCATTACCTTTGACTCT
3’ primer sequence GCCTCCTCGTTGGGATCTTC GGGTAAGCAGGCGGTCATT
Probe ATGATTTAGACGT GACGGCC CTGTCAGCTGGCCTGG
Table 2.3: Oligonucleotides and probes for E1A and Ad5
2.6.4 Quantitative PCR for viral DNA
DNA samples were all diluted to 10 ng/µl in 100 µl. Triplicates were
prepared for each sample.
The volumes used to prepare each sample are:
• Total volume = 20µl
• Template volume = 2µl
• Forward primer = 10µM
• reverse primer = 10µM
• 2⇥ reaction buffer =10µM (TaqMan Universal PCR Master Mix,
Applied Biosystems)
Oligonucleotides and probes for E1A and Ad5 are shown in Ta-
ble 2.3
Samples, were plated in a 96 well plate. The plate was covered with
an adhesive lid and centrifuged briefly to remove air bubbles. Real-
time PCR was performed on an ABI Prism 7500 (Applied Biosystems,
Foster 23 City, CA). PCR conditions were:
• 50 C for 2 minutes,
• 95 C for 10 minutes,
• followed by 40 cycles of: 95 C for 15 secs and 60 C for 60 secs.
A standard curve using 103   109 dl922-947 genomes was used for
quantification.
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2.7 southern blot
1⇥ 106cells plated and infected with dl922-947 (MOI 10 for PE04, MOI
100 for PE01 cells). 24 and 48 hours later cells were trysinised and
washed in PBS. DNA was extracted as described above. DNA concen-
tration was measured using Nanodrop ND-1000 spectrophotometer
and 10 µg genomic DNA was run on a 1% agarose gel with DNA
ladder. The gel was soaked in 200 ml 0.2 M HCl for 10 mins, with
constant gentle agitation and washed with distilled water. The gel
was then soaked for 15 mins at room temperature in Alkaline Trans-
fer buffer (0.4 M NaOH, 1 M NaCl) 500 ml. The buffer was changed
and the gel was again soaked in fresh Alkaline Transfer buffer (0.4 M
NaOH, 1 M NaCl) 500 ml, with constant gentle agitation.
Hybond N+ membrane (GE Healthcare Life Sciences) was cut to ex-
actly the same size as the gel. The membrane was floated in ddH2O
for 2 mins, and then immersed in Alkaline Transfer buffer (0.4 M
NaOH, 1 M NaCl) for at least 5 mins. DNA was transferred onto
the membrane by conventional capillary transfer over 48 hours. Probe
Labelling against viral DNA, hybridization and detection were per-
formed using the Amersham ECL Direct Nucleic Acid Labelling and
Detection systems. This was performed by Atsushi Shibata at the
Genome Damage and Stability Centre, Life Sciences at University of
Sussex, Brighton BN19RQ, UK.
2.8 immunofluorescence
Coverslips were placed in 24 well plates and were treated with 0.01%
(w/v) poly-L-lysine (Sigma) for 5 mins. Poly-L-lysine was removed
and the coverslips dried and then exposed to UV light to sterilize.
Alternatively premade polylysine coated coverslips were used.
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antibody company dilution species
RAD51 Santa-Cruz (sc-8348) 1:200 rabbit
gH2Ax Millipore (05-636) 1:800 mouse
E2 DBP kind gift of Dr. David Ornelles 1:500 mouse
BRCA2 Millipore (OP95) 1:200 rabbit
Table 2.4: Antibodies used in Immunofluorescence experiments
2⇥ 105 cells were cultured on coverslips and infected 24 hours later
with dl922-947 or treated with etoposide (100 µM for 1 hour), hydrox-
yurea (2 mM for 24 hours), or rucaparib (10 µM for 24 hours). 24 or
48 hours post treatment, the medium was aspirated and 0.04% Triton
(Sigma) in PBS was added for 1 min. The Triton was removed and
immediately the cells were fixed in 3% paraformaldehyde and 2% su-
crose (Sigma) for 10 mins and then washed three times in PBS. The
cells were stained with primary antibodies as detailed in Table 2.4 in
1.5% BSA PBS 0.1% tween for 45 mins at 37 C. The cells were washed
three times in PBS and incubated for 45 min at 37 C with antimouse
ALEXA 488 (invitrogen) and antirabbit ALEXA 568 (Invitrogen) sec-
ondary antibody (1:1000 in 1.5% BSA PBS tween). Cells were washed
again three times with PBS and co-stained with DAPI (1 in 10 000) to
define the nucleus. Coverslips were mounted on slides using mowiol
mounting medium and left overnight for the mounting solution to
set. Images were captured using a Zeiss 510 confocal microscope and
foci counted using Image J software.
2.9 experiments using small interference rna
Small interference RNA (siRNA) targeted against BRCA2, RAD51,
NONO and CETN2 were obtained from either Dharmacon (siGEN-
OME SMARTpool; GE Lifesciences) or Qiagen. A non-targeting (NT)
pool of siRNA was also used (Qiagen). All cell lines were transfected
using lipofectamine 2000 (Invitrogen) or RNAiMAX (invitrogen), apart
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from IGROV1 cells where DharmaFECT1 (Dharmacon) was used. A
final concentration of 10 nM RAD51 siRNA or 30 nM or 50 nM (de-
pending on cell line) siRNA was used for the Dharmacon SMART-
pool SiRNA. All experiments with RAD51 were repeated using a sec-
ond siRNA (Qiagen) at a concentration of 50 nM.
Depending on the experiment, cells were transfected in a 24 or 6
well plate. For experiments in a 24 well plate (cell survival experi-
ments), 1 ⇥ 104   3 ⇥ 104 cells (depending on cell line) were plated
and 24 hours later transfected with siRNA as follows; the appropri-
ate amount of siRNA (at a concention of 10-50nM) was diluted in
50 µl/well in OptiMEM (invitrogen). 1 µl/well DharmaFECT1 (dhar-
macon), lipofectamine 2000 or RNAiMAX (invitrogen) was added to
50 µl/well of OptiMEM in a separate tube. Following a 5 min incu-
bation at room temperature, siRNA solution and transfection solu-
tion were mixed by pipetting and incubated for 20 mins at room tem-
perature. 100 µl of this solution was added to each well (containing
500 µl medium). 24 hours following transfection cells were infected
with dl922-947 or dl309. Cell survival was assessed 96 hours follow-
ing infection by MTT assay. Cells survival following siRNA was com-
pared to the non targeting control (siControl). Transfection efficiency
was determined by the use of a polo-like kinase 1 (PLK1) targeting
siRNA (siPLK1). PLK1 is a polo-like kinase and is involved in mitosis
and apoptosis, its silencing causes cell death in most cell lines (Liu
and Erikson, 2003).
Wells were also transfected for protein collection to assess knock-
down concurrently with cell survival. This was performed as follows;
the appropriate amount of siRNA (at a concention of 10-50 nM) was
diluted in 250 µl/well of OptiMEM. 5 µl/well DharmaFECT1 or lipo-
fectamine 2000 was added to 250 µl/well of OptiMEM in a separate
tube. Following a 5 min incubation at room temperature, siRNA so-
lution and transfection solution were mixed by pipetting and incu-
bated for a further 20 mins at room temperature. 500 ml of this solu-
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tion was added to each well. 24-48 hours following transfection cells
were lysed and proteins assessed as described in Section 2.4.
Experiments assessing viral DNA following knockdown of RAD51
were performed in 6 well plates. 2 ⇥ 105 cells were plated and trans-
fected 24 hours later with SiRNA as described above for protein col-
lection after siRNA knockdown. 24 hours following transfection cells
were infected with dl922-947. 48 hours following infection wells were
harvested to assess viral DNA as described in Section 2.6.3.
2.10 rna harvest for brca2 transcription
2⇥ 105 cells were transfected with BRCA2 siRNA. Cells were trypsin-
ised 48 hours later, spun and washed in PBS. Ribonucleic acid (RNA)
was harvested using the RNeasy kit (Qiagen). Briefly, 350 µl Buffer
RLT lysis buffer (with 10 µl per ml mercaptoethanol) was added to
each sample. The lysate was added onto a QIA shredder (supplied)
and spun according to the protocol. 350 µl of 70% ethanol was added
and the sample applied to an RNeasy mini column (supplied) and
spun at 10,000 rpm for 15 secs. Buffer RW1 (supplied) was added to
the column and the column was again centrifuged at 10,000 rpm for
15 secs. 10 µl DNase I was added to 70 µl buffer RDD (supplied) per
sample and this was added to directly to the RNeasy silica-gel mem-
brane and then incubated at 20-30oC for 15 mins. 350 µl buffer RW1
was added to the RNeasy mini column and the samples centrifuged
at 10,000 rpm for 15 secs before transferring the column to a new col-
lection tube. 500 µl Buffer RPE was then added samples centrifuged
for 15 secs at 10,000 rpm. 500 µl Buffer RPE was again added follow-
ing by centrifugation for 2 mins at 10 000 rpm. To elute the RNA the
column was transferred to a new collection tube. 30 µl RNase- free wa-
ter was added directly to the membrane and the sample centrifuged
for 1 min at 10,000 rpm.
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2.10.1 RNA analysis
Purity and quantity was analysed using the ND1000 Spectophotome-
ter, reading absorbance at 260/280 nm (NanoDrop, Wilmington, US)
with a ratio of greater or equal to 1.8 indicating purity.
2.10.2 Reverse transcription of RNA to yield cDNA
cDNA synthesis was carried out using the Applied Biosystems High
Capacity cDNA Reverse Transcription Kit on a thermal cycler as per
the manufacturer’s instructions. For each sample 1 µg RNA was made
up with the following components to result in a final volume of 20 µl:
• 10⇥ reverse transcription buffer (2 µl)
• 25 ⇥(100nM) deoxynucleiotide mix (0.8 µl)
• 10 ⇥ reverse transcription random primers (2 µl)
• reverse transcriptase (1 µl)
• RNase inhibitor (1 µl)
• and RNase free water (to make up to a final volume of 20 µl)
The tubes which contained 50 ng/µl were then set up in a DNA En-
gine (PTC-200) Peltier thermo cycler (Bio-Rad), under the following
conditions:
• 25 C for 10 min
• 37 C for 50 min
• 85 C for 5 min
• 4 C for at least 5 min






BRCA2-PROBE 2 (6FAM) CCACTCTGCCTCGAAT(TAM)
BRCA2-PROBE 1 (6FAM) CCAAGGAAGTTGTACCGTC(TAM)
Table 2.5: BRCA2 primer and probe sequences
2.10.3 Quantitative RT-PCR
Analyses were performed using the ABI Prism 7500 Sequence Detec-
tion system Instrument and software (PE Applied Biosystems). RT-
PCR was performed as described in Section 2.6.4 using primers and
probes as shown in Table 2.5 and 18S as an internal control (Applied
Biosystems):
BRCA2 mRNA was normalised (DCT) to 18sRNA by subtracting
the cycle threshold (CT) of the 18sRNA sample from the cycle thresh-
old (CT) of each sample. The expression level of BRCA2 in the treat-
ment group samples was determined relative to the scrambled con-
trols:
DDCT = DCT treatment   DCT control group
This was expressed as a fold change in gene expression using the
formula:
Fold change = 2 DDCT
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2.11 homologous recombination reporter assay
To assess the function of homologous recombination, a recombination
substrate DR-GFP was used (Pierce et al., 1999). Briefly, pDR-GFP (a
gift from Maria Jasin (Addgene plasmid 26475)) contains two differ-
ently mutated GFP genes orientated as direct repeats and separated
by a puromycin resistance gene. One of the GFP constructs, SceGFP,
is mutated to contain the recognition site for the rare cutting endonu-
clease I-SceI. Exposure to I-SceI will therefore induce a unique double
strand break. The I-SceI site is incorporated at a BcgI restriction site
by substituting 11bp of wild type GFP sequence with those of the
I-SceI recognition site. These substituted base pairs also supply two
in frame stop codons, which terminate translation and inactivate the
protein. Downstream of SceGFP gene is an 812 bp internal GFP frag-
ment termed iGFP. Homologous sequences in the two mutated GFP
genes are separated by 3.7kb. When I-SceI-induced DSB occurs, iGFP
sequence can act as a donor strand to allow homology-mediated re-
pair and generation of a functional GFP open reading frame. GFP
expression can be detected by flow cytometry (Figure 2.1).
PEO1 and PEO4 cells were transfected with pDR-GFP using Fu-
gene HD. Following puromycin selection, 1 ⇥ 106 cells were plated
and 24 hours later transfected with either 1 µg pI-SceI or pCAAGs
(negative empty vector control). 24 hours later, cells were infected
with dl922-947 (MOI 50 for PE04 cells MOI 500 for PE01 cells). 24 hours
thereafter, cells were analysed for GFP events using a FACSCaliber.
100,000 events were recorded and results analyzed using FlowJo soft-
ware.
















B. DR-GFP recombination reporter substrate: 




pgk-pur Bcg II-SceI plasmid
D. DSB repair by HR using iGFP template
Figure 2.1: Reporter assay to assess homologous recombination function.
(A) Modified GFP gene. The modified GFP gene encodes the
GFP protein fused to a nuclear localization signal (N) and zinc
finger domain (Z). It is expressed from a CMV promoter. The
GFP is modified to contain an I-SceI site and in-frame termina-
tion codons (underlined) and termed SceGFP. (B) DR–GFP re-
combination substrate. Downstream of the SceGFP gene is iGFP,
a 5´ and 3´-truncated GFP gene. (C) When exposed to I-SceI plas-
mid, a double strand break (DSB) at the I-SceI site is created. (D)
If homologous recombination pathways are functional, this DSB
is repaired from the iGFP gene on the same chromatid or sister
chromatid, to result in a functional GFP gene. Image is adapted
from Pierce et al. (1999).
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2.12 high-throughput sirna screen
The Human DNA repair library Set V1.0 siRNA library (Qiagen, UK)
targets 230 known and putative DNA repair proteins. The library
consisted of 7⇥ 96 well plates, each well containing 5 µl of an indi-
vidual siRNA at a concentration of 2 µM. The first and last columns
of each plate were left empty and 5 µl of 2 µM non-targeting control
siRNA (siCtrl), or siPLK1 were added. Each well of the screen con-
tains enough siRNA for 2 plates (one to be infected with dl922-947,
the other mock infected) to give a final concentration of 50 nM.
14 plates each of COV318 (4000 cells per well) and OVCAR4 (2000
cells per well) cells were plated on day 1. The following day, cells were
transfected with the siRNA library using lipofectamine RNAiMAX
transfection reagent (Invitrogen) Briefly, transfection medium was
prepared as follows; 0.25 µl RNAiMAX and 50 µl OptiMEM medium
(Invitrogen) per well were incubated in a 50 mL tube for 5 mins. 50 µl
of this transfection mix was added to the 96 well plates containing
the siRNA. After 20 mins incubation, 160 µl complete medium was
added (no antibiotics). The medium was then removed from 2 plates
of the same cell line and replaced by 100 µl of the siRNA/transfection
mix for a final siRNA concentration of 50 nM. Medium was changed
6 hours after transfection. 24 hours following transfection cells were
infected with dl922-947 at MOI 5 or mock infected. Cell viability was
measured 96 hours following infection, using the CellTiter-Glo assay
(Figure 2.2).
Luminescence readings from each well were log transformed and
normalised according to the median signal on each plate and then
standardized by use of a Z-score statistic. This was done using the
median absolute deviation (MAD) to estimate the variation in each
screen (Zhang et al., 1999b):
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Z-score analysis has been described as a reliable method to analyse
high-throughput screens (Zhang et al., 1999b). In this experiment, the
Z-score represented the difference between one siRNA and the rest of
the screen. This is based on the assumption of a normal distribution
of cell viability. The standardization and normalization of the data in
each condition resulted in a Z score for each siRNA in mock infected
and virus infected cells. To establish genes synthetically lethal with
dl922-947 a DZ- score was calculated:
DZ score = Z scorex   Zs corey
where
x = virus in f ected cells, y = mock in f ected cells
Negative DZ-scores represent genes synthetically lethal with dl922-
947. DZ score of 0 represents no effect of the siRNA on viral efficacy.
Positive DZ score represents genes that if silenced result in resistance
to viral cell death. A threshold of DZ-score <-2 was used to select
potential hits.
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2.12.1 siRNA screen validation
Following analysis of the siRNA screen DZ-score data, 5 genes were
selected for validation. A custom made 96-well plate (Qiagen) was
used to validate the hits. This plate contains 4 single siRNAs per hit
gene (one siRNA per well). The siRNA was aliquoted into 10⇥ 96
well plates with 5 µl of 2 µM siRNA per well. siControl and siPLK1
were added to the plates as controls. In brief, OVCAR4 and COV318
cells were seeded on day 1, followed by siRNA transfection using
RNAiMAX (as described above), the medium was replaced 6 hr af-
ter transfection and cells infected with dl922-947 or mock infected
24 hours thereafter. Cell viability was measured by CellTitre-Glo as-
say, 96 hours after infection.
Part III
R E S U LT S
3
D N A D A M A G E A N D V I R A L C Y T O T O X I C I T Y
3.1 introduction
Replication selective oncolytic adenoviruses are a novel treatment for
ovarian cancer. The adenoviral mutant, dl922-947, has a 24 base pair
deletion in the in E1A-CR2 region. This region normally interacts
with host cell pRB, dissociating it from E2F, thereby enabling S-phase
entry and viral DNA replication (Fattaey et al., 1993). Since the RB
pathway is abnormal in nearly all ovarian cancers (Sherr and Mc-
Cormick, 2002), dl922-947 should replicate in malignant cells but not
quiescent normal cells. Although previous work has shown that dl922-
947 and other oncolytic adenoviral mutants have activity in ovarian
cancer (Lockley et al., 2006), the factors that determine tumour sensi-
tivity to oncolytic adenovirus are currently unknown.
Once inside the cell, adenoviruses hijack control of the host cell
and reprogram cellular gene expression to provide the optimal envi-
ronment for viral replication and production of new virions (Weitz-
man and Ornelles, 2005; Berk, 2005). Adenoviruses promote cell cycle
progression, stimulate unscheduled DNA synthesis and present the
cell with a huge amount of exogenous DNA. The host cell, in turn,
mounts a response to adenoviral infection in an attempt to inhibit vi-
ral gene expression (Weitzman and Ornelles, 2005). This results in a
complex interplay between the virus and host cellular responses. In-
creased knowledge of this interaction may lead to the identification
of factors that increase the therapeutic efficacy of oncolytic viruses.
Previous work has demonstrated that following infection with dl922-
947, deregulation of multiple cell cycle checkpoints occurs, which ac-
120
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celerates cell cycle progression (Connell et al., 2011, 2008). The over-
replication of genomic DNA induced by the oncolytic adenovirus,
dl922-947, is associated with the presence of extensive genomic DNA
damage (Connell et al., 2011). These results suggest that virus-induced
host cell DNA damage signalling may be a key determinant of viral
efficacy, and understanding this further could identify the factors that
promote viral cytotoxicity.
Using a panel of ovarian cancer cell lines, this chapter aims to inves-
tigate the role of genomic DNA replication and cellular DNA damage
following viral infection in determining overall viral efficacy.
3.2 results
3.2.1 dl922-947 is cytotoxic to ovarian cancer cell lines in vitro, but the
sensitivity varies between the cell lines
To evaluate the sensitivity of ovarian cancer cells to dl922-947, a panel
of cell lines was infected with dl922-947 and cell survival was mea-
sured 120 hours post-infection. The sensitivity of the cell lines varied
considerably (IC50 for TOV21G = 0.01 pfu/cell, IC50 SKOV3 = 438
pfu/cell) (Figure 3.1a). The same range of sensitivities was seen with
an E1A wild-type virus (dl309), although dl309 is less potent (Fig-
ure 3.1b), in keeping with previous data (Lockley et al., 2006).
3.2.2 Cellular infectivity to dl922-947 is not the only determinant of cyto-
toxicity
The ability of dl922-947 to infect cells varies and this could be an
important determinant of cell sensitivity to the virus. Permissiveness
to Ad5 infection was therefore evaluated by infecting cells with an E1
deleted Ad5 vector encoding green fluorescent protein (GFP) under
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Figure 3.1: Cytotoxicity of adenoviruses in ovarian cancer cells.1 ⇥ 104 cells
were infected with dl922- 947 (a) and dl309 (b) at MOI 0.01  1000
pfu/cell. Cell survival was assessed by MTT 120 hours post infec-
tion. Results are presented as percentage cell survival compared


















Figure 3.2: Permissiveness to infection with Ad5 vectors varies between cell
lines. TOV21G, IGROV1, SKOV3ip1, SKOV3 and OVCAR4 cells
were infected with Ad5 GFP MOI 7.5 in triplicate. Percentage
of GFP expressing cells was quantified by flow cytometry (bars
represent mean GFP expression +/- s.d.).
the control of the cytomegalovirus (CMV) immediate early promoter
(Ad5 GFP). Infectivity is then assessed by GFP expression measured
using flow cytometry.
Figure 3.2 shows the difference in infectivity across a panel of cell
lines. All cell lines were infected with dl922-947 at an MOI of 7.5.
Infectivity ranged from 60% (TOV21G) to less than 2% (SKOV3). To
determine whether factors other than just the permissiveness of the
cell to viral infection play a part in determining viral sensitivity this
difference in infectivity needed to be accounted for.
To control for differences in infectivity between the cell lines, SKOV3,
TOV21G and IGROV1 cells were infected with an MOI that permits
50-60% infection (Figure 3.3a) (iso-infection) and cell survival assessed
120 hours post infection. Even when differences in infectivity are con-
trolled for, there remained significant differences in cell survival (Fig-
ure 3.3b) indicating that factors other than infectivity determine sen-
sitivity to dl922-947.
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Figure 3.3: Cytotoxicity in cells equally infected with dl922-947. (a) Equal
infection of TOV21G, IGROV1 and SKOV3 cells by GFP flow cy-
tometry (MOI 2, 5, 80 respectively). Bars represent mean GFP ex-
pression +/- s.d. n/s: no significant difference between infection
of the cell lines. (b) Survival of TOV21G, IGROV1 and SKOV3
120 hours following infection with dl922-947 with an MOI that
permits 50   60% infection (MOI 2, 5, 80) showing a significant
difference in cell survival between the isoinfected cells; **** 2
tailed t-test, p=0.0001, **** 2 tailed t test, p= 0.0001. Bars repre-
sent mean cell survival +/- s.d.
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3.2.3 Cell cycle following infection with dl922-947
Previous results have shown that dl922-947 causes deregulation of the
cell cycle and over-replication of genomic DNA in highly sensitive
cells, with appearance of populations of cells with >4N DNA content
(Connell et al., 2011). This analysis has now been extended to a wider
panel of ovarian cancer cell lines to determine whether the differences
in cytotoxicity could be explained by abnormal cell cycle and genomic
DNA replication.
A panel of ovarian cancer cell lines was infected with dl922-947 at
MOI 7.5. Cell cycle was assessed 48 hours later by propidium iodide
staining and flow cytometry. The results revealed that cell lines more
sensitive to dl922-947 readily accumulated DNA contents of more
than 4N after viral infection. By 48hrs post infection, over 25% of
the most sensitive cells, TOV21G, demonstrated 4N or greater DNA
content. In comparison, in the insensitive SKOV3 cells, less than 5%
of the cell cycle exceeded 4N with little change of the cell cycle. Exam-
ples of cell cycle profiles are shown in Figure 3.4. Figure 3.5a shows
the proportion of the cell cycle with 4N or more DNA contents fol-
lowing viral infection for each cell line. To control for differences in
the cell cycle that are seen at baseline between the different cell lines,
Figure 3.5b shows the change in the proportion of the cells with >4N



























Figure 3.4: Cell cycle profiles following dl922-947 infection. Ovarian can-
cer cell lines (TOV21G, OVCAR4, IGROV1, SKOV3, SKOV3ip1,
PEO1 and PEO4) were harvested 48 hours following infection
with dl922-947 (MOI 7.5), fixed in 100% cold ethanol, stained
with propidium iodide (PI) and analysed by flow cytometry. Cell
cycle was visualised using Flowjo software. Representative cell























































Figure 3.5: dl922-947 results in DNA over-replication. Ovarian cancer cell
lines (TOV21G, IGROV1, OVCAR4, SKOV3ip1, PE01, PE04 and
SKOV3) were infected with dl922-947 at MOI 7.5. 48 hours later
cells were fixed, stained with propidium iodide and analysed by
flow cytometry. Cell cycle changes were assessed using Flowjo
software. (a) The proportion of cells with 4N or greater contents
following infection with dl922-947. Each bar shows an individual
cell line (mean +/- S.E.M). (b) Change in percentage of cells with
more than 4N DNA contents following dl922-947 infection. Each
bar shows an individual cell line (mean +/- S.E.M).
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To determine whether the differences in cytotoxicity to dl922-947
could be explained by abnormal cell cycle and genomic DNA repli-
cation, the change in the cell cycle following infection with dl922-947
was correlated with the sensitivity of each cell line to the virus. The
results from the panel of cell lines tested demonstrated a trend of an
association between viral efficacy and DNA over-replication (as deter-
mined by percentage cells with 4N and >4N DNA) 48h post-infection
with dl922-947 was observed; however this did not reach statistical
significance; Spearman r = -0.68, p=0.055 (Figure 3.6a). A close cor-
relation between viral efficacy (as determined by IC50 for dl922-947
at 120hr) and change in the percentage of cells with greater than 4N
DNA content following infection was demonstrated; Spearman r= -
0.96, p= 0.003 (Figure 3.6b).
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Figure 3.6: Cell cycle changes following dl922-947 infection and correlation
with overall efficacy. Ovarian cancer cell lines (TOV21G, OV-
CAR4, IGROV1, SKOV3, SKOV3ip1, IGROV1, PEO1 and PEO4)
were harvested 48 hours following infection with dl922-947 (MOI
7.5), fixed in 100% cold ethanol, stained with propidium iodide
(PI) and analysed by flow cytometry. (a) Correlation between
IC50 dl922-947 and percentage of cells with 4N or more than 4N
DNA contents. Points represent the IC50 of each cell line plotted
against % of cells with at least 4N DNA contents following infec-
tion +/- S.E.M. Solid line shows linear regression, r2 = 0.56, p
< 0.0001. Dotted line represents 95% CI. Spearman r= -0.75, p =
0.06. (b) Correlation between IC50 dl922-947 and change in per-
centage of the cell with more than 4N DNA contents. Points rep-
resent the IC50 of each cell line plotted against % change in >4N
DNA contents following infection +/- S.E.M. Solid line shows
linear regression, r2 = 0.72, p < 0.0001. Dotted line shows 95%
C.I. Spearman r =  0.94, p = 0.0003.
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These results demonstrate that infection with dl922-947 results in
abnormal replication of cellular DNA with the appearance of cells
with greater than 4N DNA contents. This abnormal replication is
clearly greater in sensitive cells. These findings therefore suggest that
deregulation of the cell cycle may be an important determinant of
viral efficacy.
3.2.4 Cell cycle changes following iso-infection with dl922-947
To further investigate the relationship between cell cycle changes and
viral efficacy, experiments were performed to control for differences
in viral infectivity between cell lines. Cell cycle changes were as-
sessed in cells equally infected with dl922-947 as determined by Fig-
ure 3.3a (the iso-infective dose). TOV21G, IGROV1 and SKOV3 were
iso-infected with dl922-947 (MOI 2, 5 and 80 respectively). 48 hours
later, cell cycle was assessed by flow cytometry. A significant differ-
ence in the change in the proportion of the cells with DNA content of
>4N was seen following infection between the iso-infected cells (Fig-
ure 3.7). This confirmed the above findings that dl922-947 results in
abnormal replication of cellular DNA with the appearance of popu-
lations with >4N DNA contents. These cell cycle changes are most
profound in sensitive cells and appear to be due to intrinsic differ-
ences in the host cell and not just due to differences in the ability of






















Figure 3.7: Cell cycle changes following iso-infection with dl922-947.
TOV21G, IGROV1 and SKOV3 cells were harvested 48 hours fol-
lowing infection with dl922-947 (MOI 2, 5 and 80 respectively)
fixed in 100% cold ethanol, stained with propidium iodide
and analysed by flow cytometry. Cell cycle was analysed using
Flowjo software and the change in the percentage of the cells
with >4N contents calculated (bars represent mean +/- s.d.) ** p
= 0.014, *** p = 0.0003, 2 tailed t-test.
3.2.5 Genomic damage following infection with dl922-947
Cell cycle control and the DNA damage response are closely inter-
linked (Shaltiel et al., 2015; Harper and Elledge, 2007). In addition,
abnormal cellular replication is associated with the accumulation of
replication-associated double strand DNA breaks (Truong and Wu,
2011). Since dl922-947 causes deregulation of the cell cycle that is more
profound in the sensitive cells, the next step was to assess genomic
DNA damage following infection.
Phosphorylation of H2AX (gH2AX) is considered one of the earli-
est indications of a DSB (Paull et al., 2000). Phosphorylation of H2AX
has been shown following adenoviral infection (Nichols et al., 2009;
Connell et al., 2011) but the exact relationship between the degree of
double strand break damage and viral cytotoxicity has not yet been
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determined. To assess this, gH2AX staining 48 hours following dl922-
947 infection was analysed in a panel of ovarian cancer cell lines by
flow cytometry with propidium iodide counterstaining to define cell
cycle stage. Examples of the cell cycle profiles with gH2AX staining






























Figure 3.8: Cell cycle and genomic damage following dl922-947. Ovar-
ian cancer cell lines (TOV21G, OVCAR4, IGROV1, PE01, PE04,
SKOV3ip1, SKOV3, UWB and UWB +BRCA1) were infected with
dl922-947 (MOI 7.5). 48 hours later, cells were fixed, stained with
gH2AX and counterstained with propidium iodide. Cells were
assessed using flow cytometry and analysed using Flowjo soft-
ware. Representative images are shown illustrating cell cycle
and gH2AX in mock infected cells (red) and following dl922-947
(blue). Percentages show increase in cells positive for gH2AX
following infection.
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Results demonstrated that the amount of gH2AX induced follow-
ing viral infection varied across the cell lines tested. Sensitive cells (for
example TOV21G, OVCAR4) showed a large increase in gH2AX 48
hours after infection with dl922-947 but there was very little gH2AX
in the more resistant cells (SKOV3). Interestingly gH2AX staining pre-
dominately occurred in cells with 4N or more than 4N DNA content.
Figure 3.9a shows the percentage of cells positive for gH2AX in
each cell line 48 hours following infection with dl922-947 (MOI 7.5).
A correlation was also demonstrated between the increase in gH2AX
(determined by flow cytometry) 48 hours following viral infection
and the sensitivity of those cells to dl922-947 (as determined by IC50)
(Figure 3.9b). These results suggests that cellular susceptibility to














































Figure 3.9: Relationship between genomic DNA damage and cellular sensi-
tivity to oncolytic adenovirus. (a) DNA damage following infec-
tion with dl922-947 (MOI 7.5) was assessed in ovarian cancer cell
lines by gH2AX using flow cytometry. Bars represent % H2AX
positive following infection with dl922-947 +/- S.E.M. (b) Corre-
lation between DNA damage (gH2AX by flow cytometry) follow-
ing infection with dl922-947 and sensitivity to dl922-947. Points
represent the IC50 of each cell line plotted against % of cells pos-
itive for gH2AX following infection +/- S.E.M. Solid line shows
linear regression, r2 = 0.35, dotted line represents 95% CI. Spear-
man r = -0.88, p = 0.0031.
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3.2.6 Genomic damage assessed by Immunofluorescence
To further examine the relationship between virus-induced DNA dam-
age and cellular sensitivity, gH2AX was also analysed by immunoflu-
orescence 48 hours after infection with dl922-947 at MOI 7.5. The pat-
tern of staining seen at 48 hours following infection is pannuclear
rather than that of discrete foci. Figure 3.10 shows a representative im-
age of gH2AX staining across the panel of cell lines tested. This stain-
ing pattern is consistent with previously published data, that showed
pannuclear gH2AX following group C adenoviral infection (Nichols
et al., 2009). Assessment of gH2AX staining was quantified by inten-
sity of gH2AX within the nucleus because counting of gH2AX foci
was not possible. To control for differences in background staining of
gH2AX the fold change in gH2AX intensity following infection with
dl922- 947 was calculated. Figure 3.11 shows the change in intensity
of gH2AX staining following viral infection in each cell line. Results
revealed a strong correlation between viral efficacy (as determined by
IC50) and fold change in intensity of gH2AX following viral infection


































































































































































































































































































Figure 3.11: Quantification of DNA damage assessed by immunofluores-
cence following infection with dl922-947. Presence of gH2AX
48 hours following infection with dl922-947 was detected in a
panel of ovarian cancer cell lines by immunofluorescence. In-
tensity of nuclear gH2AX staining was assessed using Image
J software in at least 50 cells per condition. Fold increase in
gH2AX following dl922-947 was calculated. Bars represent av-
erage intensity of gH2AX +/- S.E.M for each cell line.
3.2 results 138























Figure 3.12: Correlation between IC50 dl922-947 and gH2AX intensity fol-
lowing viral infection. Points represent the IC50 of each cell line
plotted against change in intensity of gH2AX following infec-
tion +/- S.E.M. Solid line shows linear regression, r2 = 0.59, p
< 0.0013 dotted line represents 95% C.I. Spearman r = -0.96, p
=0.0028.
3.2.7 Genomic damage following iso-infection with dl922-947
To further investigate the relationship between viral efficacy and ge-
nomic damage I also performed experiments using cells equally in-
fected with dl922-947. Intensity of gH2AX staining was quantified
following iso-infection in TOV21G (MOI 2), IGROV1 (MOI 5) and
SKOV3 (MOI 80). Significant differences were seen between the sen-
sitive and resistant cells (Figure 3.13b). This suggests that DNA dam-
age following infection with dl922-947 is an important marker of viral


































Figure 3.13: DNA damage following iso-infection with dl922-947. (a) Pres-
ence of gH2AX in TOV21G, IGROV1 and SKOV3 cells 48 hours
following iso-infection with dl922-947 (MOI 2, 5, 80 respec-
tively) was detected by immunofluorescence Scale bar = 20 µm.
(b) gH2AX intensity was quantified using ImageJ in TOV21G,
IGROV1 and SKOV3. Each symbol represents intensity of a sin-
gle nucleus, *** p < 0.0001, 2-tailed t-test.
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3.2.8 Differences in background DNA damage do not correlate with aden-
oviral efficacy
To assess whether there was a relationship between the extent of en-
dogenous gH2AX and adenovirus efficacy, gH2AX was assessed in
the untreated cells. Differences in background staining were clearly
visible between the cell lines and quantification of this is shown in
Figure 3.14a. There was however, no association between baseline
gH2AX and adenoviral efficacy (Figure 3.14b). Baseline, endogenous
gH2AX levels may reflect genomic instability (Podhorecka et al., 2010).






























































Figure 3.14: Background genomic damage and viral efficacy. Presence of
gH2AX in untreated cells was detected in a panel of ovarian
cancer cell lines by immunofluorescence. Images were captured
on a Zeiss 510 confocal microscope and quantification of stain-
ing was assessed using ImageJ software. (a) Bars represent in-
tensity of staining +/- S.E.M for each cell line. (b) Points rep-
resent the IC50 of each cell line plotted against background in-
tensity of gH2AX +/- S.E.M. Solid line shows linear regression.
No association seen.
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3.2.9 Genomic damage following infection with a non-replicating virus
To assess whether viral replication is required for the induction of ge-
nomic DNA damage, gH2AX was assessed by immunofluorescence
in TOV21G cells following infection with dl922-947 or the non-replicat-
ing viral vector (AdLm-X) (Figure 3.15a). The intensity of gH2AX
staining, quantified in at least 50 cells, did not increase following in-
fection with a non-replicating virus (Figure 3.15b). These results show
that the presence of virus alone does not generate a DDR but aden-












































Figure 3.15: DNA damage following infection with a non-replicating virus.
(a) Presence of gH2AX by immunofluorescence, 48 hours fol-
lowing infection with AdLMx (non-replicating adenovirus) or
dl922-947 (MOI 7.5) in TOV21G cells. Scale bar = 20 µm. (b)
gH2AX intensity was quantified in at least 30 cells. n/s: no
significant difference between mock infected and cells infected
with AdLMx, significant difference seen between gH2AX inten-
sity of cells infected with AdLMx and dl922-947 **** p < 0.0001,
2 tailed t-test.
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3.2.10 Genomic damage following infection with E1A wild type virus
Results from early in this chapter (Figure 3.1b) demonstrate that dl922-
947 is more potent than the E1A wild-type adenovirus, dl309. To as-
sess whether genomic damage varies between dl922-947 and dl309,
TOV21G and IGROV1 cells were infected with dl922-947 or dl309 at
MOI 7.5 and fixed at 16, 24 and 48 hours post infection. gH2AX stain-
ing was assessed by immunofluorescence and quantified using Im-
ageJ. Results revealed that in the highly sensitive TOV21G cells, there
was significantly more gH2AX staining at both 16 and 24 hours post
infection with dl922-947. At 48 hours this difference was lost (Fig-
ure 3.16a). The less sensitive IGROV1 cells did not show a difference
in DNA damage between the two viruses at 16 hours but there was
significantly more damage with dl922-947 at both 24 and 48 hours
(Figure 3.16b). These results demonstrate that infection with the E1A
deleted adenoviral vector, dl922-947, results in more DNA damage
compared to the E1A wild-type virus. This is consistent with dl922-
947 being more potent in ovarian cancer cells. The explanation for the
loss of a difference at the late time points in the TOV21G cells could
be due to cell death in these highly sensitive cells. Alternatively, due
to the strength of the gH2AX signal, saturation had occurred and
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Figure 3.16: DNA damage following infection with E1A wild type virus
and dl922-947. Presence of gH2AX by immunofluorescence, 16,
24 and 48 hours following infection with dl309 (E1A wild-type
adenovirus) or dl922-947 ( both infected at MOI 7.5) in TOV21G
cells (a) and IGROV1 cells (b). gH2AX intensity was quanti-
fied in at least 50 cells. Significantly higher gH2AX intensity in
the dl922-947 infected TOV21G cells compared to dl309 infected
cells at 16 and 24 hours post infection was observered. ** p <
0.002, 2 tailed t-test. Significantly higher gH2AX intensity in
the dl922-947 infected IGROV1 cells compared to dl309 infected
cells at 24 and 48 hours post infection ** p < 0.01 2-tailed t
test. n/s: no significant difference between dl922-947 and dl309
infected cells.
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3.2.11 DNA damage induced by chemotherapeutics and sensitivity to dl922-
947
To assess whether the correlation between DNA damage induced by
dl922-947 and sensitivity to the virus reflects intrinsic cellular suscep-
tibility to DNA damage as opposed to specific adenovirus-induced
damage, gH2AX staining was assessed following treatment with other
DNA damaging agents that result in DSBs. A panel of ovarian cancer
cell lines was treated with hydroxyurea (2 mM for 24 hours) or etopo-
side (100 µM for 1 hour) and gH2AX was assessed by immunofluo-
rescence. Although there appeared to be a trend of an association be-
tween the damage induced by hydroxyurea and etoposide and virus
cytotoxicity, this did not reach statistical significance (Figure 3.17b
and Figure 3.17a). There was also no correlation between the damage
induced by PARP inhibitor (10 µM for 24 hours) and sensitivity to
dl922-947 (Figure 3.17c). These experiments do, however, need to be
repeated with the addition of further cell lines and this may reveal an
association between DNA damage induced by certain DNA damag-
ing agents. In addition, these agents induce DNA damage in different
ways; etoposide causes DNA strands to break by inhibiting topoiso-
merase II (Hande, 1998). Hydroxyurea results in stalled replication
forks that collapse to DSB (Petermann et al., 2010). In contrast, PARP
inhibitors prevent single strand break repair by inhibiting the PARP1
enzyme. To induce double stand DNA damage PARP inhibitors rely
on progression of the cell through the cell cycle and double strand
breaks occur at the replication forks (Davar et al., 2012; Bryant et al.,
2005; Farmer et al., 2005). In contrast to these types of DSBs, the DNA
damage induced by dl922-947 is likely to be a result of viral replica-
tion and aberrant cell cycle progression. This may explain why sensi-
tivity to dl922-947 does not correlate with DNA damage induced by
chemotherapy agents.
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Figure 3.17: Correlation between adenovirus efficacy and DNA damage in-
duced by chemotherapy agents. Ovarian cancer cells (TOV21G,
IGROV1, OVCAR4, SKOV3ip1, PEO4, PEO1, SKOV3) were
treated with etoposide (100 µM for 1 hour) (a), hydroxyurea
(2 mM for 24 hour) (b), or the PARP inhibitor, rucaparib (10mM
for 24 hour) (c). DSBs were assessed by gH2AX immunofluores-
cence and the intensity of gH2AX staining was correlated with
cellular sensitivity to dl922-947 (IC50). Each point represents a
cell line, Solid black line shows the linear regression, dotted
line represents 95% C.I. No correlation found between DNA




These data show that ovarian cancer cells have a wide range of sen-
sitivity to the E1A-CR2 mutant adenovirus, dl922-947 and that dl922-
947 is more potent than an E1A wild-type virus. In this chapter, I
have sought to determine the role of the cell cycle and DNA damage
in determining the cytotoxicity of dl922-947.
Infectivity is an important determinant of cell sensitivity to virus.
However, even following iso-infection, there still remain significant
differences in sensitivity to dl922-947. The explanation for this differ-
ence remains to be identified but these data suggest that the DDR
pathways of the cells may be critical.
Once adenovirus has entered the host cell, its priority is to optimize
the host cell for replication of the viral genome. The virus drives the
cell into an S phase-like state thereby creating an intracellular en-
vironment needed for viral replication (Flint and Shenk, 1989). The
results presented here, together with previously published data, re-
veal that following infection with dl922-947 abnormal replication of
cellular DNA occurs (Ingemarsdotter et al., 2015; Connell et al., 2011).
There is also a stark contrast between sensitive and insensitive ovar-
ian cancer cells, with sensitive cells readily accumulating DNA of
more than 4N content but little change to the cell cycle occurs in the
more resistant cells. A correlation exists between cytotoxicity of dl922-
947 and populations with more than 4N DNA content. This suggests
that cell cycle deregulation following infection may be important in
determining sensitivity.
Why cells abnormally replicate their DNA following infection with
dl922-947 is not fully understood. Similar results have been shown
following infection with E1A wild-type virus. E1A expressing cells
accumulate in the S and G2/M phases of the cell cycle (Howe and
Bayley, 1992; Grand et al., 1998) and abnormal re-replication occurs
in late S phase (Singhal et al., 2013). E1A expression is critical to viral
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replication; it is the first viral gene to be expressed and expression
depends entirely on host factors. Previous results have shown that
expression of E1A following infection with dl922-947 correlates with
cytotoxicity (Flak et al., 2010; Ingemarsdotter et al., 2015). To date,
most research looking at cell cycle and adenovirus has focused on
the CR2 region of E1A and its ability to drive the cell into S phase
through its interaction with pRB (Nevins, 1992; Nemajerova et al.,
2008). Much less is known, however, about the nature of the cellular
DNA that replicates in these virally infected cells.
Since dl922-947 has a deletion in E1A-CR2, there are therefore re-
gions in the viral DNA that are responsible for driving the abnormal
replication seen following adenoviral infection. dl922-947 and other
adenoviral vectors have been shown to over-ride multiple cell cycle
checkpoints in tumour cells to allow the virus to drive quiescent cells
into S phase, resulting in mitotic catastrophe (Connell et al., 2008;
Cherubini et al., 2006). It has also been demonstrated that inhibi-
tion of the cell cycle CHK1 promotes over-replication in cells resistant
to dl922-947 (Connell et al., 2011). An interaction between cell cycle
checkpoints and adenovirus is clearly important in driving the cell
through the cell cycle but whether this alone can explain the abnor-
mal re-replication seen in sensitive cells remains to be determined.
One study suggests that E1A induces changes in the dynamics of
the replication pattern, with increased replicon length, fork velocity
and inter-origin distance and fewer replication origins (Singhal et al.,
2013). The molecular explanation for these changes has yet to be iden-
tified but it appears that adenovirus may have a direct effect on host
cell replication kinetics highlighting the complexity of the interaction
between virus and host cell. Further investigation into this abnormal
replication may offer opportunities for ways of potentiating oncolytic
adenoviral cytotoxicity.
Unscheduled DNA synthesis induces accumulation of DNA lesions
(Saleh-Gohari et al., 2005; Baird et al., 2008; Machida and Dutta, 2005).
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The aberrant replication pattern seen following adenoviral infection
and dl922-947 has been shown to lead to replication stress and ac-
tivation of the DDR pathways (Singhal et al., 2013; Connell et al.,
2011). Upon recognition of DSBs, H2AX, a variant of histone H2A,
is rapidly phosphorylated by phosphatidylinositol 3-kinase (PI3K)-
elated kinases: ATM, ATR and DNA-PK (Ward and Chen, 2001; Park
et al., 2003; Burma et al., 2001). This signal is then amplified through
recruitment of other signal factors (Paull et al., 2000; Rogakou et al.,
1998). gH2AX is an early marker of DSB formation and was assessed
by cell cycle flow and immunofluorescence following infection with
dl922-947. The data show that the extent of gH2AX induced by dl922-
947 correlates with viral efficacy, and that the damage occurs specif-
ically in cells with DNA content of 4N or greater. This suggests that
dsDNA damage in infected cells may result from abnormal replica-
tion and replication stress.
The assessment of gH2AX by immunofluorescence demonstrated a
much closer correlation between gH2AX compared to flow cytometry.
Immunofluorescence is a very sensitive marker for measuring gH2AX
(Löbrich et al., 2010) as each separate cell is able to be visualised and
measured, and this may explain the difference in the degree of cor-
relation between gH2AX measured by immunofluorescence and flow
cytometry. Nevertheless both techniques show that there is clearly
greater gH2AX in cells sensitive to dl922-947 compared to those resis-
tant to virus suggesting that the degree of DSB is important in deter-
mining viral efficacy. Since infection with a non-replicating virus did
not induce gH2AX the results show that phosphorylation of H2AX is
a result of viral replication.
This staining pattern for gH2AX is, however, pan-nuclear rather
than as discrete foci. The exact explanation for this pattern of stain-
ing is unclear. It is however, consistent with previously published
data (Nichols et al., 2009). Patterns of gH2AX staining have also been
shown to vary throughout the cell cycle with pan-nuclear staining
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seen in uninfected M-phase cells (Hernández et al., 2013). Pan-nuclear
staining is also associated with apoptosis (Podhorecka et al., 2010).
Co-staining infected cells with cell phase specific markers (eg cyclin
A for S-phase, CENP-F for G2) may shed some further light on the
pattern of staining and cell cycle. Nichols et al. (2009) suggest that
since gH2AX staining occurs throughout the nucleus it is distinct
from H2AX phosphorylation at double strand breaks. It is suggested
that it represents a response to viral replication and improper recruit-
ment of repair factors. Although the exact significance of this pan-
nuclear staining following viral infection is unknown, the presence
of gH2AX may represent a signal to the cell to activate downstream
pathways of the DDR and my results clearly demonstrate that in-
creased gH2AX staining occurs in cells more sensitive to dl922-947.
To establish whether cells sensitive to virus are also more sensi-
tive to double strand DNA damage induced by other agents, gH2AX
staining was quantified following treatment with etoposide, hydrox-
yurea and rucaparib. The data show DSB damage induced by etopo-
side, hydroxyurea and PARP inhibitor does not correlate with viral
sensitivity. All three of these agents induce damage in different ways.
Etoposide inhibits topoisomerase II (which aids in DNA unwind-
ing), prevents re-ligation of the DNA and in doing so causes DNA
strands to break and the damage is repaired by both HR and NHEJ
(Hande, 1998). Hydroxyurea depletes the cells of deoxynucleotide
triphosphates (dNTPs), which initially results in stalled replication
forks that, after prolonged treatment, collapse to DSB (Petermann
et al., 2010). These DSBs are ultimately repaired by HR (Petermann
et al., 2010). The PARP family of enzymes are crucial to the repair
of single strand breaks (SSBs) via the base excision repair pathway
(Hoeijmakers, 2001). PARP inhibitors cause the cell to be flooded with
unprepared endogenously produced SSBs which, when encountered
by a replication fork, cause fork collapse and the formation of DSBs
(Bryant et al., 2005; Farmer et al., 2005; Davar et al., 2012). These
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results suggest that dl922-947 induces genomic damage in a novel
way that appears to rely on viral replication and aberrant cell cycle
progression. Further investigation is therefore required with further
cell lines and further types of DNA damaging agents to determine
whether sensitivity to dl922-947 can be explained by innate cellular
susceptibility to certain types of DNA damage.
Many unanswered questions remain. Firstly, what is the exact mech-
anism of cell death following viral infection? Work from our group
has shown that that dl922-947 induces a novel mechanism of cell
death independent of classical apoptosis (Baird et al., 2008). The re-
sults presented here show that DNA and cell cycle appear to be im-
portant in cytotoxicity following dl922-947 infection but the mecha-
nism by which they result in, or contribute to, cell death is currently
not known. The DDR response and cell cycle are closely interlinked
and it remains to be determined which factor is driving cell death.
It is also not clear whether phosphorylation of H2AX is a result
of abnormal cellular DNA replication and replication stress, a result
of DSBs by an alternative mechanism driven by the virus or whether
the virus itself is activating a DDR without actually causing DNA
DSBs. Alternatively does the gH2AX just present a form of apoptotic
or dying cell? If, however, the presence of viral replication is driving
phosphorylation of H2AX, then is up regulation of the DDR required
by the virus for replication? The next chapter attempts to investigate
this question further by looking at the role of DNA repair proteins in
viral replication.
4
H O M O L O G O U S R E C O M B I N AT I O N A N D V I R A L
C Y T O T O X I C I T Y
4.1 introduction
Results from Chapter 3 show that dl922-947 has considerable activity
in ovarian cancer but the sensitivity of ovarian cancer cells to dl922-
947 varies considerably, even between cells with similar infectivity.
Results also revealed that infection with dl922-947 induces a DNA
damage response by the phosphorylation of H2AX and that viral sen-
sitivity closely correlates with the extent of DNA damage. In this
chapter I investigate the role of cellular DNA repair in determining
viral efficacy.
Understanding the role of the DNA repair pathways in novel treat-
ments is particularly important for HGSOC where approximately
15% patients have germline mutations in BRCA1 or BRCA2 — key
components of the HR DNA repair pathway. In addition, data from
the Cancer Genome Atlas consortium (TCGA) inferred that HR de-
fects may be present in 50% HGSOC, through a variety of additional
mechanisms including somatic BRCA1/2 mutation and epigenetic
loss of BRCA1 expression (TGCA, 2011). This distinction between
HR competent and HR incompetent tumours has significant clinical
relevance. Many studies have shown that patients with HR incom-
petent, BRCA mutant cancers present at a significantly younger age
(Synowiec et al., 2016; Alsop et al., 2012) and have significantly im-
proved survival compared to non BRCA mutant tumours (Boyd et al.,
2000; Bolton et al., 2012). Importantly, BRCA mutant cancers are more
likely to respond to platinum chemotherapy, currently the main treat-
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ment for ovarian cancer (Tan et al., 2008; Gorodnova et al., 2015) and
secondary mutations that result in gain of function of BRCA1 and
BRCA2 restoring the function of HR are associated with platinum
resistance (Sakai et al., 2008). There is also great interest in the use
of PARP inhibitors in HR defective HGSOC (reviewed in (Wiggans
et al., 2015)). Conversely, there are, however, few therapeutic targets
available for HR competent tumours, which have a poorer progno-
sis and are less likely to respond to platinum-based chemotherapy
(Mukhopadhyay et al., 2012). There is a critical clinical need to find
strategies for these patients.
The interplay between viral infection and the host cell DNA dam-
age response is complex. Among the challenges to the host cell is
the viral DNA genome, which is viewed by the cell as DNA damage
and results in activation of the DNA damage response (Weitzman
and Ornelles, 2005; Carson et al., 2003). In order for adenoviruses to
replicate efficiently, they need to circumvent the cellular DNA dam-
age response and they achieve this through a series of mechanisms
encoded by the E4 region of the virus. Although the inhibition of the
NHEJ pathway is well documented, the role of the HR pathway in
Ad5 infection has been less well investigated in adenoviral biology.
Given that the HR pathway is so important in ovarian cancer, this
chapter focuses on key components of the pathway in determining
viral efficacy.
4.2 results
4.2.1 Adenovirus cytotoxicity is greater in HR competent ovarian cancer
cells
The results from the previous chapter suggest that a cell’s susceptibil-
ity to DNA damage following viral infection may determine overall
oncolytic viral efficacy. I therefore hypothesised that the correlation
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between cellular susceptibility to DNA double strand break damage
and virus efficacy might reflect the cell’s ability to repair DSBs. There
are two main pathways by which cells repair DSB, HR and NHEJ.
Since HR pathway is important in ovarian cancer and it has been well
documented that NHEJ is inhibited following adenoviral infection
(Weitzman and Ornelles, 2005), I have therefore focused on the role
of the HR pathway in determining efficacy of oncolytic adenovirus.
To investigate the link between HR function and viral cytotoxicity
I initially used the PE01/ PE04 cell pair. These cells originate from
the same ovarian cancer patient. PE01 are BRCA2-deficient ovarian
cancer cells derived from ascites of a patient with poorly differen-
tiated ovarian cancer at the time of first relapse and cisplatin sen-
sitivity. PE04 cells were derived from the same patient at the time
of platinum resistance and have a secondary BRCA2 mutation with
restoration of the open reading frame and are thus BRCA2 functional
and HR competent (Sakai et al., 2009). I first confirmed the function
of the HR pathway in these cells using a previously described as-
say of HR (Mukhopadhyay et al., 2010). This assay quantifies RAD51
foci following treatment with the PARP inhibitor rucaparib. RAD51
plays a crucial role in HR: it mediates the search for the homologous
DNA sequence and, once the homologous sequence is found, RAD51
filaments facilitate the invasion of the ssDNA overhang into the ho-
mologous double-stranded DNA (dsDNA) sequence (Karpenshif and
Bernstein, 2012). Once RAD51 filaments are formed, the cell is com-
mitted to perform homology-mediated repair to correct the damaged
DNA template (Holthausen et al., 2010). Cells with competent HR
pathways have been shown to at least double the number of RAD51
foci following treatment with rucaparib whereas cells that do not in-
crease RAD51 foci following rucaparib treatment are deemed HR de-
fective (Mukhopadhyay et al., 2010).
I confirmed that PE04 cells increased RAD51 foci following PARP
inhibitor treatment and thus demonstrate functional HR, whilst PE01
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are HR defective (Figure 4.1a and Figure 4.1b). In keeping with this,
I also confirmed that BRCA2 mutant PE01 are more sensitive than
BRCA2 proficient PE04 to both cisplatin (Figure 4.2b) and the PARP
























































Figure 4.1: HR competence assessed in PE01 and PE04 cells. (a) Cells were
treated with rucaparib (10 µM, 24 hours), permeabilized, fixed in
4% PFA, and stained for RAD51 and gH2AX. Representative im-
munofluorescence image shown. Scale bar = 10 µm. (b) RAD51
foci were counted in at least 30 nuclei per treatment condition.
Bars show mean (+/- s.d.) number RAD51 foci per cell. Dotted
line, 2 ⇥ number foci untreated cells.
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Figure 4.2: Cisplatin and rucaparib dose response curves. 1 ⇥ 104 PE01 and
PE04 cells were treated with rucaparib (a) and cisplatin (b) in
triplicate. Cell survival was measured 72 hours later by MTT
(cisplatin) or 96 hours later by sulphorhodamine B (rucaparib)
assay. Results presented as percentage cell survival compared to
untreated cells (mean +/- s.d. n = 3) *** p = 0.005.
Unexpectedly, despite the fact that the PE01 cells are unable to re-
pair dsDNA breaks, I found PE04 to be significantly more sensitive
to cytotoxicity induced by the E1A CR2 deleted Ad5 virus dl922-947
(Figure 4.3a) as well as to dl309 virus (E1A wild-type) (Figure 4.3b)
and wild-type Ad5 virus (Figure 4.3c). This increased sensitivity to
adenovirus in cells with functional HR pathways appears to be ade-
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novirus type 5 specific as there was no difference in sensitivity be-
tween the BRCA2 mutant and BRCA2 functional cells lines to Ad11
and Ad35 (both group B viruses) (Figure 4.4).
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Figure 4.3: Sensitivity of PE01 and PE04 cells to adenovirus type 5. 1 ⇥ 104
cells were treated with increasing concentrations (MOI 0.01  
1000) of dl922-947 (a), dl309 (b) and wild-type Ad5 (c), cell sur-
vival was assessed by MTT assay 120 hours post infection. Re-
sults presented as percentage cell survival compared to mock
infected cells (mean +/- s.d. n = 3), * p = 0.01, ** p = 0.0091. 2
tailed t-test.
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Figure 4.4: Sensitivity of PE01 and PE04 cells to group B adenovirus. 1x104
cells were treated with increasing concentrations (MOI 0.01  
1000) of Ad11 (a) or Ad35 (a), cell survival was assessed by MTT
assay 120 hours post infection. Results presented as percentage
cell survival compared to mock infected cells (experiments pe-
formed by Suzanne Dowson).
4.2.2 HR competence and viral efficacy in a panel of ovarian cancer cell
lines
To further assess whether HR function influences viral effiacy, HR
function was assessed in a panel of ovarian cancer cell lines using the
assay described above. Using this assay TOV21G, OVCAR4, UWB1.289
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+BRCA1, COV318, PE04 and SKOV3 cells were defined as HR compe-
tent. In contrast, SKOV3ip1, UWB, IGROV1, PE01 and OVSAHO cells
were defined as HR incompetent (Figure 4.5). Of the HR incompetent
cells, PE01 and OVSAHO have a known BRCA2 mutation (Domcke
et al., 2013; Sakai et al., 2009), UWB1.289 has a BRCA1 mutation (Del-
loRusso et al., 2007) and IGROV1 has a mutation both in BRCA1 and

































Figure 4.5: HR compentence of a panel of ovarian cancer cell lines. A panel
of ovarian cancer cells (TOV21G, OVCAR4, COV318, UWB1.289,
UWB1.289 +BRCA1, PE01, PE04, SKOV3ip1, SKOV3, IGROV1
and OVSAHO) were treated with rucaparib (10 µM, 24 hours),
permeabilized, fixed in 4% PFA, and stained for RAD51. RAD51
foci were counted in at least 30 nuclei per treatment condi-
tion. Bars show fold change of RAD51 foci following treat-
ment with rucaparib (+/- S.E.M.) number RAD51 foci per cell.
Dotted line, 2 fold increase of RAD51 foci following ruca-
parib treatment. Results show that TOV21G, OVCAR4, COV318,
UWB1.289+BRCA1, PE04, SKOV3 are HR compent and PE01,
OVSAHO, UWB and SKOV3ip1 are HR incompetent.
To assess whether HR competence influences viral effiacy, HR com-
petence was plotted against the IC50 to dl922-947 (Figure 4.6). Al-
though the differences are not significant, the results follow the same
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pattern seen in the PE01 and PE04 cells, that HR competent cells are
more sensitive to adenoviral effiacy. This suggests that the HR path-
way may be important in determining sensitivity to virus.
















Figure 4.6: Association between IC50 dl922-947 and HR competence. Sensi-
tivity to dl922-947 was assessed in a panel of cell lines, the IC50
was calculated and plotted against HR competence as assessed
by Figure 4.5. Results suggest a trend that HR competent cells
are more sensitive to dl922-947 but this was not significant. Solid
line represents median value.
4.2.3 Viral infectivity and cytotoxicity in a matched HR competent and
incompetent cell line
To investigate the differences in adenovirus sensitivity between the
BRCA2 deficient and proficient PE01 and PE04 cells, respectively, I
next assessed viral infectivity using an Ad5 GFP virus (E1 deleted
Ad5 vector encoding GFP under the CMV immediate early promotor).
Results revealed that the PE04 cells were 10 times more infectable
with Ad5 vectors than the PE01 cells (Figure 4.7a). To determine
whether this difference in infectability could explain the different in
viral efficacy, I determined the dose of virus that achieved equal in-
fection between the PE01 and PE04 cells (the iso-infective dose) (MOI
6 PE04, MOI 60 PE01 or MOI 10 PE04, MOI 100 PE01) (Figure 4.7b).
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Even at iso-infection MOI, PE04 cells remained significantly more sen-
sitive to both dl922-947, (Figure 4.8a) and dl309 (Figure 4.8b). This
confirms the results in the previous chapter that infectivity is not the
only determinant of viral cytotoxicity.
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Figure 4.7: Viral infectivity in an HR competent and incompetent cell pair.
(a) PE01 and PE04 cells were infected with Ad5 CMV-GFP with
increasing doses of virus. Infectivity was assessed by GFP pos-
itivity 24hours later by flow cytometry. (b) Equal infection be-
tween PE01 and PE04 cells was achieved at MOI 60 (PE01) and
MOI 6 (PE04) or MOI 100 (PE01) and 10 (PE04). PE01 and PE04
cells were infected in triplicate with Ad CMV-GFP at MOI 60 and
100 (PE01) and MOI 6 and 10 (PE04). Infectivity was assessed by
GFP positivity 24 hours later by flow cytometry. Bars represent
mean percentage of GFP positive cells +/- s.d, n = 3. n/s: no
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Figure 4.8: Viral cytotoxicity in an HR competent and incompetent cell line
following iso-infection. 1⇥ 104 cells were infected with dl922-947
(a) or dl309 (b) at the iso-infective dose (MOI 10 or 6 for PE04 and
MOI 100 and 60 for PE01) and cell survival assessed by MTT 144
hours later (mean +/- s.d. n = 3, **** p< 0.0001, ** p =0.0086; 2
tailed t-test).
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4.2.4 Viral lifecycle in the matched HR competent and incompetent cell
lines
Following the observation that the HR competent cell line are more
sensitive to viral cell death, I next investigated aspects of viral life-
cycle in these cell lines. Viral replication was assessed using a TCID50
assay, this revealed no significant difference in the number of infec-
tious virions generated following iso-infection at 24, 48 and 72 hours
(Figure 4.9). Viral protein expression was assessed by immunoblot.
There was comparable early (E1A) and late (Ad5, structural proteins)
















Figure 4.9: Viral replication in an HR competent and incompetent cell line.
PE01 and PE04 cells were infected with dl922-947 MOI 100 (PE01)
or 10 (PE04) for up to 72 hours. Virus replication was assessed




































Figure 4.10: Protein expression in an HR competent and incompetent cell
line. (a) PE01 and PE04 cells were infected with dl922-947 MOI
100 (PE01) or 10 (PE04). Protein was harvested up to 72 hours
post-infection. Expression of E1A and adenovirus 5 structural
proteins was assessed by immunoblot, MCM3 was used as a
loading control. (b) Quantification of E1A immunoblots follow-
ing 24, 48 and 72 hours following infection with dl922-947 in
PE01 and PE04 cells. n/s: no significant difference in E1A pro-
tein expression between the PE01 and PE04 cells at each time
point, 2 tailed t-test. n = 3.
Quantitative PCR indicated that there was more viral DNA gener-
ated in PE04 at 72hours (Figure 4.11). This was confirmed by South-
ern blotting as shown in Figure 4.12. In addition, Southern blotting
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also revealed no obvious abnormalities in viral DNA processing, and
specifically no obvious concatemers in either cell line (Figure 4.12).
This suggests that the viral DNA is processed correctly despite differ-


























Figure 4.11: Assessment of viral DNA in an HR competent and incompetent
cell line. PE01 and PE04 cells were infected with dl922-947 MOI
100 (PE01) or 10 (PE04) for up to 72 hours. Virus DNA assessed
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Figure 4.12: Assessment of viral DNA in an HR competent and incompe-
tent cell line. PE01 and PE04 cells were infected with dl922-
947 MOI 100 (PE01) or 10 (PE04) at 48 and 72h. DNA was ex-
tracted and subjected to neutral pulsed-field gel electrophoresis,
probed with HRP-labelled adenovirus type 5 probe. 100 ng puri-
fied dl922-947 DNA was run as positive control (+). Experiment
performed with Atsushi Shibata.
4.2.5 DNA damage and cell cycle in PE01 and PE04 cells
Chapter 3 showed that viral efficacy closely correlated with cell cycle
changes and DNA damage (Section 3.2.3 and Section 3.2.5). I there-
fore went on to investigate whether the difference in sensitivity to
Ad5 vectors between HR proficient and deficient cells was due to
their differential accumulation of DNA damage following viral infec-
tion. DNA damage and cell cycle was assessed by flow cytometry us-
ing propidium iodide (PI) and co-staining with gH2AX in both mock
infected cells and 48 hours following infection with dl922-947 at the
iso-infective dose. Examples of the cell cycle profiles and distribution
of gH2AX staining is shown in Figure 4.13.
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Figure 4.13: DNA damage and cell cycle in a matched HR competent and
incompetent cell pair. PE01 and PE04 cells were harvested 48
hours following infection with dl922-947 (MOI 100 and 10 re-
spectively) or mock infection, fixed in 70% cold ethanol, incu-
bated with an anti-gH2AX antibody, counter-stained with PI
and analysed by flow cytometry. Representative images shown,
percentage of gH2AX increase was compared to mock infected
cells.
As previously observed (Cooke et al., 2010), and in keeping with
their BRCA2 mutation, the PE01 cells are genomically unstable and
demonstrated a greater basal level of DNA damage and a higher
proportion of cells with >4N DNA contents on flow cytometry (Fig-
ure 4.14a and Figure 4.14b). However, following iso-infection the more
sensitive PE04 cells showed a greater increase in the proportion of
cells with >4N (Figure 4.15a) and a greater amount of DNA damage
compared to the PE01 cells (Figure 4.15a). This was consistent with
the results from my previous chapter (Section 3.2.6 and Section 3.2.7)
showing that virus-induced DNA damage correlates with sensitivity
and also in keeping with previous data (Connell et al., 2011; Inge-
















































Figure 4.14: Cell cycle and DNA damage in PE01 and PE04 cells at baseline.
(a) gH2AX staining (quantified by mean fluorescence intensity)
Significantly greater baseline gH2AX staining in the PE01 cells
* p = 0.02, 2 tailed t-test. (b) Amount of cells with more than 4N
DNA content in untreated PE01 and PE04 cells. Significantly
higher proportion of PE01 cells with more than 4N DNA con-
tent at baseline, *** p = 0.0001, 2 tailed t-test. Bars represent

































































Figure 4.15: DNA damage and cell cycle following iso-infection with dl922-
947. (a) Increase in gH2AX-positive cells following dl922-947
(MOI 100 for PE01 MOI 10 for PE04). ** p = 0.0012. (b) cells
with more than 4N DNA following iso-infection. ** p = 0.0046,
2 tailed t-test.
4.2.6 The addition of PARP inhibitor does not increase cytotoxicity to
dl922-947
PARP inhibitors, such as rucaparib and olaparib are increasingly be-
ing used clinically for patients with BRCA mutant ovarian cancer
(Lee et al., 2013). The most well documented role of Poly(ADP-ribose)
polymerase 1 (PARP1) is its essential role in the base excision repair
(BER) pathway that repairs single strand breaks (SSBs) (Lieber, 2010).
It is thought that PARP inhibition results in the accumulation of SSBs
that are converted to DSBs at replication forks. These DSBs are un-
able to be repaired in HR incompetent cells, resulting in cell death
whereas cells with competent HR pathways are unaffected by PARP
(Yap et al., 2011). I therefore hypothesed that treatment with PARP
inhibitors might increase the cytotoxicity of dl922-947 since the SSBs
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generated by PARP inhibition would be rapidly converted to DSBs
due to cell cycle progression as a result of dl922-947 infection.
To investigate this, a range of ovarian cancer cell lines were infected
with dl922-947 at increasing concentrations and 24 hours following
infection rucaparib was added (at a range of concentrations). In all
the cell lines tested (both HR competent and defective) there was
no effect of the addition of PARP inhibitor on viral dose response
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Figure 4.16: PARP inhibitor does not increase cytotoxicity to dl922-947. 1 ⇥
104 HR competent cells (TOV21G, PE04, SKOV3, TOV21G) and
an HR defective cells (PE01) were plated in 24 well plates and
24 hours later infected with increasing concentrations of dl922-
947 (MOI 0.01   1000). 24 hours later rucaparib was added to
all wells at a concentration of 0, 1, 3 and 6 µM. Cell survival as-
sesssed 120 hours following rucaparib treatment by MTT assay.
Results presented as cell survival compared to mock infected
or normalised to rucaparib alone treated cells (mean +/- s.d, n
= 3).
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4.2.7 MRE11 is degraded following infection with dl922-947
Adenovirus has been shown to block aspects of the cellular DNA
repair response. The MRN complex (MRE11, RAD50, NBS1) is a ma-
jor target following Ad5 infection and MRE11 has been shown to
be degraded following infection (Stracker et al., 2002). To investigate
whether dl922-947 produces a similar reduction, MRE11 was assessed
by immunoblot following infection with dl922-947. Consistent with
previous observations, MRE11 is reduced in both the PE01 and PE04
cells (Figure 4.17). In addition there was no significant difference be-
tween the degree of degradation of MRE11 in the PE01 and PE04 cells
following viral iso-infection. This indicates that differences in MRE11
degradation between cell lines does not explain the differences in sen-
sitivity between the HR competent and incompetent cell line.
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Figure 4.17: MRE11 is degraded following infection with dl922-947. PE01
and PE04 cells were harvested at 16, 24 and 48hours follow-
ing infection with dl922-947 (MOI 100 and 10 respectively).
Expression of E1A and MRE11 was detected by immunoblot.
MCM3 was used as a loading control. Representative blot
shown. Graph shows decrease of MRE11 following infection
with dl922-947. Densitometry of bands was assessed using Im-
ageJ, normalised to loading control and presented as propor-
tion of mock infected cells, n = 3. (PE01: * p = 0.03, *** p = 0.004,
**** p <0.0001, PE04: * p = 0.3; 2 tailed t-test results compared to
mock infected MRE11). No significant difference in reduction
of MRE11 was seen between the two cell lines, 2 tailed t-test.
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4.2.8 Inhibiting NHEJ has no effect on viral cytotoxicity in both the HR
competent and incompetent cell lines
Adenovirus has also been shown to inhibit NHEJ through mecha-
nisms that include proteosomal degradation of DNA Ligase IV (Baker
et al., 2007) and the viral proteins, E4-34kDa and E4-11kDa both bind
and inactivate DNA PK, which is an essential kinase for NHEJ (Boyer
et al., 1999a). I therefore hypothesised that the HR defective cell line
may have up-regulation of NHEJ to compensate for lack of the HR
pathway to repair DSBs: and in turn, this up regulation could affect
viral cytotoxicity. To investigate this, NHEJ was inhibited using the
DNA-PKcs inhibitor, Nu7026 (Nutley et al., 2005). There was no dif-
ference in sensitivity to the DNA-PK inhibitor between the PE01 and
PE04 cells suggesting that there are no significant differences in the
reliance on NHEJ function between these cell lines (Figure 4.18). This
is consistent with previous findings which show that BRCA2 mutant
cells show no increase in NHEJ (Xia et al., 2001). In addition, Nu7026
had no significant effect on viral cytotoxicity (Figure 4.19). Taken to-
gether, these results suggest that differences in NHEJ function cannot
explain the difference in viral cytotoxicity between the BRCA2 com-
petent and incompetent cell pair.
4.2 results 178




















Figure 4.18: Sensitivity of BRCA2 deficient and proficient cells to DNA PK
inhibitor. 2500 PE01 and PE04 cells were plated in a 96 well
plate and treated with increasing concentrations of Nu7026.
Cell survival was assessed by Cell Titer glo assay 120 hours
post treatment. Results presented as percentage cell survival
compared to untreated cells (mean +/- s.d. n = 3).



















Figure 4.19: Effect of inhibition of DNA PK to viral cytotoxicity. 2500 PE01
and PE04 cells were plated in 96 well plate and infected with
increasing concentrations dl922-947. 24 hours later 10 µM of
Nu7026 was added and survival was assessed by cell titer glo
assay 120 hours post infection. Results presented as percentage
cell survival normalised to either mock infected cells or cells
treated with Nu7026 alone (mean +/- s.d. n = 3).
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4.2.9 RAD51 is maintained at early time points following viral infection
As dicussed earlier, RAD51 is a crucial downstream protein involved
in HR repair, it is re-localised within the nucleus in response to DNA
damage and catalyzes repair by HR by invading the homologous
DNA strand (Baumann and West, 1998). Interestingly, despite degra-
dation of MRE11, expression of RAD51 was maintained at 48 hours in
both the PE01 and PE04 cells. RAD51 protein was, however, reduced
at later time points (Figure 4.20). RAD51 has a short half life (around
5 hours) (Zhu et al., 2013) and since adenoviral infection results in
the inhibition of cellular protein synthesis in later stages of infection
(Huang and Schneider, 1991), this reduction in RAD51 may be be the
result of reduced mRNA translation rather than protein degradation.
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Figure 4.20: RAD51 is maintained at early time-points following infection
with dl922-947. PE01 and PE04 cells were harvested following
infection with dl922-947 (MOI 100 and 10 respectively). Expres-
sion of RAD51 was detected by immunoblot. Ku70 was used
as a loading control. Representative blot shown. Graph shows
RAD51 expression following infection with dl922-947. Densito-
metry of bands was assessed using ImageJ, normalised to load-
ing control and presented as proportion of mock infected cells,
n = 3. * p =0.01, **** p < 0.0001, 2 tailed t-test results compared
to mock infected RAD51.
4.2.10 BRCA2 co-localises with viral replication centres
Adenoviral replication takes place within the nucleus of the cell in
regions known as viral replication centers (VRC). These VRCs can be
visualised by confocal microscopy using an antibody directed against
the adenoviral protein, E2 DNA binding protein (E2 DBP) (Reich
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et al., 1983). To assess whether core HR proteins may play a role in vi-
ral replication I analysed co-localisation between BRCA2 and E2 DBP
in virus infected cells. There was clear co-localisation between BRCA2
and E2 DBP in the PE04 cells shown in Figure 4.21a. As expected no
BRCA2 was observed in the PE01 (Figure 4.21b).
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Figure 4.21: BRCA2 co-localises with viral replication centres. PE01 and
PE04 cells were fixed in 4% PFA following infection with dl922-
947 (MOI 300 and 30, respectively). Expression of adenovirus
E2 DNA binding protein and BRCA2 was assessed by confocal
microscopy in PE04 (a) and PE01 (b) cells. Scale bar = 10 µm.
TOV21G and HeLa cells are two further cell lines that demonstrate
HR competence (Figure 4.22). Following infection with dl922-947 co-
localisation was also seen between BRCA2 and VRCs in both the
TOV21G (Figure 4.23a) and HeLa (Figure 4.23b) cells. These results

























Figure 4.22: Assessment of HR function in TOV21G and HeLa cells. Cells
were treated with rucaparib (10mM, 24 hours), permeabilised,
fixed in 4% PFA, and stained for RAD51. RAD51 foci were
counted in at least 30 nuclei per treatment condition. Bars show
mean (+/- s.d.) number RAD51 foci per cell. Dotted line, 2 ⇥
number of foci in untreated cells. TOV21G and HeLa cells dou-
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Figure 4.23: BRCA2 co-localises with viral replication centres. TOV21G (a)
and HeLa (a) cells were fixed in 4% PFA following infection
with dl922-947 (MOI 10). Expression of adenovirus E2 DNA
binding protein and BRCA2 was visualised by confocal mi-
croscopy. Scale bar = 10 µm.
4.2.11 BRCA2 influences adenovirus efficacy in HR competent cells
To investigate whether BRCA2 function influences the response to
dl922-947 in the HR competent cell lines, I depleted BRCA2 using
siRNA. To quantify knockdown, western blotting of BRCA2 protein
level was attempted. However, following multiple attempts using a
variety of conditions, I was unable to achieve reliable and repeatable
blots. BRCA2 knockdown following siRNA was therefore confirmed






























Figure 4.24: BRCA2 knockdown confirmed by quantative PCR. 48 hours fol-
lowing transfection of BRCA2 siRNA (SMART pool, Dharma-
con) or control siRNA, cells were harvested in trizol, RNA ex-
tracted and quantative RT-PCR performed to quantify relative
expression BRCA2 normalised to 18s. *** p < 0.001 2 tailed t-
test.
Following BRCA2 knockdown, I found a small but significant re-
duction in cytotoxicity following infection with dl922-947 in PE04
cells (Figure 4.25a). This was recapitulated in TOV21G and HeLa cells
(Figure 4.25b) and (Figure 4.25c). Taken together, my data suggest that

















































Figure 4.25: BRCA2 knockdown decreases adenovirus efficacy. 24h follow-
ing siRNA-mediated BRCA2 knockdown, PE04 (a), TOV21G (b)
and HeLa (c) cells were infected with dl922-947 (MOI 30 for
PE04, MOI 1 for TOV21G; MOI 8 for HeLa). Survival was as-
sessed 96 hours post-infection by MTT assay; PE04: * p = 0.038.
TOV21G: *** p = 0.007. HeLa: ** p = 0.0016 2 tailed t-test.
4.2.12 RAD51 co-localises with VRC in HR competent and incompetent
cells
Following the finding that BRCA2 influenced viral cytotoxicity, I want-
ed to look at the role of another core HR protein, RAD51. Immunoflu-
oresence revealed clear co-localisation between RAD51 and E2 DBP
following infection with dl922-947 in PE04 cells (Figure 4.26a). This
finding was confirmed in two other HR competent cells lines, TOV21G
(Figure 4.26b) and HeLa (Figure 4.26c).
It is documented that, in BRCA2-deficient cells, RAD51 is unable to
form foci at the site of DNA damage (Yang et al., 2011). However, to
my surprise, I observed RAD51 foci co-localised with E2 DBP in PE01
cells (Figure 4.27), despite the absence of BRCA2. To further assess
this, I looked at IGROV1 cells which are hypermutated and contain
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Figure 4.26: RAD51 co-localises with viral replication centres in HR com-
petent cells. PE04 (a), TOV21G (b), and HeLa cells (c) were in-
fected with dl922-947 (MOI30 for PE04, MOI 10 for HeLa and
TOV21G). 24 hours following infection cells were fixed in 4%
PFA. Expression of adenovirus E2 DNA binding protein and
RAD51 was assessed by confocal microscopy. Scale bar = 10 µm.
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cells were unable to form RAD51 foci following PARP inhibition (Fig-
ure 4.28a) and were therefore HR defective (Figure 4.28b). Consisi-
tent with the finding in PE01 cells, IGROV1 cells also revealed co-
localisation between viral replication centres and RAD51 in infected
cells (Figure 4.29).
PE01 (BRCA2 mutant)
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Figure 4.27: RAD51 co-localises with viral replication centres in the BRCA2
mutant, HR incompetent, PE01 cells. PE01 cells were infected
with dl922-947 (MOI 300). 24 hours following infection, cells
were fixed in 4% PFA. Expression of adenovirus E2 DNA bind-
ing protein and RAD51 was assessed by confocal microscopy.


































Figure 4.28: Assessment of HR function in IGROV1 cells. (a) 24 hours follow-
ing treament with rucaparib, IGROV1 cells were permeabilised,
fixed in 4% PFA and stained for RAD51 and gH2AX. Represen-
tative image shown. Scale bar = 10 µm.. (b) RAD51 foci were
counted in at least 30 nuclei per condition. Bars shown mean
(+/- s.d.). Dotted line, 2 ⇥ number of foci in untreated cells.
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Figure 4.29: RAD51 co-localises with viral replication centres in the the HR
incompetent, IGROV1 cell line. IGROV1 cells were infected
with dl922-947 (MOI 10). 24 hours following infection cells were
fixed in 4% PFA. Expression of adenovirus E2 DNA binding
protein and RAD51 was assessed by confocal microscopy. Scale
bar = 10 µm..
To further assess the interaction between RAD51 and E2 DBP, co-
immunoprecipitation was performed in the TOV21G cells following
infection with dl922-947. This suggested a direct interaction between








Figure 4.30: Co-immunoprecipitation of E2 DBP with RAD51. 24 hours fol-
lowing infection with dl922-947 (MOI 10), TOV21G cells were
lysed and incubated with IP matrix beads conjugated to anti-
RAD51 antibody (mouse, Santa Cruz, H-92) (IP:RAD51) or con-
trol antibody (IP:control). Proteins were then detected by im-
munoblotting, identifying E2 DBP binding to RAD51. Primary
antibodies used for immunoblotting: rabbit anti-Ad5 E2 DBP
and mouse anti-RAD51 (Abcam, ab213).
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These data show that RAD51 can localise to viral replication centres
and that this is independent of recruitment to DNA damage foci.
4.2.13 RAD51 influences adenovirus efficacy in both HR competent and
HR deficient cells.
To investigate the requirement for RAD51 in viral cytotoxicity, I de-
pleted RAD51 using two different siRNA constructs in both PE01
and PE04 cells and knockdown was confirmed by immunoblot (Fig-
ure 4.31).
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Figure 4.31: Immunoblot showing knockdown of RAD51 in both PE01 and
PE04 cells using two different siRNA pools (SMART pool from
Dharmacon and single siRAD51 from Qiagen). 48 hours follow-
ing transfection with siRAD51 or siControl (siCrl), cells were
harvested and lysed. Expression of RAD51 was detected by im-
munoblot; MCM3 was used as a loading control.
RAD51 depletion resulted in significant reductions in the efficacy
of dl922-947 in both the HR competent PE04 cells (Figure 4.32a) and
the BRCA2 mutant PE01 cells (Figure 4.32b). Depletion of RAD51 also
caused significant reductions in the efficacy of the E1A wild-type ade-
noviral vector, dl309, in both the HR competent (Figure 4.33a) and
HR incompetent cell lines (Figure 4.33b). These findings were recapit-
ulated in HR competent HeLa and TOV21G cells (Figure 4.34a) and








































































Figure 4.32: RAD51 siRNA reduces cytotoxicity to dl922-947 in HR com-
petent and incompetent cell lines. 24 hours following siRNA-
mediated RAD51 knockdown (left: SMART pool, right: qiagen)
PE04 cells (a) and PE01 cells (b) were infected with dl922-947
(MOI 50 for PE04 and MOI 500 for PE01). Cell survival was as-
sessed 96 hours after infection by the MTT assay. PE04: * p =







































































Figure 4.33: RAD51 siRNA reduces cytotoxicity to dl309 in the HR com-
petent and incompetent cell pair. 24 hours following siRNA-
mediated RAD51 knockdown (left: SMART pool, right: Qiagen)
PE04 (a) and PE01 (b) cells were infected with dl309 (MOI 80
for PE04 and MOI 800 for PE01) survival was assessed 96 hours
after infection by the MTT assay. PE04: *** p = 0.0007, *** p =
























































































Figure 4.34: RAD51 knockdown reduces cytotoxicity in HR competent cell
lines. 24 hours following siRNA-mediated RAD51 knockdown,
TOV21G (a) and HeLa (b) cells were infected with dl922-947
(MOI 1 and 8 respectively). Cell survival was assessed 96 hours
after infection by the MTT assay. To ensure knockdown was
achieved, RAD51 knockdown was confirmed by immunoblot:
48 hours following transfection with siRAD51 or siControl
(siCrl), cells were harvested and lysed. Expression of RAD51
was detected by immunoblot, MCM3 was used as a loading
control. TOV21G: ** p = 0.0084, ***; p= < 0.0001. HeLa: ** p =
























Figure 4.35: RAD51 knockdown reduces cytotoxicity in an incompetent cell
line. 24 hours following siRNA-mediated RAD51 knockdown,
IGROV1 cells were infected with dl922-947 (MOI 5). Cell sur-
vival was assessed 96 hours after infection by the MTT assay.
To ensure knockdown was achieved, RAD51 knockdown was
confirmed by immunoblot: 48 hours following transfection with
siRAD51 or siControl (siCrl), cells were harvested and lysed. Ex-
pression of RAD51 was detected by immunoblot, MCM3 was
used as a loading control. ** p = 0.0035 2 tailed t-test.
4.2.14 RAD51 influences adenovirus replication in both HR competent
and HR deficient cells.
Investigation of the viral lifecycle of dl922-947 in the HR incompetent
PE01 cell line and the HR competent PE04 cells revealed a significant
increase in viral DNA in the more sensitive PE04 cells (Figure 4.11).
To further assess whether the increase in viral replication is due to
the presence of functional HR, viral DNA in infected cells was as-
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sessed following depletion of RAD51. SiRNA-mediated knockdown
of RAD51 resulted in reduced viral replication in both the HR com-
petent PE04 cells (Figure 4.36a) and the HR competent TOV21G cells
(Figure 4.36b). RAD51 depletion also resulted in reduced viral repli-
cation in the HR incompetent PE01 cells (Figure 4.36c). These results
suggest that presence of RAD51, a key component of the HR pathway,


























































































































Figure 4.36: Viral replication is reduced following knockdown of RAD51.
PE04 (a), TOV21G (b) and PE01 (c) cells were infected with
dl922-947 (MOI 100 for PE01 and MOI 10 for TOV21G and
PE04). 24 hours after knockdown of RAD51 with SiRNA. Cells
were harvested 48 hours later, DNA extracted and early and late
viral proteins (E1A and Hexon) were assessed by quantitative
PCR. **** p = < 0.0001, ***; p = < 0.0001, 2 tailed t-test.
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4.2.15 dl922-947 does not inhibit HR function in HR competent cell lines
To assess whether adenovirus infection impaired the capacity of cells
to repair DNA DSBs by HR, I first analysed RAD51 and gH2AX foci
by confocal microscopy. In HR competent cells infected with dl922-
947, RAD51 was able to localise, at least partially, to sites of DNA
DSB damage, suggesting that HR function remains grossly intact fol-
lowing adenovirus infection (Figure 4.37). This functionality was fur-
ther assessed using a fluorescence reporter assay , which incorporates
a green fluorescence protein reporter (DR-GFP) as a repair substrate
into the genome and assays non-crossover gene conversion events
in response to DNA DSB damage (see Section 2.11 for full details).
The HR competence of PE04 cells was again confirmed by this as-
say, with a significant increase in GFP events following expression
of I-Scel compared to control plasmid, whereas PE01 showed no in-
crease (Figure 4.38a). To investigate the effect of adenovirus infection
on overall HR function, this assay was repeated 48 hours after in-
fection with dl922-947 — results again showed that PE04, but not
PE01, was able to repair I-SceI-induced DNA DSB damage using HR
(Figure 4.38b). This implies that Ad5 infection does not functionally
impair homology-mediated repair.
DAPI  H2AX RAD51 Merge
Figure 4.37: gH2AX and RAD51 foci following infection with dl922-947.
PE04 cells were infected with dl922-947 (MOI 10). 24h post-
infection, cells were fixed. Expression of gH2AX and RAD51



















































































Figure 4.38: dl922-947 infection does not alter the function of HR. (a) PE01
and PE04 cells stably expressing DR-GFP plasmid were trans-
fected with a plasmid encoding the rare cutting endonuclease
(pI-SceI) or control plasmid. 24 hours thereafter, expression of
GFP was assessed by flow cytometry. Data show fold change
in GFP positive events following pI-SceI transfection relative to
control plasmid (dotted line). Bars represent mean +/- s.d. * p
< 0.05 compared to control plasmid transfection. No change in
GFP events were seen in the PE01 cells following pI-Scel trans-
fection confirming HR incompetence. In contrast, a 2 fold in-
crease in GFP events was seen following pI-Scel transfection
confirming their HR competence. (b) PE01 and PE04 cells sta-
bly expressing DR-GFP plasmid were infected with dl922-947
(MOI 50 and 500 respectively). 24 hours later, they were trans-
fected with pI-SceI or control plasmid. 24 hours thereafter, ex-
pression of GFP was assessed by flow cytometry. The presence
of dl922-947 did not change GFP events following plasmid trasn-
fection. Data again show fold change in GFP positive events fol-
lowing pI-SceI transfection relative to control plasmid (dotted
line). Bars represent mean +/- s.d. ***: p < 0.001 compared to
control plasmid transfection 2 tailed t-test.
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As previously stated, loss of HR function makes cells sensitive to
PARP inhibitor and cisplatin treatment. To further confirm that dl922-
947 does not impair HR, PE04 cells were treated with the PARP in-
hibitor rucaparib or cisplatin 24 hours following dl922-947 or mock
infection: the presence of dl922-947 was unable to sensitize PE04 cells
to rucaparib (Figure 4.39a) or cisplatin (Figure 4.39b). This again im-






































Figure 4.39: Adenovirus infection does not increase sensitivity to PARP in-
hibitor or cisplatin. PE04 cells were infected with dl922-947
(MOI 50) and 24 hours later treated with rucaparib (0.01 – 300
mM) for 72h (a) or cisplatin (0.01-1000mM) for 72 hours (b) No
change in the cells’ sensitivity to PARP inhibitor or cisplatin
was seen.
4.3 discussion 200
Together, these results indicate that Ad5 vectors do not inhibit HR
function in infected cells — rather, components of the HR machinery
localise to VRC and bind directly to E2 DBP. This interaction pro-
motes viral DNA replication and increases overall cytotoxicity.
4.3 discussion
In this chapter I show that components of the HR pathway required
for DNA DSB repair significantly influence the activity of Ad5 vec-
tors. Using matched BRCA2 mutant and functional ovarian cancer
cells, I show that the activity of both E1A wild-type (dl309) and E1A
CR2-deleted (dl922-947) Ad5 viruses is greater in the presence of func-
tional HR, with increased cytotoxicity and viral DNA replication. I
have shown that BRCA2 co-localises with VRC within the nucleus.
These results were recapitulated in other malignant cell lines, HeLa
and TOV21G, that are BRCA2 wild-type and HR competent. I have
also demonstrated that RAD51, a key partner of BRCA2, also influ-
ences Ad5 activity. Interestingly I also show that RAD51 influences
adenovirus activity and locates to VRC in the absence of functional
BRCA2.
Genomic analysis have shown that HR is vitally important in the bi-
ology of HGSOC (TGCA, 2011). Studies have shown a distinct clinical
phenotype associated with HR proficient compared to HR deficient
tumours. BRCA mutated ovarian cancer patients demonstrate supe-
rior response to platinum chemotherapy and longer platinum-free
durations than wild-type BRCA ovarian cancer patients with BRCA2
mutation carriers having the best prognosis (Yang et al., 2011; Bolton
et al., 2012). In contrast, tumours with intact HR are less likely to re-
spond to platinum-based chemotherapy (Mukhopadhyay et al., 2012)
and PARP inhibitors (Bryant et al., 2005) and in BRCA mutated can-
cers, secondary mutations that result in gain of function of BRCA1
or BRCA2 are associated with platinum resistance (Sakai et al., 2008;
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Swisher et al., 2008). Thus, an understanding of the interaction be-
tween DDR pathways and any novel therapy, including oncolytic ade-
novirus therapy, is particularly important. Investigation of these path-
ways and in particular the HR pathway could aid patient selection for
future clinical trials and open up opportunities to enhance the effiacy
of treatments.
HR is one of two main mechanisms that repair highly toxic DNA
DSBs. HR uses the undamaged sister chromatid to carry out high
fidelity repair of predominantly replication-associated DSBs (Daley
et al., 2013) and therefore can only function during S and G2 phases
of the cell cycle when an intact sister chromatid can serve as a tem-
plate for repair (Branzei and Foiani, 2008). Although this pathway
repairs only a minor proportion of DSBs, it is important becauses
it is high fidelity and crucial for the maintenance of genomic stabil-
ity (Moynahan and Jasin, 2010). HR also deals with stalled and col-
lapsed replication forks (Carr and Lambert, 2013; Petermann et al.,
2010). HR is a complex process involving multiple proteins. RAD51
catalyses the defining step of HR: strand exchange, during which sin-
gle stranded DNA invades homologous duplex DNA, displacing the
identical strand of the duplex and forming a displacement loop (Sung,
1994; Baumann et al., 1996). BRCA2 is critical as it mediates the load-
ing of RAD51 onto 3’-single strand DNA overhangs (created by CtIP
ond MRE11 nuclease activity), creating a RAD51 nucleoprotein fila-
ment (Jensen et al., 2010). The nucleoprotein filament then catalyses
the critical step of HR, strand invasion and homology search on the
intact sister chromatid .
In contrast to HR, NHEJ represents the major DSB repair pathway
in mammalian cells. NHEJ ligates DSBs with minimal end process-
ing. It is not error free but it is active in all phases of the cell cy-
cle, predominating in G0 and G1 (Lieber, 2010; Branzei and Foiani,
2008). The core NHEJ proteins are Ku70, Ku80, DNA-dependent pro-
tein kinase catalytic subunit (DNA-PKcs), Artemis and DNA ligase
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4. How cells choose between NHEJ and HR repair is a subject of in-
tense interest. Clearly, cell cycle is a vital determinant, with NHEJ
dominant in G1 (Delacôte and Lopez, 2008; Shrivastav et al., 2008).
However, other factors play a part in pathway choice. For example,
factors that inhibit resection such as the Ku heterodimer (Fattah et al.,
2010) and 53BP1 (reviewed in Panier and Boulton, 2014) will favour
NHEJ, whereas CtIP and Mre11 nuclease promote resection and there-
fore HR (Symington and Gautier, 2011). The complexity of DNA DSB
damage is also a significant determinant of repair pathway choice.
In S/G2 phase, data suggest that NHEJ initially attempts repair but
if rapid end-joining does not occur, resection occurs promoting HR
repair (Shibata et al., 2011). The repair of cellular DSBs is therefore
a complex process that has many levels of control and its ultimate
aim is to maintain integrity of the genome (Friedberg et al., 2006). Al-
though results from this chapter and the previous one show that the
DDR is clearly activated following infection with dl922-947 whether
the repair pathways downstream of H2AX phosphorylation are able
to repair DSB damage is currently not clear.
The interaction between adenoviral infection and the DDR is com-
plex; in contrast to other forms of DNA damage, such as irradiation,
where damage occurs almost instantaneously, viral infection repre-
sents a dynamic onslaught to the cell, which makes analysis challeng-
ing.
Activation of the cellular DDR could be deleterious to viral repli-
cation Ad5, therefore, inhibits DDR using a variety of mechanisms.
A major target of the virus following Ad5 infection is the MRN com-
plex (comprised of MRE11, RAD50 and NBS1) (Stracker et al., 2002).
The MRN complex is inactivated by several mechanisms following
Ad5 infection. E1B-55K together with E4orf6 form an E3 ubiquitin
ligase complex with the cellular proteins Cul5, Rbx1 and elongins
B and C and targets MRE11 for proteosomal degradation (Harada
et al., 2002; Querido et al., 2001). A second mechanism is the mis-
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localisation of the MRN components by E4-orf3 and E1B-55K from
the nucleoplasm to nuclear tracks (Evans and Hearing, 2005) and
cytoplasmic aggresomes (Araujo et al., 2005). This both sequesters
the MRN complex away from the viral genomes and also results in
MRE11 degradation. Consistent with these previous findings, I show
that MRE11 expression diminishes following infection with dl922-947,
in both HR competent and incompetent ovarian cancer cells. Infection
by adenovirus also targets the NHEJ pathway by mechanisms such
as proteasome-mediated degradation of DNA Ligase IV and inactiva-
tion of DNAPK (by viral E4-34kDa and E4-11kDa) (Baker et al., 2007;
Boyer et al., 1999a). The results revealed that there is no difference
in the NHEJ pathways between the BRCA2 WT and mutant cells. In
addition, my Southern blot showed no concatemer formation in ei-
ther PE04 or PE01 cells, suggesting that viral DNA can be processed
correctly regardless of the state of cellular HR competence. The ex-
planation of why the BRCA2 mutant cells are more resistant to viral
infection is therefore not due to differences in the ability of the virus
to inhibit factors such as MRE11 and the NHEJ pathway. Instead my
results indicate that the virus requires functional HR for more effi-
cient replication.
The relocation of other DDR proteins, including RPA32 (Stracker
et al., 2005), ATR, ATRIP, RAD9, TOPBP1, RAD17 and hnRNPUL1
(Blackford et al., 2008; Carson et al., 2009, 2003), to VRC following
Ad5 infection has been described previously by others. However, it
has been unclear whether this relocalisation inhibits DNA damage
repair function or whether it is required for viral replication (Turnell
and Grand, 2012). In the case of BRCA2 and RAD51, my data suggest
the latter, as loss of either protein reduces Ad5 replication. In addition,
using three different techniques to assess HR function, my results
suggest that the ability of cells to repair DNA DSB damage via HR
is not inhibited following Ad5 infection. This reinforces the idea that
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Ad5 utilises components of the HR pathway rather than degrading
and inhibiting them as is the case with NHEJ.
Other DNA viruses have been shown to require components of
the DNA repair pathways for efficient replication. ATM is required
for optimal replication of SV40 (Sowd et al., 2013, 2014), Herpes sim-
plex virus-1 (HSV-1) requires ATM and the MRN complex for virus
replication (Lilley et al., 2005; Balasubramanian et al., 2010; Alekseev
et al., 2014). Proteins involved in HR (RPA32, RAD51 and RAD52)
have been shown to localise to EBV VRCs. It has been suggested that
the HR proteins may be utilised by EBV to facilitate genome produc-
tion as depletion of RPA32 and RAD51 inhibits viral DNA synthesis
(Kudoh et al., 2009). It is possible that that one of the determining
factors in the relationship of viruses to the DDR is the structure of
viral DNA and how the DNA is replicated (Turnell and Grand, 2012).
The observation that adenoviral replication is more efficient in the
presence of functional BRCA2 and RAD51 may be limited to Ad5 vec-
tors as sensitivity to Ad11 and Ad35 does not vary between BRCA2
WT and mutant cells. Previous data has also demonstrated that sub-
strates amongst the DDR proteins vary with different adenoviral sero-
types. For example p53 and MRE11 are not degraded by group B and
D viruses (Forrester et al., 2011; Cheng et al., 2011). Why different
DNA viruses and different adenoviral serotypes have evolved dif-
ferent approaches to the DDR pathways remains to be understood.
Nonetheless, there are features that are common to all DNA viruses.
These viruses are able to override cell cycle checkpoints and drive
cells into S phase to enable viral replication. Both data from this chap-
ter and the previous one demonstrates the importance of this to vi-
ral efficacy. It is also clear that adenoviruses and other DNA viruses
go to considerable lengths to manipulate components of the cellular
DDR highlighting both the complexity of this interaction and also the
importance of understanding this relationship in the development of
more effective oncolytic viruses.
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Several other key questions remain. First, how do cells retain the
apparent capacity to repair DSB damage by HR following the pro-
teasomal degradation of MRE11, which is critical for end-resection?
Although MRE11 is clearly critical to end resection, other molecules,
in particular CtIP and Exo1, can also fulfill this role (Makharashvili
et al., 2014). It is therefore possible that other proteins substitute for
the MRE11 end-resection function following Ad5 infection. Also, I
show that degradation of MRE11 is not complete — thus, there may
be a dosage effect whereby the remaining MRE11 retains sufficient
end resection capacity following adenovirus infection. Nonetheless,
whatever residual HR capacity remains following infection is still un-
able to repair virus-induced genomic DNA damage. This may result
from both the cell cycle and DNA replication states induced by the
virus. Adenovirus infection drives infected cells into an S phase-like
state (Cherubini et al., 2006) but genomic DNA replication is clearly
disorganised, which may prevent reliable generation of intact sister
chromatids. Adenovirus infection overrides multiple cell cycle check-
points, with appearance of multiple abnormal mitoses (Connell et al.,
2008). Thus, cells may slip rapidly through S and G2 phases, thereby
precluding HR repair. This re-emphasises the challenge of investigat-
ing cellular responses to adenovirus infection, where changes are dy-
namic and evolve over a period of 48 – 72 hours.
Further unanswered questions include, how do BRCA2 and RAD51
relocate to VRC and which adenovirus proteins drive the process?
Also, what exactly is their function in viral replication? Following Ad
infection, Ad5E4orf3 is responsible for re-localisation of PML bodies
into cytoplasmic tracks (Carvalho et al., 1995; Doucas et al., 1996).
It has been proposed that, during Ad infection, MRN complex is
initially located to these tracts and then transported to aggresomes
where it is degraded (Evans and Hearing, 2005; Araujo et al., 2005).
Whether these tracks are also responsible for movement of cellular
proteins like RAD51 into VRC is unknown. My immunoprecipitation
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suggests a direct interaction between RAD51 and E2DBP. E2DBP is a
multifunctional protein: it is involved in the initiation and elongation
of viral DNA replication (De Jong and Van der Vliet, 1999) as well as
the regulation of early RNA synthesis (Kitchingman, 1995). It is not
known whether the interaction with BRCA2 or RAD51 could influ-
ence these functions resulting in more efficient viral DNA replication.
Unfortunately my attempt at immunoblot and immunoprecipitation
of BRCA2 were unsuccessful, so I do not know whether there is also
a similar direct interaction with E2DBP. I also do not know whether
other viral proteins associate with RAD51 and BRCA2.
Interestingly, the role of RAD51 in viral efficacy appears indepen-
dent of its function in HR as knockdown of RAD51 in HR incompe-
tent cell lines also reduces viral efficacy. My data, however, show that
the presence of BRCA2 together with RAD51 results in more efficient
viral replication. Adenovirus DNA replication generates a displaced
single strand of parental DNA in addition to a duplex formed of a
newly synthesised daughter strand plus the other parental strand, a
structure that could resemble a replication fork. Previous work has
shown that, although functional BRCA2 is necessary for RAD51 fo-
cus formation after exogenous damage, it is not required for the
formation of S phase-associated RAD51 foci (Tarsounas et al., 2003).
Both RAD51 and BRCA2 have recently been shown to protect newly
replicated DNA strands at stalled replication forks from degradation
(Hashimoto et al., 2010; Schlacher et al., 2011) and this role is inde-
pendent of their function in HR. It is possible that adenovirus utilises
this function of RAD51 and BRCA2 resulting in more accurate and
efficient viral DNA replication, and that RAD51 can execute this role
alone. Certainly, no BRCA2 homologue has been identified in lower
eukaryotes, including S.cerevisiae in which RAD51 alone can resolve
replication stress (Mozlin et al., 2008). Clearly, adenoviral replication
and cytotoxicity can still occur in the absence of BRCA2 and RAD51,
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suggesting that these proteins are supportive rather than critical to
the adenoviral lifecycle.
In summary, this chapter shows for the first time that adenovirus
type 5 re-localises components of the HR pathway to VRC and that
viral replication is enhanced in the presence of functional HR. These
data suggests that these viruses may have specific activity in poor
prognosis ovarian cancers, those with platinum and PARP inhibitor
resistance though intact HR function. Given the importance of HR in
the biology of high grade serous ovarian cancer, an understanding
of the interaction between HR and any novel therapy is particularly
important in patient selection for clinical trials and identification of
novel virus/drug combinations.
5
H I G H - T H R O U G H P U T D N A D A M A G E A N D R E PA I R
S C R E E N
5.1 introduction
HGSOC is characterised by genomic instability and defects within the
DNA damage repair pathways. Although these defects contribute to
oncogenesis, exploiting these tumour specific defects also offers novel
therapeutic targets (Helleday et al., 2008). Targeted therapy based on
inhibiting the DDR offers the potential to tailor treatment to patients
with tumours lacking specific DDR functions (O’Connor, 2015). The
use of PARP inhibitors in HGSOC with defective HR illustrates the
single agent activity of DDR inhibitors (Tutt et al., 2010). DDR in-
hibitors have the potential to augment the efficacy of other thera-
pies such as chemotherapy or radiotherapy and this is being tested
both in the preclinical and clinical setting (Curtin, 2012). In addition,
chemotherapy resistance may be mediated through changes in the
DDR pathways and therefore DDR inhibitors may play a role in re-
versal of treatment resistance (Curtin, 2012). This chapter investigates
whether these concepts can be applied to oncolytic viral therapy and
whether there are components of the DDR that can be targeted to
enhance the efficacy of dl922-947.
Results from Chapter 3 show that the DDR is activated follow-
ing oncolytic adenoviral infection and there is a close relationship
between the degrees of DSB signaling by gH2AX and viral efficacy.
Results from Chapter 4 show the importance of the DNA repair path-
ways and reveal that components of the HR pathway, RAD51 and
BRCA2, are utilised in viral replication and that defects within the
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this pathway may result in resistance to oncolytic adenovirus. Many
other studies have shown that activation of the host DNA repair path-
way could be deleterious to viral replication and therefore adenovirus
has developed a number of strategies to inhibit these pathways (re-
viewed in Weitzman and Ornelles (2005)). This highlights the com-
plexities of the interaction between adenovirus and the host cell but
also raises the question of whether the DDR can be manipulated to
enhance the efficacy of oncolytic virus. This chapter aims to identify
components of the DNA damage repair pathway that are syntheti-
cally lethal with the oncolytic virus, dl922-947. This is achieved by




The Human DNA repair library Set V1.0 siRNA library (Qiagen, UK)
targets 230 known and putative DNA repair proteins. Each gene in
the library was targeted by two distinct siRNAs, with one siRNA
per well of a 96 well plate. This siRNA library targets over 98% of
all known DNA repair proteins. In particular it targets all the major
components of BER (21 genes), MMR (11 genes), NER (28 genes), HR
(19 genes) and NHEJ (28 genes) plus 15 DNA polymerases (Lord et al.,
2008; Wood et al., 2005).
The first step was to identify appropriate cell lines to use in the
siRNA screen. OVCAR4 and COV318 cells were chosen as they have
been shown to have the characteristic features of HGSOC with copy
number alterations and a TP53 mutation (Domcke et al., 2013). OV-
CAR4 and COV318 cells both display similar sensitivity to the on-
colytic virus dl922-947 (Figure 5.1) indicating that comparison of the
results between the screens in the two cell lines would be possible.
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Both cell lines were able to form RAD51 foci in response to DSB
damage induced by rucaparib (Figure 5.2a) and fulfilled the criteria
of competent HR by doubling RAD51 foci following rucaparib treat-
ment (Figure 5.2b) (Mukhopadhyay et al., 2010). Consistent with this,
these cells have also been shown to be BRCA1 and 2 wild-type (Dom-
cke et al., 2013) and displayed resistance to the PARP inhibitor, ruca-
parib (Figure 5.3). As expected from a HGSOC cell line, both cell
lines displayed sensitivity to cisplatin (IC50 OVCAR4 0.5 µM, IC50
COV318 2.9 µM) (Figure 5.1). These results indicated that OVCAR4
and COV318 cells would make a good model of HGSOC to use in a
high throughput siRNA screen to identify genes that would enhance



















IC50 (mean +/- s.d.)
4.5 +/- 0.96
4.6 +/- 0.29 n/s
Figure 5.1: Sensitivity of OVCAR4 and COV318 cells to dl922-947. 2000 OV-
CAR4 and 4000 COV318 cells were treated with increasing con-
centrations of dl922-947, cell survival was assessed by Cell Titre
glo 120 hours post infection. Results presented as percentage cell
survival compared to mock infected cells (mean +/- s.d. n = 3),
n/s: no significant difference between the IC50 results between




























































Figure 5.2: HR competence assessed in OVCAR4 and COV318 cells. (a) Cells
were treated with rucaparib (10 µM, 24 hours), permeabilised,
fixed in 4% PFA, and stained for RAD51 and gH2AX. Repre-
sentative immunofluorescence image shown. Scale bar = 20 µm.
(b) RAD51 foci were counted in at least 30 nuclei per treatment
condition. Bars show mean (+/- s.d.) number RAD51 foci per
cell. Dotted line, 2 ⇥ number foci untreated cells. *** p=0.001,
****p<0.0001, 2 tailed t-test
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Figure 5.3: Sensitivity of OVCAR4 and COV318 cells to rucaparib (a) and
cisplatin (b). 2000 OVCAR4 and 4000 COV318 cells were treated
with increasing concentrations of cisplatin or rucaparib in a 96
well plate, cell survival was assessed by Cell Titre glo 120 hours
following treatment. Results presented as percentage cell sur-
vival compared to untreated cells +/- s.d.
5.2.2 Optimisation experiments
A series of optimisation experiments were performed to determine
the optimal protocol to perform the siRNA screen. The aim was to
identify conditions where the transfection reagent was minimally tox-
ic but yielded efficient transfection. To do this a non-targeting control
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siRNA (siCtrl) was used to assess toxicity and siRNA targeting PLK1
assessed transfection efficacy. PLK1 is a polo-like kinase implicated
in mitosis and apoptosis; its silencing causes cell death in most cell
lines (Liu and Erikson, 2003). From these validation experiments, the
conditions that yielded the best results were with 2000 OVCAR4 cells
and 4000 COV318 cells per well of a 96 well plate using RNAi max
(invitrogen) as the transfection reagent (Figure 5.4).
Next, experiments were performed to identify the appropriate dose
of virus to use in the screen. To see both increased efficacy and re-
sistance to dl922-947 following siRNA I aimed to have around 60-
70% cell death in cells treated with dl922-947. Following optimisation
















Figure 5.4: Optimisation of transfection reagents. 2000 OVCAR4 cells and
4000 COV318 cells were seeded in 96 well plates. 24 hours later
the cells were transfected with RNAi MAX and 50 nM of control
siRNA or siPLK1. The medium was changed after 6 hours. 120
hours following transfection cell survival was measured by Cell
Titre glo. Data normalised to untransfected cells +/- s.d.
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Figure 5.5: Optimisation of dose of virus. 2000 OVCAR4 cells and 4000
COV318 cells were seeded in 96 well plates. 24 hours later the
cells were transfected with RNAi MAX and 50 nM of control
siRNA. The medium was changed after 6 hours. 24 hours fol-
lowing transfection cells were infected with dl922-947 (MOI 5)
or mock infected. 96 hours following infection cell survival was
measured by Cell Titre glo. Bars represent survival compared to
mock infected cells +/- s.d.
5.2.3 DNA damage and repair screen
OVCAR4 cells and COV318 cells were plated in 96 well plates (14
plates per cell line) and transfected the following day with the Human
DNA repair library. SiCrl and siPLK1 were included on each plate for
transfection controls. Medium was changed 6 hours later. 24 hours
following transfection cells were infected with dl922-947 MOI 5. Cell
viability was assessed 96 hours following infection by Cell Titre glo.
For full details see materials and methods Section 2.12 and Figure 2.2.
Analysis of the results was performed by calculating Z scores. This
is an established method for analysing the output from high through-
put screens (Zhang et al., 1999a). Luminescence readings from each
well were log transformed and normalised according to the median
signal on each plate. These scores were then standardised by the use
of a Z score statistic (the MAD score) to estimate variation in each
screen. The Z score represents the magnitude of difference between
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one siRNA compared to the rest of the screen. This is based on the as-
sumption of a normal distribution of cell viability upon siRNA library
transfection in a specific cell line. The screen was completed in dupli-
cate and Z scores were calculated to show the effect of the siRNA in
the mock infected wells, the cells infected with virus and a final DZ
score showing the effect of virus (the difference between the mock
and viral infected cells). Negative DZ scores represent genes synthet-
ically lethal with dl922-947. Positive DZ scores represent genes that
result in resistance to dl922-947 (DZ scores for all genes in the screen
is shown in Section A.2).
Comparison of the screens revealed a close correlation between
the duplicates suggesting good reproducibility (Figure 5.6). OVCAR4
cells show greater correlation between the two screens indicating the
results from this cell line are probably more robust than the results
from COV318 cells. This difference reflects the more efficient trans-
fection seen in these cells. The final DZ score showing the effect due
to virus effect was calculated and the duplicates of the screen were
combined and are displayed in Figure 5.7a and Figure 5.7b. In ad-
dition Figure 5.8 shows the results presented as a waterfall plot. A
robust significance or ’hit’ threshold was defined as a DZ of -2 or less.
This threshold is higlighted in figures Figure 5.7a, Figure 5.7b and
Figure 5.8 by the red dotted line. Figure 5.8 also shows examples of
genes that, when silenced, results in increased sensitivity (negative
















































Figure 5.6: Reproducibility of HTS. Correlation of the effect of SiRNA on
cell viability in mock infected cells and cells infected with dl922-
947 (MOI 5) in the duplicate screens. (a) Correlation of Z score
in OVCAR4 cells in mock infected cells (Spearman r = 0.92, p <
0.0001) and cells infected with dl922-947 (Spearman r = 0.81, p < .
(b) Correlation of Z score in COV318 cells in mock infected cells
(Spearman r = 0.72, p < 0.0001) and cells infected with dl922-947




























Figure 5.7: Scatter plot showing average DZ scores for virus effect in OV-
CAR4 cells (a) and COV318 (b). DZ score of 0 = no change in
cytotoxicity to virus; DZ score of > 0 = resistance to virus; DZ
score < 0 increased sensitivity to virus. Red line indicates -2 av-














































Figure 5.8: Waterfall plot of Scatter plot showing average DZ scores for virus
effect in OVCAR4 cells (a) and COV318 (b). Red line indicates
-2 average DZ score significance level. Each point represents the
average DZ score for each siRNA. Examples of genes that sensit-
ised both OVCAR4 and COV318 cells to virus are shown in red,
example of genes that resulted in resistance are shown in blue.
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5.2.4 Hits from screen that resulted in increased sensitivity to dl922-947
Hits were identified based on a DZ score of -2. This identified 5 genes
that sensitised both OVCAR4 and COV318 cells to dl922-947: RBM4,
CCT5, CETN2, MMP9, NONO, MBD1. Figure 5.9 shows the DZ score
for the effect of virus for the individual hits identified for the two
siRNAs used in the screen (labelled siRNA1 and siRNA2). Although
a good correlation between the effects of the siRNAs was seen in
both the cell lines, the two individual siRNAs did not appear to have
the same effect. This could be due to one siRNA giving more effi-
cient knockdown or that the effect was due to off target effects of the










































































Figure 5.9: Genes selected from the high-throughput siRNA screen that re-
sulted in sensitisation to dl922-947. Genes were selected from the
screen if the DZ score reached -2. Graphs show the average DZ
score for each siRNA in the OVCAR4 and COV318 cells. Dotted
line represents -2 average DZ score significance level.
The genes identified as being potentially synthetically lethal with
dl922-947 have diverse roles as summarised below:
NONO (non-POU domain containing, octamer-binding):
• ssDNA and RNA binding protein (Yang et al., 1993)
• Involved in transcriptional regulation and RNA splicing (Emili
et al., 2002).
• Recruited to sites of DNA damage, promotes NHEJ, inhibits HR
(Krietsch et al., 2012).
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RBM4 (RNA Binding motif protein 4):
• RNA binding protein involved in processes such as alternative
splicing of pre-mRNA (Lai et al., 2003) and translation regula-
tion (Lin et al., 2007).
• Required for micro-RNA gene silencing and associates with
members of the argonaute family (Lin and Tarn, 2009)
CCT5 (Chaperonin Containing TCP1, Subunit 5)
• Molecular chaperone that is a member of the chaperonin con-
taining TCP1 complex (CCT). The complex folds various pro-
teins, including actin and tubulin (Kubota et al., 1994).
CETN2 (centrin 2):
• The centrins are small calcium binding proteins that are ubiq-
uitous centrosome components (Satisbury, 1995). Centrin 2 is
required for centriole duplication and centrioles play a role in
organising spindle pole morphology and in the completion of
cytokinesis (Salisbury et al., 2002).
• CETN2 is required for efficient Nucleotide excision repair (NER)
(Dantas et al., 2012). It stabilises the xeroderma pigmentosum
group C responsible gene product (XPC) repair complex and
stimulates NER (Araki et al., 2001).
MMP9 (Matrix metalloproteinase 9)
• The MMP family are zinc-dependent endopeptidases that have
been shown to play a central role in many normal and patholog-
ical conditions including wound healing, angiogenesis, embryo-
genesis, arthritis and tumor metastasis (Nagase and Woessner,
1999) .
• has also been shown to interact with Ku at the cell membrane
of highly invasive hematopoietic cells (Monferran et al., 2004)
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MBD1 (Methyl-CpG binding domain protein 1):
• binds to methylated CpG islands and couples DNA methylation
to transcriptional repression (Ng et al., 2000)
• has been implicated in gene regulation, chromatin formation
and genome stability (Lopez-Serra et al., 2006)
• binds to mediator of DNA damage checkpoint protein 1 (MDC1),
which is induced by radiation and regulates NBS1 activation in
the presence of DNA damage (Xu et al., 2013).
5.2.5 Screen hits that resulted in resistance to dl922-947
I next identified the genes from the screen that showed positive DZ
scores. This suggests inhibition of these genes results in resistance
to dl922-947. Despite extensive optimisation of the screen, the virus
dose of MOI5 did not result in as much cell death as predicted (less
than 10% cell death in one screen) (Figure 5.10). This impacted the
ability to see genes that would result in resistance to dl922-947. A
positive DZ score of 1 was therefore used to identify genes that re-
sulted in resistance to virus. Figure 5.11 shows the average DZ scores
for the two different siRNAs in the OVCAR4 and the COV318 cell
lines. Despite the technical difficulties, the screen showed that RAD51
and BRCA2 both resulted in positive Z scores, in agreement with the
results from Chapter 4. Along with these important HR genes, fur-
ther HR associated genes were identified - RAD54L (Tan et al., 2003),
RAD9A (Lieberman, 2006) along with BRCA1. This adds strength to
the results from the previous chapter, that viral replication may in-
volve components of the HR pathway. Interestingly, knockdown of
RPA1 and RPA3 also resulted resistance to virus (Figure 5.11). RPA is
involved early in the repair of DSBs. Following end resection at DSBs,
RPA binds to ssDNA prior to RAD51 and is involved in regulating















Figure 5.10: Cell survival following infection with dl922-947 in the siControl
wells. The luminescence values from the siControl wells were
analysed from the screen data to determine cell survival follow-
ing MOI5. Bars represent average percentage cell survival +/-
s.d. in siControl wells in all the plates of the screen.
Further genes identified that resulted in resistance to dl922-947
were DDX48 (RNA helicase) and NUP205 (nucleoporin 205kDa, sub-
unit of the nuclear pore complex) (Figure 5.12). Nuclear pore com-
plexes (NPCs) control transport of macromolecules between the nu-
cleus and cytoplasm (Theerthagiri et al., 2010). NUP205 has recently
been shown to be actively dephosphorylated by the Ad5-encoded pro-
tein E4orf4 and is required by Ad5 to regulate viral gene expression
and efficient viral replication (Lu et al., 2014) (Figure 5.12).
These results may reveal important information about the interac-
tion of oncolytic virus and the host cell and further investigation of



























































































Figure 5.11: Genes selected from the high-throughput siRNA screen that re-
sulted in resistance to dl922-947. HR related genes were selected
from the screen if the DZ score reached 1. Graphs show the aver-
age DZ score for each siRNA in the OVCAR4 and COV318 cells.




























Figure 5.12: Genes selected from the high-throughput siRNA screen that re-
sulted in resistance to dl922-947. HR related genes were selected
from the screen if the DZ score reached 1. Graphs show the av-
erage z score for each siRNA in the OVCAR4 and COV318 cells.
Dotted line represents 1 average Z score significance level.
5.2.6 Validation of siRNA hits
In addition to silencing a target gene, siRNAs potentially suppress
the expression of a large number of other genes through off target
effects. Therefore, I repeated the HTS assay separately with four indi-
vidual siRNAs targeting each of the selected genes that sensitised to
dl922-947 using a custom made 96 well plate from Qiagen. Successful
validation of a ’hit’ gene would be determined if at least 2 out of the
4 individual siRNAs sensitised to dl922-947 (Echeverri et al., 2006).
As shown in Figure 5.13a and Figure 5.13b none of the genes val-
idated using this method. Despite the disappointing results, one of
the siRNAs targeting NONO did result in significantly increased cy-
totoxicity with dl922-947 in both the OVCAR4 and the COV318 cells.
Further experiments are therefore required to assess the significance
of this finding.
There are a number of possible explanations for the lack of consi-
tent positive findings with all the siRNAs. Firstly, it is possible the
siRNAs were not achieving efficient knockdown with all of the siR-
NAs. Alternatively, the effects I saw in the screen were due to off tar-
get effects rather than silencing of the gene in question. In addition,
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experiments using a 96 well plate to assess viral cell death following
siRNA knockdown may not be the ideal format. In the experiments
previously performed to look at viral efficacy following siRNA medi-
ated knockdown, optimal results were achieved with a larger number
of cells in a 24 well plate (for example: Figure 4.35 and Figure 4.34b).
Further validation experiments are therefore required, with assess-
ment of the degree of knockdown by immunoblot in parallel.
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Figure 5.13: High-throughput screen validation. 2000 OVCAR4 (a) and 4000
COV318 (b) cells were plated on 96 well plates. 24 hours later
cells were transfected with 4 siRNAs targeting each of the genes
identified from the screen as ’hits’ along with siControl. 24
hours thereafter cells were infected with dl922-947 MOI5 or
mock infected. Cell viability was measured 96 hours following
infection by Cell Titre glo. The bars represent the mean of 3
independent experiments +/- S.E.M. t-tests peformed to com-
pare each individual siRNA to siControl in each cell line: ** p =
0.0095 , **** p < 0.0001, * p = 0.02.
5.2 results 228
5.2.7 Further validation of hits
Despite the disappointing results, one of the siRNAs targeting NONO
did result in significantly increased cytotoxicity with dl922-947 in
both the OVCAR4 and the COV318 cells. To assess whether NONO is
a novel target that is synthetically lethal with dl922-947, I performed
further validation experiments. Following from the methods used in
the previous chapter, where more reliable results were achieved using
a larger number of cells, I repeated the experiment in a 24 well plate.
I have also used a SMART pool targeted NONO instead of single
siRNAs. Knockdown of NONO resulted in increased cytotoxicity to
dl922-947 (at MOI 5, 10 and 20) in the OVCAR4 cells (Figure 5.14a). A
similar trend was also seen in the COV318 cells although the effects
were not as significant (Figure 5.14b). Immunoblot was performed
to determine the degree of knockdown of NONO 48 hours follow-
ing transfection of the siRNA (Figure 5.15). Complete knockdown
was not achieved in either cell line. However, there appeared to be a
greater degree of knockdown in the OVCAR4 cells compared to the
COV318. This may explain why the cytotoxic effect in the COV318
cells was not as significant as in the OVCAR4 cells. These results







































Figure 5.14: NONO siRNA increases cytotoxicity to dl922-947. 24 hours fol-
lowing siRNA-mediated NONO knockdown (using SMART
pool) OVCAR4 cells (a) and COV318 cells (b) were infected
with dl922-947 (MOI 5). Cell survival was assessed 96 hours
after infection by the MTT assay. Bars represent cell survival
compared to mock infected cells, (mean of 2 independent exper-
iments +/- s.d.) OVCAR4: *** p < 0.0007, ** p = 0.0047 COV318:
* p< 0.04, n/s no signnificant difference between siControl and
siNONO, 2 tailed t-test.
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Figure 5.15: Immunoblot showing knockdown of NONO in both OVCAR4
and COV318 cells using SMART pool siNONO from Dharma-
con. 48 hours following transfection with siNONO or siControl
(siCrl), cells were harvested and lysed. Expression of NONO
was detected by immunoblot, bactin was used as a loading con-
trol.
Further validation of this result is required. Initially I would like
to repeat the above experiment again with the SMART pool but also
use at least 2 single siRNAs in a 24 well plate format to confirm the
result. Concurrently I would ensure knockdown was achieved at the
protein level by immunoblot.
Once validation of the target is achieved, I would aim to assess
the mechanism behind how the gene influences adenoviral biology.
This would involve assessing aspects of viral lifecycle along with the
cellular response following knockdown of the gene. Ideally these ex-
periments would be repeated in further cell lines including both HR
competent and incompetent cells.
5.3 discussion
This chapter demonstrates the use of a high-throughput siRNA screen
targeting DNA repair proteins to identify targets that influence the
efficacy of the oncolytic virus, dl922-947. Using this technique, over
200 genes have been assessed and the results indicate that the DNA
binding protein, NONO, may be a novel target that enhances viral
cytotoxicity.
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High throughput siRNA screens offer a powerful tool for identify-
ing previously unknown targets (Mohr and Perrimon, 2012; Campeau
and Gobeil, 2011). However, as these results demonstrate, there are
challenges when using this technique. Despite extensive optimisation
experiments to identify cell number, transfection reagent and dose of
virus, the results from the screen showed inconsistencies. Firstly the
two siRNAs within the screen itself did not yield the same results.
Then, using 4 different siRNAs to validate the possible hits, sensitisa-
tion to dl922-947 was not achieved with all the siRNAs used for each
gene suggesting that the screen had identified false positive results.
False positives (and false negatives) represent a major challenge in
high throughput screening (Mohr and Perrimon, 2012). There may be
a number of possible explanations for these results. The first is that
the effect seen is due to an off target effect rather than knockdown
of the gene in question. Off targets effects are a known problem with
the use of siRNA (Birmingham et al., 2006). Alternatively, each of the
siRNAs used resulted in different degrees of knockdown of the target
genes with some being more effective than others. A limitation if the
screen is that a single concentration of siRNA was used (50nM). At
this concentration, some of the siRNAs might not be able to silence
their genes effectively or they might be able to silence their genes but
have significant off target effects. There also may be a dosage effect
where a certain degree of knockdown is needed to influence viral effi-
cacy but if more or less is achieved this effect is lost. Finally, it is also
possible that the format of the experiment may not be optimal for see-
ing differences in cytotoxicity from virus following knockdown. Viral
cell death is acutely sensitive to cell number. In a 96 well plate only
2000-4000 cells are plated per well. This small number of cells need to
be both transfected and then infected with virus. Any small variation
in cell number may have a significant impact on the end point of viral
cytotoxicity.
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This screen was only performed in two cell lines. Both OVCAR4
and COV318 have been shown to be representative of HGSOC, how-
ever they are also both BRCA1 and 2 wild type and HR functional.
Since 50% of HGSOC shows defects within the HR pathway (TGCA,
2011) it would be important to repeat this screen in cells which are
HR defective. In cells with loss of one repair pathway, there can be up-
regulation or reliance on alternative repair pathways to compensate
for the loss (Curtin, 2012). It is therefore possible that further targets
may be identified that are synthetically lethal with dl922-947 in cells
with defective HR.
Furthermore, this screen was only performed at one time-point.
The cellular effects of dl922-947 are dynamic and evolve over a num-
ber of hours (Russell, 2000). The virus interacts with the host cell
at all time-points throughout infection from cell entry to viral repli-
cation, assembly of new virions and culminating in cell death and
release of mature virions (Berk, 2005; Flint and Shenk, 1989). Differ-
ent cellular genes are required by adenovirus at various times during
infection (Berk, 2005) and in addition the host cell mounts a complex
antiviral response that evolves throughout infection (Weitzman and
Ornelles, 2005). It is possible that assessing cell survival or aspects of
viral life-cycle following knockdown of genes at different points fol-
lowing infection would reveal further genes that could influence effi-
cacy to viral cell death. In addition, cell survival was assessed at 96
hours following infection to see maximal viral cytotoxicity. However,
this was also 120 hours following knockdown by siRNA. Typically
siRNA mediated knockdown are maximal at 48-72 hours (Holmes
et al., 2010). In addition, the optimal timing of knockdown of each
gene may vary (Perrimon and Mathey-Prevot, 2007). By 120 hours
knockdown is likely to be lost (Mocellin and Provenzano, 2004) and
therefore the effect on cytotoxicity may not be evident.
Statistical evaluation of the assay performance is a very critical step
in high throughput screening data analysis. A number of data anal-
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ysis methods have been developed to correct for plate to plate assay
variability and systematic errors, and assess assay quality. The main
assumption made when analysing this screen data is that the data is
normally distributed. A log transformation was applied to the data
to achieve more symmetrically distributed data around the mean as
in a normal distribution (Goktug et al., 2013). Median and median
absolute deviation (MAD) are then used as statistical parameters as
opposed to mean and standard deviation, to diminish the effect of
outliers on the final analysis results (Goktug et al., 2013; Chung et al.,
2008). A Z score (the number of standard deviations from the mean)
was then used to normalise data. This indicates the strength of each
siRNA relative to the rest of the sample distribution. A limitation
to the use of a Z score is that, due to the effect of outliers, weak
hits may have been missed (Goktug et al., 2013). In order to correct
systematic errors occurring in a plate-specific manner (for example,
different cell-growth rates in each well due to evaporation issues that
can be seen at the edges of plates) a plate-wise normalisation was
also applied to the data (Zhang et al., 2008). Although a number of
statistical tests are applied to screen data results, false positives and
false negatives remain a recognised problem (Malo et al., 2010). Some
researchers recommend alternative statistical tests including trimmed
mean polish (Malo et al., 2010) and strictly standardized mean differ-
ence (SSMD) (Zhang and Heyse, 2009). As knowledge of the use of
high-throughput siRNA screens increases it is likely that the statisti-
cal analysis will continue to be refined and optimised.
The hits identified from the screen have diverse roles within the
cell including functions within the DDR. Following validation exper-
iments NONO was identified as the most promising gene which dis-
plays synthetic lethality with dl922-947. Further investigation is re-
quired to validate its role in influencing cytotoxicity. NONO (non
POU domain containing octamer binding protein) is a multifunc-
tional protein and highly expressed in a variety of cell lines and
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tissues (Passon et al., 2012). It has a well documented role in al-
ternative splicing (Emili et al., 2002) and contributes to transcrip-
tional regulation (Rosonina et al., 2005; Kaneko et al., 2007). In ad-
dition, it has been shown that a complex of SFPQ (Spicing factor
proline/glutamine-Rich) and NONO cooperates with Ku protein at
an early step of NHEJ, stimulating end joining activity (Udayakumar
and Dynan, 2015). Attenuation of NONO protein expression delays
the resolution of gH2AX foci after ionizing irradiation and leads to an
accumulation of chromosomal aberrations (Li et al., 2009b). Recruit-
ment of NONO to DNA damage sites has been shown to be com-
pletely dependent on PAR, generated by activated PARP1 (Krietsch
et al., 2012). Furthermore, upon PAR-dependent recruitment, NONO
stimulates NHEJ and represses HR in vivo (Krietsch et al., 2012).
NONO has been shown to be highly expressed in breast cancer
tissues as compared with the adjacent normal tissues in human pa-
tients. It is proposed that through regulation of SREBP 1a (a master
activator for genes involved in lipid biosynthesis), NONO supports
the increased cellular demand of lipids for breast cancer growth (Zhu
et al., 2015). A rearrangement between this gene and the transcription
factor E3 gene has been observed in papillary renal cell carcinoma
(Clark et al., 1997).
Further experiments are obviously required to investigate role of
NONO in influencing cytotoxicity of cells to dl922-947. There is cur-
rently no published data on the role of NONO in adenoviral biology
suggesting that these results may represent a novel finding. It may be
that expression of NONO influences adenoviral replication through
its ability to up-regulate NHEJ and down regulate HR. It is possible
that knockdown of NONO results in stimulation of factors involved
in the HR pathway which are subsequently required for viral replica-
tion (as shown in Chapter 4). NONO has been shown to play a role in
regulating viral gene expression in Epstein Barr virus (EBV). NONO,
together with SFPQ, associate with a non-coding RNA produced by
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EBV which interacts with the host transcription factor paired box pro-
tein 5 (PAX5). This regulates both EBV gene regulation and lytic repli-
cation (Lee et al., 2016). These results raise the possibility of whether
NONO also interacts with the non-coding viral associated (VA) RNAs
in adenovirus.
Despite the limitations of this screen, the results are supportive of
the data from Chapter 4. Knockdown of both RAD51 and BRCA2 re-
sulted in resistance to dl922-947 along with other genes from the HR
pathway, including RAD54L and BRCA1. In addition RPA1 and RPA3
produced similar results. RPA binds to ssDNA prior to RAD51 bind-
ing and is both a positive and negative regulator of RAD51 function.
BRCA1, BRCA2 and RAD54L also play a role in regulating binding of
RAD51 to ssDNA (Shrivastav et al., 2008; Tan et al., 2003; Cousineau
et al., 2005). These results imply that it could be the regulation of
RAD51 binding to ssDNA that influences viral cytotoxicity.
In summary, these results have identified novel targets that both in-
crease efficacy of oncolytic adenovirus (NONO) and also those which
result in resistance to the virus (e.g. RPA). These data illustrate the
complex interaction between dl922-947 and the cellular DDR and fur-
ther investigation of these genes may reveal new information regard-
ing the interaction between adenovirus and the host cell. Since the
DDR pathway is frequently mutated in ovarian cancer, these results
could also lead to the identification of patients who would bene-
fit from oncolytic adenoviral therapy. In addition, knowledge of the
genes and pathways involved in determining oncolytic viral cytotoxi-
city may result in mechanisms to enhance the potency of these viruses
and guide appropriate virus/drug or chemotherapy combinations.
Part IV
D I S C U S S I O N
6
D I S C U S S I O N
6.1 a brief summary
Survival for women with ovarian cancer has changed little since the
introduction of platinum based chemotherapy more than 30 years ago
(Vaughan et al., 2011). Late stage and recurrent ovarian cancer has a
poor prognosis, response to therapy beyond first line treatment is low
and chemotherapy resistance represents a major challenge (Korkmaz
et al., 2016). There is a need for new and more effective therapies.
Replication competent oncolytic viruses are a novel treatment for
human malignancies. These viruses have been engineered such that
they take advantage of cancer specific changes for preferential repli-
cation in tumour cells resulting in tumour cell death and release of
mature virions that go on to infect neighbouring cells. The results pre-
sented here show that the E1A-CR2 deleted adenoviral vector, dl922-
947, has considerable efficacy in ovarian cancer cell lines but sensitiv-
ity to viral cytotoxicity varies. This thesis has focused on the role of
the DDR in determining the potency of oncolytic virus.
The results demonstrate the importance of both the cell cycle and
the DDR. The degree of de-regulation of the cell cycle and the extent
of DSB damage that occur following viral infection closely correlate
with dl922-947 potency. The data reveal that viral replication and cyto-
toxicity are enhanced in the presence of functional HR pathways and
that adenovirus relocalises key components of the HR pathway to
VRC. Finally, through the use of a high throughput siRNA screen, ad-
ditional components of the DDR pathways have been identified that
both increased sensitivity to virus (e.g. NONO) and also promote re-
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sistance (e.g. RPA). Together these results suggest that viral efficacy
is determined, at least in part, by intrinsic properties of the tumour
cell’s DDR pathways.
Defects within the DDR pathways are common in human malig-
nancies. HGSOC in particular is characterised by genomic instability
and defects within the HR pathway. An understanding of the inter-
action between the DDR and any novel therapy is therefore vitally
important for patient selection for clinical trials and identification of
novel virus/drug combinations.
6.2 conclusions and future work
Ultimately, the aim of this work is to translate the findings to clinical
trials and treatment of patients. Evidence for the clinical use of on-
colytic adenoviral therapy has been provided by the E1B-55K deleted
adenoviral vector, ONXY-015 (Larson et al., 2015). However, although
ONYX 015 demonstrated safety, it did not show significant clinical ef-
ficacy as a single agent (Larson et al., 2015). To improve anti-tumour
efficacy, ONXY 015 was the first oncolytic virus to be combined with
chemotherapy in a clinical trial (Khuri et al., 2000). Local responses
were achieved with direct injection of the virus when combined with
cisplatin and 5-fluorouracil (5-FU) in patients with head and neck can-
cer (Khuri et al., 2000). H101 is similar to ONYX-015 and following
successful clinical trials, has now been approved for use for treating
advanced head and neck cancer in China (Yu and Fang, 2007). This
illustrates that oncolytic viruses have the potential to be used as part
of the standard treatment in the management of patients with cancer.
There are also a number of notable examples of other non-adenovi-
ral oncolytics that have entered late-phase clinical trials. One of the
most recent trials is a phase III trial of T-VEC (talimogene laher-
parepvec), an oncolytic herpes simplex virus expressing granulocyte-
macrophage colony stimulating factor (GM-CSF) in melanoma. In this
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trial, patients were randomised to either intralesional virus or sub-
cutaneous GM-CSF. Overall response rates in the T-VEC arm were
26.4% compared to 5.7% in the GM-CSF arm with significantly higher
durable responses in the T-VEC arm (16.3% vs 2.1%) (Andtbacka
et al., 2015). Vaccinia and reovirus are also promising potential thera-
pies. JX594 is an oncolytic vaccinia virus, also engineered to express
GM-CSF. It has shown efficacy when administered intratumourally
to patients with unresectable hepatocellular carcinoma with an objec-
tive response seen in 3 of 10 evaluable patients (Park et al., 2008). A
further phase II dose finding trial has demonstrated that overall sur-
vival is related to dose (14.1 months in the high dose group vs 6.7
months) (Heo et al., 2013). A phase II study of an engineered pox
virus, PROSTVAC-VF, with GMCSF, given to men with castration-
resistant prostate cancer, has shown an 8 month survival benefit when
compared to controls (21.1 months vs 16.6 months) (Kantoff et al.,
2010).
The above examples show that oncolytic viruses show promise
but there remains a considerable disparity between the efficacy of
oncolytic virus seen in preclinical work compared with success in
clinical trials. For viral therapy to move forward, the reasons behind
the difficulty in translating in vitro results into a clinical setting need
to be addressed. Some of the key challenges in studying oncolytic
viruses are outlined below.
6.2.1 The mechanism of cell death
There are many unanswered questions regarding the mechanism of
action of oncolytic adenovirus, not least the mode of death that is in-
duced. Oncolytic viruses can kill infected cancer cells in many ways,
ranging from direct cell lysis through to a variety of cytotoxic im-
mune mediated mechanisms (Russell et al., 2012). The conventional
concepts of cell death such as apoptosis, necrosis or autophagy do
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not appear to explain the mechanism of cell death (Baird et al., 2008).
This may be partially explained by the fact that oncolytic viruses, in-
cluding adenovirus, take over and deregulate multiple cellular path-
ways including control of the molecular cell death machinery of the
infected cell. This allows the virus to fully exploit the host cell for
preferential replication of its own genome and assembly of new viral
particles. If the mechanism of oncolysis can be identified, then it may
be possible for it to be manipulated for therapeutic gain.
The data presented here show that the greater the amount of DNA
damage induced by the virus, the greater the cell death. It remains
to be determined whether the DNA damage is causing cell death or
whether it is just a marker of dying cells. If it is the former, then
promoting DSBs in the context of viral infection could increase cyto-
toxicity. Data to support this come from preclinical studies showing
the synergistic activity of combining the administration of ionising
radiation (IR) and oncolytic adenovirus (Lamfers et al., 2002; Bieler
et al., 2008; Passaro et al., 2013; Zhang et al., 2003b). However, results
suggest that the interaction between IR and viral cytotoxicity is more
complex than simply the generation of DSBs. Enhanced viral replica-
tion following IR has been reported in some studies (Lamfers et al.,
2002; Geoerger et al., 2003) but not all (reviewed in (Touchefeu et al.,
2011)). The results presented in this thesis show that over-replication
of genomic DNA correlates with viral potency. If the mechanism for
inducing DNA damage also causes cell cycle arrest, then this could
influence the efficacy of the oncolytic virus. In support of this hy-
pothesis, previous results have also shown that irradiation timing is
crucial for an effect. In a preclinical study of anaplastic thyroid carci-
noma (ATC) synergistic effects were only seen when ATC cells were
irradiated 24h prior to infection with dl922-947. This observation was
attributed to changes in the cell cycle following IR that produced an
optimal environment for viral replication (Passaro et al., 2013). It is
not possible to uncouple the cell cycle changes from the DDR and
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this demonstrates one of the challenges in assessing the specific role
of DNA damage in viral efficacy.
In addition, to maximise oncolytic viral potency you need to max-
imise viral replication within the cells. It is possible that increasing
DSBs may cause cell death prior to optimal viral replication and limit
the amount of infectious virions produced from the cell. This could
in turn reduce viral cytotoxicity. Results from my thesis show the im-
portance of the DNA repair pathways for enhanced viral replication.
If the mechanism of inducing additional cellular damage also influ-
ences the pathways that are involved in viral replication, this could
also have a negative impact on viral cytotoxicity.
The exploitation of the DDR to increase viral efficacy is clearly com-
plex and inter-linked with the cell cycle. A greater understanding of
the mechanism behind virally induced DSBs is needed to fully exploit
the potential to increase DSBs in the context of viral infection.
6.2.2 Identification of biomarkers
The key to any successful therapy is targeting the right treatment to
the right patient. Development of predictive biomarkers are becom-
ing increasingly important tools in drug development and clinical
research (de Gramont et al., 2015). Results have revealed the impor-
tance of the DDR in determining cytotoxicity to dl922-947 and iden-
tified functional HR pathways as being a possible biomarker. This
raises the question of how these tumours with competent HR path-
ways can be identified. The assay used within this thesis identified
HR competent tumours by their ability to produce RAD51 foci in re-
sponse to PARP inhibitor treatment. This functional assay has been
used successfully in ovarian cancer clinical samples (Mukhopadhyay
et al., 2010), and a similar strategy using IR to induce DNA damage
has been assessed in breast cancer samples (Naipal et al., 2014). There
are, however, difficulties in translating this functional assay into clini-
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cal practice. One of the challenges for this assay is the requirement of
the cell/tissue to be cultured and have dividing cells that go through
S phase. This is necessary since HR only functions in S phase, and
the generation of DSBs following PARP inhibitor treatment requires
the cell to encounter a SSB at a replication fork that will only occur if
the cell is cycling. Whether a form of this assay can be translated into
routine clinical practice remains to be determined. Further strategies
that have been developed to identify HR defective tumours from HR
competent tumours include assessment of genomic scars (reviewed
in (Watkins et al., 2014)), the use of gene expression profiles ((Kon-
stantinopoulos et al., 2010) and next generation sequencing (Penning-
ton et al., 2014). The main challenge is to select a method that is
robust, simple and reproducible for routine clinical practice (De Pic-
ciotto et al., 2016).
Although components of the HR pathway are important in deter-
mining the potency of dl922-947, viral replication and cytotoxicity can
still occur even in cells with mutations within the HR pathway sug-
gesting that other factors are involved. Previous work has identified
basal p21 expression as an important factor in identifying cells sensi-
tive to adenovirus cytotoxicity and correlates with expression of E1A
(Flak et al., 2010). It is postulated that high levels of p21 prior to
adenoviral infection produces a cellular environment that promotes
viral replication and this is thought to be through its interaction with
cyclin D. Adenovirus interacts with a huge array of cellular compo-
nents and deregulates multiple pathways within the host cell. In ad-
dition, viral infection is a dynamic process that evolves over many
hours. This is in contrast to other therapies like chemotherapy and ir-
radiation where damage occurs almost instantaneously and yet even
with many chemotherapy agents, predictive biomarkers are yet to
be found. These complexities surrounding viral infection question
whether it is possible to identify a single biomarker that could pre-
dict which tumours are most likely to respond.
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6.2.3 The role of the immune system
Investigating oncolytic viruses is further complicated by the complex
interaction with the immune system. On one hand, the ability of
viruses to induce a host antiviral immune response may also result
in clearance of the virus through neutralising antibodies and/or cy-
totoxic T-cell-mediated immune responses thus hindering their effec-
tiveness (reviewed in (Ferguson et al., 2012)). These antiviral immune
responses are also responsible for the dose limiting toxicities of on-
colytic viral therapy (Reid et al., 2002). On the other hand, it has also
become apparent that the immune response triggered by oncolytic
viruses is a critical component of their anti-tumour effect (Melcher
et al., 2011). Following oncolytic viral cell death, tumour cells release
tumour associated antigens (TAAs) and potentially novel cancer anti-
gens (neo-antigens). They also release pathogen-associated molecu-
lar patterns (PAMPs) and danger-associated molecular pattern sig-
nals (DAMPs) and cytokines. Together these factors can promote an
adaptive immune response that has potential to modify the immune
suppressive nature of the tumour microenvironment (Kaufman et al.,
2015b) and mediate tumour regression at distant sites that are not ex-
posed to the virus (Kaufman et al., 2015b; Mastrangelo and Lattime,
2002; Cerullo et al., 2010). Data presented in this thesis are from ex-
periments performed using cell culture only, and it is clear that to
assess the relevance of these findings fully, in vivo experiments are
needed within an immune competent model.
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6.3 potential future directions
6.3.1 Development of experimental models
The role of the immune microenvironment in HGSOC and the impor-
tance of the immune system in the efficacy of oncolytic adenovirus
highlight the need for better experimental models. It is important to
perform experiments in culture conditions that more closely resem-
ble the tumour microenvironment (Bowtell et al., 2015). This could in-
clude 3D matrices and co-culture of malignant cells with fibroblasts
and immune cells (Bowtell et al., 2015). There is also a need for an
accurate and representative murine models of human ovarian cancer
(Vaughan et al., 2011). Recent research has demonstrated the inade-
quacy of commonly used cell lines as models for HGSOC (Domcke
et al., 2013). Primary cells obtained directly from patients may better
represent HGSOC and ideally the findings from this thesis should be
reproduced in these cells.
There is clearly a need for preclinical assessment of adenoviral gene
therapy within the context of an immune competent host. Unfortu-
nately, this is challenging because murine cells do not support pro-
ductive replication of human adenovirus (Young et al., 2012). Previ-
ous work has shown that, although murine cells can be infected with
human adenovirus, there is failure of adenovirus protein synthesis,
especially late structural proteins. This can be partially overcome by
the in trans expression of L4-100K (a non-structural late viral pro-
tein) suggesting that murine models that support human adenovirus
replication could potentially be generated (Young et al., 2012). Fur-
ther work investigating this is needed. Syrian hamsters are partially
permissive to human adenovirus (Thomas et al., 2006) and therefore
could be a useful alternative, although there are few Syrian hamster
experimental tools (e.g. antibodies, transgenic models), which makes
analysis challenging.
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Evaluating the immune response and tumour microenvironment in
response to oncolytic adenovirus may lead to increased understand-
ing of the factors that result in optimal viral efficacy whilst minimis-
ing toxicity.
6.3.2 Extending findings to other viruses and DNA repair pathways
This thesis has shown the importance of the DDR and HR pathway
in the potency of group C Ad5 vectors. I have demonstrated that the
presence of factors of the HR pathway, RAD51 and BRCA2, result in
increased viral replication and both proteins are found in VRCs sug-
gesting they may have a direct role in viral replication. RAD51 binds
to ssDNA and BRCA2 stabilises this interaction. The results from HTS
identified a number of other factors that resulted in resistance to virus
and many of these also interact with ssDNA (e.g.RPA) or regulate the
binding of RAD51 with ssDNA (e.g.RAD54L). This suggests that it
may be the ability of these proteins to bind, and stabilise, ssDNA that
the virus utilises to promote viral replication. Adenoviruses have a
unique mechanism of replicating their DNA: only one strand is repli-
cated at a time, and replication generates a displaced single strand of
parental DNA in addition to a duplex formed of a daughter strand
plus the other parental strand. The displaced strand forms a circu-
lar structure that subsequently undergoes second strand synthesis
(de Jong et al., 2003). It is possible that the role of these cellular HR
proteins is to stabilise and protect the free viral ssDNA strand to pre-
vent degradation.
There are a multitude of other viral vectors in clinical development
including other adenoviral serotypes (reviewed in (Larson et al., 2015;
Turnbull et al., 2015)). All viruses are obligate parasites and interact
with the host cell but the mechanisms of viral lifecycle, especially the
mechanism of viral replication, vary considerably. It is likely that the
specific protein interactions will be very different and may depend on
6.3 potential future directions 246
the mechanism of viral replication (Turnell and Grand, 2012). Even
different adenoviral serotypes vary in their interaction with host cell
proteins (Forrester et al., 2011). It is therefore possible that the find-
ings from this thesis are specific to group C adenovirus. One impor-
tant question is whether these findings can be extended to other viral
vectors. To fully investigate the clinical relevance of these findings,
assessment of the DDR in determining the efficacy of other oncolytic
viruses should be undertaken.
This thesis has focused on the HR pathway in HGSOC but many
other hereditary and sporadic cancers are characterised by defects in
DNA repair pathways. For example, MMR defects are seen in col-
orectal cancer (Cunningham et al., 2001) along with gastric cancer
(Fleisher et al., 1999), endometrial cancer (Esteller et al., 1998) as well
as ovarian cancer (Xiao et al., 2014). Defects within the BER path-
way are found in germ cell tumours (Robertson et al., 2001). Loss of
ERCC1, a component of the NER pathway, is seen in glioma (Chen
et al., 2010) and lung cancer (Kiyohara and Yoshimasu, 2007). These
are just a few examples of DDR defects found in human malignan-
cies but the prevalence of these defects highlights the importance of
assessing further components in the DDR in determining the potency
of oncolytic viruses.
This thesis has investigated the pathways involved in repair of
DNA DSBs. It is yet to be fully determined whether the repair of
other DNA lesions could play a role in the lifecycle of oncolytic aden-
ovirus. The results, however, show that the combination of dl922-947
and PARP inhibitor did not affect viral efficacy, implying that gener-
ation of SSBs may not influence viral cell death. In addition, the HTS
did not identify factors involved in the MMR, BER or NER pathways
suggesting that these pathways do not play a significant role in vi-
ral mediated cell death, under these experimental conditions. Further
experiments with cell lines deficient and proficient in specific DNA
damage repair pathways will assess this further.
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6.3.3 Combination treatment
Oncolytic viruses have demonstrated tolerable safety profiles and
there is potential for combining their treatment with other cancer
agents to improve therapeutic response. Combination of oncolytic
adenovirus with agents such as chemotherapy and radiotherapy has
been studied in preclinical testing. For example, increased clinical effi-
cacy has been seen with combinations of adenovirus and gemcitabine,
cisplatin, temozolamide, irinotecan and paclitaxel (Bhattacharyya et al.,
2011; Hallden and Portella, 2012; Bressy and Benihoud, 2014). The
mechanism of action of these agents and their influence on the DDR
and cell cycle needs to be carefully considered to optimise their poten-
tial. Understanding the basic biology of adenoviruses and the mech-
anism of sensitisation by chemotherapeutics and other therapies will
assist in translating these preclinical studies to clinical trials.
The importance of the immune microenvironment in both HGSOC
and the role of the immune system in the cytotoxicity of oncolytic
viruses provides a strong rational for combining immune checkpoint
inhibitors with oncolytic viruses (Turnbull et al., 2015). Evidence for
the potential success of this strategy comes from preliminary analysis
of a phase 1b clinical trial of T-VEC and ipilimumab, a monoclonal
antibody against cytotoxic T lymphocyte antigen 4 (CTLA4) have re-
ported response rates of 41% with a 24% complete response rate in
patients with advanced melanoma (Puzanov et al., 2014). Since both
of these agents interact with and manipulate the immune system, the
potential immunbe mediated toxicity is a particular concern when in-
vestigating this combination. The results of further clinical trials are
awaited.
Knowledge regarding the interaction of oncolytic virus and the
DDR raises the possibility that components of the damage response
pathways can be targeted to enhance viral efficacy. For example, in-
hibition of CHK1 has been shown to promote over-replication of ge-
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nomic DNA and DNA damage following infection with dl922-947
which is associated with enhanced cytotoxicity both in vitro and in
vivo (Connell et al., 2011). The development of new inhibitors of the
DDR, and increased knowledge of defects within the DDR in tu-
mours, may lead to further novel virus/drug combinations.
6.3.4 Development of future clinical trials
Oncolytic viruses are live viruses that proliferate upon clinical ad-
ministration. There are important biosafety considerations due to the
replication potential of these agents. Safe storage, preparation, han-
dling and administration of the virus all need to be carefully consid-
ered (Kaufman et al., 2015b). One unique potential safety risk is the
concern that an oncolytic virus might spread from the treated patient
and mutate to regain its wild-type pathogenic potential (Russell et al.,
2012). Virus shedding has been documented in urine or respiratory se-
cretions (Liu et al., 2007), but oncolytic virus transmission to contacts
and carers has not yet been seen (Russell et al., 2012). The potential
of the theoretical risks of viral shedding depends on the nature of the
virus, the comorbidity of the patient and the co morbidities of close
contacts (for example immune compromised individuals).
Currently there are few data on correlating viral dose with in vivo
replication (Kaufman et al., 2015b), therefore establishing the safe and
effective dose can be challenging. In addition, since oncolytic viruses
are removed by the immune system, many other factors need to be
considered such as the presence of pre-existing neutralising antibod-
ies and the competency of the patient’s immune system at the time
of oncolytic viral administration. These factors could affect both the
safety and efficacy of the treatment (Kaufman et al., 2015b).
The route of administration of the virus also needs careful con-
sideration. Many of the successful trials with oncolytic virus have
used intratumoural injection (Turnbull et al., 2015). This is not pos-
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sible with HGSOC where there may not be an accessible injectable
target and the disease has often spread throughout the abdomen. Ad-
ministration of the virus directly into the peritoneal cavity may of-
fer the best solution. This was the route used in previous oncolytic
viral trials in ovarian cancer including the original ONYX-015 trial
(Vasey et al., 2002) as well as the trial of the infectivity enhanced D24-
RGD adenovirus (Kimball et al., 2010). The current clinical trial of the
oncolytic adenovirus ColoAd1 is also using intraperitoneal delivery
(NCT02028117).
A question raised from oncolytic viral therapy trials is how re-
sponse should be evaluated. It is now clear that immune therapies
can result in pseudoprogressive changes (therapy mediated tumour
swelling), which can transiently occur before a tumour regresses (Wol-
chok et al., 2009). Patterns of acute tumour enlargement followed by
regression have been seen after intrahepatic injection of ONYX-015 in
combination with 5-FU/leucovorin for hepatic colorectal metastasis
in 11 out of 24 patients (Reid et al., 2002). Delayed responses were
also seen in the trial of T-VEC, which were preceded by apparent tu-
mour progression (Senzer et al., 2009). These data suggest that pseu-
doprogression may be a feature of oncolytic viral therapy and need
to be taken into account when evaluating tumour responses (Larson
et al., 2015)
To address some of these issues, future clinical trials should ideally
include data on the pharmacodynamics of virus delivery. This should
include immune responses to the virus, assessment of virus shedding
and evidence for lack of viral replication in normal tissue (Kaufman
et al., 2015b). Biopsies of tissue are needed at trial entry and ideally
following virus administration to confirm intratumour viral replica-
tion and will give vital information on potential biomarkers. Careful
design of clinical trials is vital to fully assess the potential of oncolytic
viruses and guide future development of these agents.
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6.4 concluding remarks
Resistance to therapies that are used to treat malignancy is a major
problem, and novel approaches are therefore needed. The ability of
oncolytic viruses to replicate along with their capacity to take over
and deregulate multiple cellular pathways make them a unique ther-
apeutic option. This thesis has demonstrated the importance of the
cellular DDR in determining the efficacy of oncolytic adenovirus in
ovarian cancer and suggests that, if this complex interaction between
the host and the virus can be completely understood, the full capac-
ity of oncolytic viruses could be realised. The distinct properties of
oncolytic viruses have the potential to make up an important compo-
nent in the strategy to tackle the complex, evolving nature of cancer.
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DNA Damage and Repair
RAD51 and BRCA2 Enhance Oncolytic Adenovirus
Type 5 Activity in Ovarian Cancer
Laura A. Tookman1, Ashley K. Browne1, Claire M. Connell1, Gemma Bridge1,
Carin K. Ingemarsdotter1, Suzanne Dowson2, Atsushi Shibata3, Michelle Lockley1,
Sarah A. Martin1, and Iain A. McNeish1,2
Abstract
Homologous recombination (HR) function is critically
important in high-grade serous ovarian cancer (HGSOC).
HGSOC with intact HR has a worse prognosis and is less
likely to respond to platinum chemotherapy and PARP inhi-
bitors. Oncolytic adenovirus, a novel therapy for human
malignancies, stimulates a potent DNA damage response that
influences overall antitumor activity. Here, the importance of
HR was investigated by determining the efficacy of adenovirus
type 5 (Ad5) vectors in ovarian cancer. Using matched BRCA2-
mutant and wild-type HGSOC cells, it was demonstrated that
intact HR function promotes viral DNA replication and aug-
ments overall efficacy, without influencing viral DNA proces-
sing. These data were confirmed in a wider panel of HR
competent and defective ovarian cancer lines. Mechanistically,
both BRCA2 and RAD51 localize to viral replication centers
within the infected cell nucleus and that RAD51 localization
occurs independently of BRCA2. In addition, a direct interac-
tion was identified between RAD51 and adenovirus E2
DNA binding protein. Finally, using functional assays of HR
competence, despite inducing degradation of MRE11, Ad5
infection does not alter cellular ability to repair DNA dou-
ble-strand break damage via HR. These data reveal that Ad5
redistributes critical HR components to viral replication centers
and enhances cytotoxicity.
Implications: Oncolytic adenoviral therapy may be most clin-
ically relevant in tumors with intact HR function. Mol Cancer Res;
14(1); 44–55. !2015 AACR.
Introduction
Aberrant DNA damage responses (DDR) are common in
human malignancies (1). This is particularly true in high-grade
serous ovarian cancer (HGSOC), where approximately 15%
patients have germline mutations in BRCA1 or BRCA2 (2). More-
over, data from The Cancer Genome Atlas (TCGA) consortium
inferred that homologous recombination (HR) defects may be
present in 50%HGSOC, through a variety of additional mechan-
isms, including somatic BRCA1/2mutation and epigenetic loss of
BRCA1 expression (3). A separate study, which used functional
assays of HR competence in primary ascites cells from women
with advanced HGSOC, strikingly concurred with TCGA, with
52% (26/50) showing HR deficiency (4). There is great interest in
the use of poly-(ADP ribose) polymerase (PARP) inhibitors in
HR-defective HGSOC (5), but there are few therapeutic targets
available for HR-competent tumors, which have a poorer prog-
nosis (6) and are less likely to respond to platinum-based che-
motherapy (4).
Oncolytic adenoviruses are a potential novel therapy for ovar-
ian and other human cancers. These viruses infectmalignant cells,
multiply selectively within them and cause cell death with release
of mature virions that infect neighboring cells. An understanding
of the complex interplay between the virus and host cells is vital to
increase efficacy, develop biomarkers, and improve patient selec-
tion in clinical trials. E1A CR2-deleted Ad5 vectors, such as dl922-
947 (7) and D24 (8), replicate selectively within cells with a
defective Rb pathway, a frequent abnormality in manymalignan-
cies, includingHGSOC(3).Wehavepreviously shown that dl922-
947 has considerable activity in ovarian cancer and ismore potent
than E1A wild-type adenoviruses and the E1B-55K deletion-
mutant dl1520 (9, 10). dl922-947 induces death via a necrosis-
like mechanism (11), but the sensitivity of ovarian cancer cells to
dl922-947 varies considerably, even between cells with similar
infectivity (12).
Infection by many DNA viruses, including adenovirus, triggers
a DDR, which viruses seek to circumvent through a series of
mechanisms. A major target following adenovirus type 5 (Ad5)
infection is the MRN complex (MRE11, RAD50, NBS1) and
components of the non-homologous end-joining (NHEJ) path-
way. Immediately following infection, before E1A is expressed,
core protein VII protects the viral genome from recognition by
MRN (13). As early proteins are expressed, MRN is inactivated by
severalmechanisms, including proteosomal degradation (14, 15)
and mislocalization to PML-containing "nuclear tracks" (16, 17).
Specific mechanisms that inhibit NHEJ include proteosomal
degradation of DNA Ligase IV (18) and inactivation of DNA-
dependent protein kinase (DNA-PK; ref. 19).
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Beyond the observation that the BLM helicase is also degraded
following Ad5 infection (20), there has been little specific inves-
tigation into the role of components of the HR pathway in
adenovirus biology. Previously, we showed that oncolytic ade-
novirus activity is associated with profound deregulation of cell-
cycle checkpoints and cell-cycle progression (21), inducing cel-
lular DNAdamage, with subsequent activation of DDRpathways,
including ATR-Chk1 (22). Here, we have investigated the rela-
tionship between homology-mediated DSB repair and oncolytic
adenovirus activity in ovarian cancer further. Our data indicate for
the first time that keyHR components BRCA2 andRAD51 interact
with viral DNA replication centers and promote both virus rep-
lication and cytotoxicity.
Materials and Methods
Cell lines, viruses, and chemotherapy
Cells were cultured in Dulbecco's modified Eagle medium
(DMEM) or RPMI (both Sigma) supplemented with 10% heat-
inactivated FBS (Biosera), 100 units/mL penicillin and 100 mg/
mL streptomycin (PAA Laboratories). Cell lines were maintained
at 37!C in a humidified atmosphere with 5% CO2 and routinely
passaged twice aweekusing 0.5% trypsin inPBS. All cell lineswere
routinely tested for mycoplasma and underwent 10-loci STR pro-
filing to verify their authenticity, most recently in July 2014.
SKOV3 and HeLa were obtained from Cancer Research UK Cell
Services (Clare Hall, Hertfordshire, UK), TOV21G from Prof. F.
Balkwill (Barts Cancer Institute, UK) and IGROV1 from NCI.
PEO1 and PEO4 were kindly provided by Dr. Simon Langdon
(University of Edinburgh,UK).Of these cell lines, IGROV1, PEO1,
PEO4, and SKOV3 cells were maintained in RPMI, HeLa, and
TOV21G cells in DMEM.
All viruses, including wild-type Ad5, Ad11 and Ad35, were
originally obtained fromDr. Y.Wang (Barts Cancer Institute, UK).
The Ad5 mutant dl922-947 is deleted in the region encoding
amino acids 122 to 129 of E1A CR2. It also contains a 745-bp
deletion in E3B (nt 30,005–30,750) that is substituted by a 642-bp
non-codingDNA fragment (7). dl309has the sameE3Bdeletion as
dl922-947 but is E1A wild-type. Ad GFP is deleted in E1 and E3B
and has green fluorescent protein (GFP) in the E1 position under
control of the cytomegalovirus (CMV) immediate early promoter.
Cisplatin (Accord Healthcare) was obtained for the chemo-
therapy pharmacy, St Bartholomew's Hospital, London. Ruca-
parib was provided by Clovis Oncology.
Cell survival assays
For adenovirus and cisplatin experiments, cell survival was
measured using the MTT assay (23) using a Wallac1420 Multi-
label reader (PerkinElmer Life and Analytical Sciences). A total of
104 cells were infected in 24-well plates in serum-free medium.
Cell viability was measured after 120 hours. CellTitre Glo (Pro-
mega) and sulphorhodamine B assays were used in assays involv-
ing PARP inhibitors. For clonogenic assays, cells were infected in
24-well plates as above. Then, 72 hours after infection, cells were
trypsinized and 100 to 200 cells were plated onto 6-well plates in
triplicate. Colonies were stained with Crystal Violet 10 days
thereafter and counted.
Virus infectivity assay
Cells (5 " 105) were infected with Ad GFP. GFP fluorescence
was assessed 24 hours after infection on a FACSCaliber (Becton
Dickinson). All conditions were repeated in triplicate and ana-
lyzed using FlowJo software.
Viral replication assays: TCID50 and quantitative PCR
Cells (2 " 105) were infected with dl922-947 in serum-free
medium and re-fed 2 hours later with serum containingmedium.
Up to 72 hours after infection, cells were harvested in 0.1 mol/L
Tris pH 8.0 and subjected to 3 rounds of freeze/thawing (liquid
N2/37!C); all time points were harvested in triplicate. The super-
natant was titred on JH293 cells.
Cells (2 " 105) were harvested at 24 to 72 hours following
infection, washed twice in ice-cold PBS, and scrapped into 500 mL
PBS. Extraction of viral DNA was performed using the QIAmp
DNA Blood Mini Kit (Qiagen). Real-time PCR was performed
using ABI Prism7500. Oligonucleotides and probes were as
follows:
E1A: sense: 50-CCACCTACCCTTCACGAACTG; antisense: 50-GC-
CTCCTCGTTGGGATCTTC; probe: ATGATTTAGACGT GACGGCC
Hexon: sense: 50-GGTGGCCATTACCTTTGACTCT; antisense: 50-
GGGTAAGCAGGCGGTCATT; probe: 50-CTGTCAGCTGGCCTGG
PCR conditions were as follows: 50!C for 2 minutes, 95!C for
10 minutes, followed by 40 cycles of 95!C for 15 seconds, and
60!C for 60 seconds. A standard curve using 103 to 109 dl922-947
genomes was used for quantification.
Reverse transcriptase PCR
For analysis of BRCA2 expression, 1 mgDNase-treated RNAwas
reverse transcribed using the Applied Biosystems High Capacity
cDNA Reverse Transcription Kit (Life Technologies). The follow-
ing primers and probes were used to assess BRCA2 transcription.
BRCA2-sense 1: 50-CAGAAGCCCTTTGAGAGTGGA; BRCA2-anti-
sense 1: 50-TGAGACCATTCACAGGCCAA; BRCA2 probe 1: 50-
(6FAM)CCAAGGAAGTTGTACCGTC(TAM); BRCA2-sense 2: 50-
CCACAGCCAGGCAGTCTGTAT; BRCA2-antisense 2: 50-AGAA-
CACGCAGAGGGAACTTG BRCA2 probe 2: 50-(6FAM)CCAC-
TCTGCCTCGAAT(TAM). Data were normalized to 18S.
Immunoblotting
Protein lysates were electrophoresed on precast gels (Invitro-
gen) and transferred onto nitrocellulose membranes (GE
Healthcare) by semi-dry blotting. Antibody binding was visu-
alized using enhanced chemiluminescence (GE Healthcare).
Antibodies were obtained as follows: E1A (mouse, Becton
Dickinson 554155), Ad5 (goat, Abcam Ab36851), RAD51
(rabbit, Santa-Cruz sc-8348), mcm3 (rabbit, Abcam ab36851),
Ku70 (goat, Santa-Cruz, sc-1486), and (rabbit, Cell Signaling,
4895). All HRP-conjugated secondary antibodies were obtained
from Dako.
Southern blotting
Cells (106) plated and infected with dl922-947 (MOI 10 for
PEO4, MOI 100 for PEO1 cells). Forty-eight and 72 hours later,
cells were trysinized and washed in TBS. Extraction of DNA was
performed using the QIAmpDNA BloodMini Kit (Qiagen). DNA
concentration was measured using Nanodrop ND-1000 spectro-
photometer and 10 mg genomic DNA was electrophoresed on a
1% agarose gel. The gel was soaked in 200 mL 0.2 mol/L HCl for
10 minutes, washed and then soaked in alkaline transfer buffer
(0.4 mol/L NaOH, 1 mol/L NaCl). DNA was transferred onto a
Hybond Nþ membrane (GE Healthcare Life Sciences) by
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conventional capillary transfer over 48 hours. Probe Labeling
against viral DNA, hybridization, and detection was performed
using the Amersham ECL Direct Nucleic Acid Labeling and
Detection systems.
Flow cytometry
For cell-cycle analyses, cells were trypsinized, washed twice in
ice-cold PBS, and fixed in ice-cold 100% ethanol. Cells were then
washed with PBS and resuspended in 200 mL propidium iodide
(PI) and 100 mg/mL RNase A (MP Biomedicals). For gH2AX
analysis, cells were harvested, washed, and fixed in ice-cold
70% ethanol. After incubation with primary anti-gH2AX mAb
or IgG control, cells were washed and then incubated with FITC-
conjugated anti-mouse secondary antibody (Invitrogen) for 1
hour in the dark and analyzed using a FACSCaliber flow cyt-
ometer. Results analyzed using FlowJo software.
Immunofluorescence and coimmunoprecipitation
Cells were seeded on poly-L-lysine–coated coverslips and
treated with rucaparib (10 mmol/L for 24 hours) or dl922-
947 for up to 48 hours. Following treatment, medium was
aspirated and 0.04% Triton (Sigma) in PBS added for 1 minute.
Cells were then fixed in 3% paraformaldehyde and 2% sucrose
for 10 minutes. The cells were stained with anti-gH2AX anti-
body (Millipore) or a rabbit anti-Ad5 E2-DNA binding protein
(E2-DBP, a kind gift of Dr. David Ornelles, Wake Forest Medical
Center, NC) and costained with anti-RAD51 or anti-BRCA2
antibody for 45 minutes at 37!C. Following incubation for 45
minutes at 37!C with secondary antibodies, cells were cost-
ained with DAPI. Coverslips were mounted on slides and
images captured using a Zeiss 510 or 710 confocal microscope
and foci were counted using ImageJ software.
TOV21G cells (2 " 106) were infected with dl922-947 (MOI
10) and lysed 24 hours later in 800 mL RIPA lysis buffer (with
complete protease inhibitors, Roche). Sepharose beads (35 mL;
Santa Cruz) were incubated with anti-RAD51 antibody (Santa
Cruz, H-92, sc8349) or control antibody (anti-HA, Sigma
H6908) for 1 hour at 4!C. Lysates were then incubated with
the IP matrix beads for 1 hour at room temperature and washed
with RIPA lysis buffer. SDS loading buffer was added, samples
boiled, and proteins detected by Western blot as described
earlier. Primary antibodies used were rabbit anti-Ad5 E2 DBP
and anti-RAD51 (Abcam, ab213).
siRNA
Small-interference RNA (siRNA) targeted against BRCA2 and
RAD51 were obtained from either Dharmacon (siGENOME
SMARTpool; GE Life Sciences) or Qiagen. A nontargeting (NT)
pool of siRNA was also used (Qiagen). All cell lines were
transfected using lipofectamine 2000 (Invitrogen), apart from
IGROV1 cells where DharmaFECT1 (Dharmacon) was used. A
final concentration of 10 nmol/L RAD51 siRNA and 30 nmol/L
or 50 nmol/L (depending on the cell line) BRCA2 siRNA was
used. Twenty-four hours following transfection, cells were
infected with dl922-947 or dl309. Cell survival was assessed
120 hours later by the MTT assay. Cell survival following siRNA
was compared with the scrambled control. All experiments
were repeated using a second siRNA (Qiagen) at a concentra-
tion of 50 nmol/L.
HR reporter assay
Full details of the assay are reported elsewhere (24). Briefly,
pDR-GFP (a gift from Maria Jasin; Addgene plasmid 26475;
ref. 25) contains two differently mutated GFP genes orientated
as direct repeats and separated by a puromycin resistance gene.
One of the GFP constructs, SceGFP, is mutated to contain the
recognition site for the rare-cutting endonuclease I-SceI; as a
result, exposure to I-SceI will induce a unique double-strand
break. The I-SceI site is incorporated at a BcgI restriction site by
substituting 11 bp of wild-type GFP sequence with those of the
I-SceI recognition site. These substituted base pairs also supply
two in-frame stop codons, which terminate translation and inac-
tivate the protein. Downstream of the SceGFP gene is an 812-bp
internal GFP fragment termed iGFP. Homologous sequences in
the twomutated GFP genes are separated by 3.7 kb. When I-SceI–
induced DSB occurs, iGFP sequence can act a donor strand to
allow homology-mediated repair and generation of a functional
GFP open reading frame—this in turn can be detected by flow
cytometry.
PEO1 and PEO4 cells were transfected with pDR-GFP using
FugeneHD. Following puromycin selection, 106 cells were plated
and 24 hours later transfected with either 1 mg pI-SceI or pCAAGs
(negative empty vector control). Twenty-four hours later, cells
were infectedwith dl922-947 (MOI 50 for PEO4 cellsMOI 500 for
PEO1 cells). Twenty-four hours thereafter, cells were analyzed for
GFP events using a FACSCaliber. Events (100,000) were recorded
and results analyzed using FlowJo software.
Results
Adenovirus cytotoxicity is greater in HR-competent ovarian
cancer cells
To investigate the link between cellular HR function and
adenovirus activity, we first utilized the PEO1/PEO4 cell pair
(26). These cells originate from the same ovarian cancer patient:
PEO1 was derived at the time of first, platinum-sensitive relapse
and contains a deleterious BRCA2mutation; PEO4was derived at
subsequent relapse, when platinum resistance had developed,
and contains a secondary BRCA2mutation that restores the open
reading frame (27). Using a previously described assay of HR
competence, based upon formation of RAD51 foci in response to
DSB damage (28), we confirmed that PEO4 cells demonstrate
functional HR, while PEO1 are HR defective (Fig. 1A and Sup-
plementary Fig. S1).Wealso confirmed that BRCA2-mutant PEO1
are more sensitive than BRCA2 wild-type PEO4 to both cisplatin
and the PARP inhibitor rucaparib (Supplementary Fig. S2).
We found PEO4 to be significantly more sensitive to cyto-
toxicity induced by the E1A CR2-deleted Ad5 vector dl922-947
(Fig. 1B) as well as Ad5 WT and dl309 (E1A wild-type; Fig. 1C).
PEO4 were slightly more infectable with Ad5 vectors than
PEO1 (data not shown). However, even when MOI was adjust-
ed to ensure equal levels of infection (hereafter called iso-
infection), PEO4 remained significantly more sensitive to both
dl922-947 and dl309 (Fig. 1D). This increased sensitivity in
PEO4 was confirmed by the clonogenic assay (Supplementary
Fig. S3). By immunoblot, there was comparable early (E1A)
and late viral protein expression in iso-infected cells (Fig. 1E).
Assessing viral replication, there was no significant difference in
the number of infectious virions generated following iso-infec-
tion (Fig. 1F). However, quantitative PCR indicated that there
was more viral DNA generated in PEO4 (Fig. 1G), which was
Tookman et al.
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Greater efficacy and viral DNA replication in HR-competent than HR-defective ovarian cancer cells. A, competence of HRwas assessed in PEO1 and PEO4 cells. Cells
were treated with rucaparib (10 mmol/L, 24 hours), permeabilized, fixed in 4% PFA, and stained for RAD51 and gH2AX. RAD51 foci were counted in at least
30 nuclei per treatment condition. Bars, mean ($SD) number of RAD51 foci per cell. Dotted line, 2" number of foci in untreated cells. B, 104 PEO1 and PEO4 cells were
infected in triplicate with dl922-947. Cell survival was measured 120 hours after infection by the MTT assay. Mean $ SD IC50 for four experiments are shown:
% , P ¼ 0.011. C, 104 PEO1 and PEO4 cells were infected in triplicate with Ad5 WT (left) or dl309 (right) (MOI 0.001–1000 pfu/cell). Cell survival was measured
120 hours after infection by the MTT assay. D, PEO1 and PEO4 cells were infected with Ad CMV-GFP (left) at MOI 60 and 100 (PEO1) and 6 and 10 (PEO4). GFP
positivity was assessed 24 hours after infection by flow cytometry. PEO1 and PEO4 cells were also infected with dl922-947 (right) at MOI 60 and 100 (PEO1)
and 6 and 10 (PEO4). Cell survival was assessed 120 hours after infection by the MTT assay. Data, mean $SD; n ¼ 3. %%% , P < 0.001. E, PEO1 and PEO4 cells
were infected with dl922-947 MOI 100 (PEO1) or 10 (PEO4). Protein was harvested up to 72 hours after infection. Expression of E1A and adenovirus
5 structural proteins was assessed by immunoblot. E1A band density was assessed from three separate exposures: 24, 48, and 72 hours; mean ($SD).
E1A:KU70 ratio was 1.3 $ 0.2, 1.4 $ 0.1, and 1.4 $ 0.2 for PEO1, and 0.7 $ 0.4, 1.2 $ 0.3, and 1.6 $ 0.2 for PEO4. F and G, PEO1 and PEO4 cells were infected with
dl922-947 MOI 100 (PEO1) or 10 (PEO4) for up to 72 hours. Virus replication was assessed by TCID50 (1F) or quantitative PCR (1G). %%% , P < 0.001. H, PEO1 and
PEO4 cells were infected with dl922-947 MOI 100 (PEO1) or 10 (PEO4) for up to 72 hours. DNA was extracted and subjected to neutral pulsed-field gel
electrophoresis, probed with HRP-labeled adenovirus type 5 probe. 100 ng purified dl922-947 DNA was run as a positive control (þ).
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confirmed by Southern blotting (Fig. 1H). There were no
obvious abnormalities in viral DNA processing on the Southern
blot, and specifically no obvious concatemers in either cell line
(Fig. 1H and Supplementary Fig. S4 for long exposure). The
increased sensitivity appeared to be Ad5 specific, as there was
no difference between PEO1 and PEO4 in sensitivity to the
group B adenoviruses Ad11 and Ad35 (Supplementary Fig. S5).
Adenovirus DNA replication triggers the DDR and interacts
with core HR machinery
We first investigatedwhether the difference in sensitivity to Ad5
vectors betweenHR-proficient andHR-deficient cellswas reflected
in their accumulation of DNA damage. In keeping with their
germline BRCA2 mutation and genomic instability (29), unin-
fected PEO1 cells demonstrated greater basal levels of DNA
damage (gH2AX positivity) and a higher proportion of the cells
with >4NDNAcontent onflow cytometry than PEO4 (Fig. 2A and
Supplementary Figs. S1 and S6).However, following iso-infection
with dl922-947, there were significantly greater increases in both
gH2AX positivity and >4N DNA in PEO4 (Fig. 2A), consistent
with our previous observations that virus-induced DNA damage
correlates with sensitivity (22, 30).
Inhibition of NHEJ using theDNA-PKcs inhibitor NU7026 had
no effect on cytotoxicity (data not shown), and, as previously
noted (14), there was a reduction in expression of MRE11 fol-
lowing dl922-947 infection in both PEO1 and PEO4 (Fig. 2B),
and the reduction was similar in both cell lines. However, expres-
sion of RAD51 did not diminish following infection in either
PEO1 or PEO4 (Fig. 2C). By confocal microscopy, BRCA2 expres-
sion was maintained in PEO4 following dl922-947 infection.
Interestingly, there was clear colocalization between BRCA2 and
viral replication centers (VRC), as indicated by expression of viral
E2 DNA binding protein (E2 DBP; Fig. 2D). Furthermore, we also
saw clear colocalization between RAD51 and E2 DBP in PEO4
(Fig. 2E). It is widely known that, in BRCA2-deficient cells, RAD51
is unable to form foci at the site of DNA damage (Supplementary
Fig. S1; ref. 28).However, to our surprise, we observedRAD51 foci
colocalized with E2 DBP in PEO1 cells, despite the absence of
BRCA2 (Fig. 2E). These findingswere confirmed in two other lines
that demonstratedHR competence, TOV21G, andHeLa (Fig. 3A),
as well as in IGROV1 cells, which are hypermutated and contain
mutations in both BRCA1 and BRCA2 (ref. 31; http://cancer.
sanger.ac.uk/cell_lines) and were HR defective in our assay (Fig.
3A). In both HR-competent lines, there was colocalization
between viral replication centers and BRCA2 (Fig. 3B; Supple-
mentary Fig. S7), while all three lines, regardless of HR status,
showed RAD51 foci associated with E2 DBP (Fig. 3C). Coimmu-
noprecipitation suggested a direct interaction between RAD51
and E2 DBP following Ad5 infection in TOV21G cells (Fig. 3D).
Thus, for the first time, these data show that RAD51 and BRCA2
can localize to viral replication centers and that this is indepen-
dent of recruitment to DNA damage foci.
RAD51 and BRCA2 influence adenovirus efficacy in both
HR-competent and HR-deficient cells
To investigate the requirement for RAD51 in viral replication
and cytotoxicity, we depleted RAD51 using two different siRNA
constructs in both PEO1 and PEO4 cells (Fig. 4A). RAD51
depletion caused significant reductions in efficacy of dl922-947
in both cell lines (Fig. 4B and Supplementary Fig. S8), and also
reduced viral replication (Fig. 4C). Again, these findings were
recapitulated in HR-competent HeLa and TOV21G cells, with
reductions in both viral cytotoxicity (both dl922-947 and dl309)
and replication (Fig. 4D and E; Supplementary Fig. S9) upon
RAD51 silencing, as well as by clonogenic assay in PEO1 and
PEO4 cells (Supplementary Fig. S10). Moreover, we were able to
confirm this finding in HR-defective IGROV1 cells (Fig. 4F). We
also found a small but significant reduction in cytotoxicity fol-
lowing BRCA2 knockdown in PEO4 (Fig. 5A), which was reca-
pitulated in TOV21G and HeLa cells (Fig. 5B and C). Taken
together, our data suggest that recruitment of RAD51 and BRCA2
to VRC augments viral replication and cytotoxicity, and is inde-
pendent of its role in the response to DNA damage.
dl922-947 does not inhibit HR function in HR-competent cell
lines
To assesswhether adenovirus infection impaired the capacity of
cells to repair DNA double-strand break damage by HR, we first
used confocal microscopy. In HR-competent cells infected with
dl922-947, RAD51was able to localize, at least partially, to sites of
DNA DSB damage, suggesting that HR function remains grossly
intact following adenovirus infection (Fig. 6A). This functionality
was further assessed using a fluorescence reporter assay, which
incorporates a green fluorescence protein reporter (DR-GFP) as a
repair substrate into the genome and assays non-crossover gene
conversion events in response toDNADSB damage (seeMaterials
and Methods for full assay details). The HR competence of PEO4
cells was again confirmed by this assay, with a significant increase
in GFP events following expression of I-Scel compared with
control plasmid, whereas PEO1 showed no increase (Fig. 6B).
RAD51 knockdown abolished any increase GFP events in PEO4
(Supplementary Fig. S11). To investigate the effect of adenovirus
infection on overall HR function, this assaywas repeated 48 hours
after infection with dl922-947, results again showed that PEO4,
but not PEO1, was able to repair I-SceI–induced DNA DSB
damage using HR (Fig. 6C). This implies that Ad5 infection does
not functionally impair homology-mediated repair. To confirm
this, PEO4 cells were treatedwith the PARP inhibitor rucaparib 24
hours following dl922-947 or mock infection: the presence of
dl922-947 was unable to sensitize PEO4 cells to rucaparib (Fig.
6D), again indicating that HR function remains intact following
Ad5 infection.
Together, these results indicate that Ad5 vectors do not inhibit
HR function in infected cells—rather, components of the HR
machinery localize to VRC and bind directly to E2 DBP. This
interaction promotes viral DNA replication and increases overall
cytotoxicity.
Discussion
In this article, we show for the first time that components of the
HR pathway of DNA double-strand break repair significantly
influence the activity of Ad5 vectors. Using matched BRCA2-
mutant and wild-type ovarian cancer cells, we show that the
activity of both E1A wild-type (Ad5 WT and dl309) and E1A
CR2-deleted (dl922-947) Ad5 viruses is greater in the presence of
functional BRCA2, with increased cytotoxicity and viral DNA
replication, and that BRCA2 colocalizes with VRC within the
nucleus. These results were recapitulated in other malignant cell
lines, HeLa and TOV21G, that are BRCA2 wild-type and HR
competent. Moreover, we were able to demonstrate that RAD51,
a key partner of BRCA2, also influences Ad5 activity. Strikingly, we
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dl922-947 replication induces genomic DNA damage; RAD51 and BRCA2 colocalize with sites of adenovirus replication. A, PEO1 and PEO4 cells were harvested 48
hours following infection with dl922-947 (MOI 100 and 10, respectively) or mock infection, fixed in 70% cold ethanol, incubated with an anti-gH2AX Ab,
counterstained with PI, and analyzed by flow cytometry (left). Increase in gH2AX-positive cells and cells with >4N DNA are plotted (right); bars, mean $SD; n¼ 3.
%%% , P < 0.001. B and C, PEO1 and PEO4 cells were harvested following infection with dl922-947 (MOI 100 and 10, respectively). Expression of E1A, MRE11 (B),
and RAD51 (C) was detected by immunoblot. D and E, PEO1 and PEO4 cells were fixed in 4% PFA following infectionwith dl922-947 (MOI 300 and 30, respectively).
Expression of adenovirus E2 DNA binding protein, BRCA2 (D), and RAD51 (E) was assessed by confocal microscopy.
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RAD51 and BRCA2 colocalize with sites of adenovirus replication in multiple malignant cell lines. A, HR competence was assessed in TOV21G, HeLa, and IGROV1 cells
as for Fig. 1A. Bars, mean ($SD) number of RAD51 foci per cell. Dotted line, 2" number of foci in untreated cells. TOV21G and HeLa demonstrate HR
competence, while IGROV1 are HR defective. B and C, cells were fixed in 4% PFA following infection with dl922-947 (MOI 10). Expression of adenovirus E2 DNA
binding protein, BRCA2 (B), andRAD51 (C)was assessedby confocalmicroscopy. D, RAD51was immunoprecipitated fromTOV21G infectedwithdl922-947 (MOI 10),
and the presence of E2 DNA binding protein was detected by immunoblotting.
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RAD51 knockdown decreases adenovirus efficacy and replication. A, using two different siRNA pools, RAD51 was knocked down in both PEO1 and PEO4 cells.
B and C, 24 hours following siRNA-mediated RAD51 knockdown, PEO1 (MOI 300) and PEO4 cells (MOI 30) were infected with dl922-947 (left) and dl309
(right, MOI 500 and 50). Survival was assessed 96 hours after infection by the MTT assay (B). Viral replication was also assessed 48 hours after infection by
quantitative PCR (C). % , P < 0.05; %%% , P < 0.001. D–F, 24 hours following siRNA-mediated RAD51 knockdown, TOV21G (D), HeLa (E), and IGROV1 (F) cells were
infected with dl922-947 (MOI 1, 8, and 5 respectively). Survival was assessed 96 hours after infection by the MTT assay. RAD51 knockdown was confirmed by
immunoblot. Viral replication was also assessed in TOV21G 48 hours after infection. %% , P < 0.01; %%% , P < 0.001.
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show that RAD51 influences adenovirus activity and locates to
VRC in the absence of functional BRCA2.
HR is vitally important in the biology of HGSOC. Tumors with
intact HR are less likely to respond to platinum-based chemo-
therapy (4) and have a worse overall prognosis (6). HR is a
complex process involving multiple proteins. However, BRCA2
is particularly important, as it mediates the loading of RAD51
onto 30-single-stranded DNA overhangs (created by MRE11
nuclease activity), creating a RAD51 nucleoprotein filament. The
nucleoprotein filament then catalyzes the critical step of HR,
namely strand invasion and homology search on the sister
chromatid.
The interaction between adenoviral infection and the DDR is
complex; in contrast to other forms of DNA damage, such as
irradiation, where damage occurs almost instantaneously, viral
infection represents a dynamic onslaught to the cell, whichmakes
analysis challenging. However, the DDR is clearly activated fol-
lowing viral infection—here and previously (22), we show robust
phosphorylation of H2AX following infection with dl922-947
and other Ad5 viruses, which others have also observed (32). We
have also shown that Ad5 infection activates replication-depen-
dent ATR/Chk1 signaling (22). Ad5 inhibits DDR using a variety
of mechanisms, prime among which is proteasome-mediated
degradation of key cellular proteins, including MRE11 and DNA
Ligase IV. Degradation is largely orchestrated by E1B55K and
E4orf6, in concert with cellular proteins Cul5, Rbx1, and elongins
B andC (15, 33), while infectionwith E4-deleted viruses results in
concatemer formation (34). Consistent with these previous find-
ings, we show here that MRE11 expression diminishes following
Ad5 infection in ovarian cancer cells, regardless of their HR
competence, and that inhibition of DNA-PK has no effect on
overall cytotoxicity in bothHR-competent andHR-defective cells.
In addition, our Southern blot showed no concatemer formation
in either PEO4 or PEO1 cells, suggesting that viral DNA can be
processed correctly regardless of the state of cellular HR
competence.
The relocation of other DDR proteins, including RPA32 (35),
ATR, ATRIP, Rad9, TOPBP1, Rad17, and hnRNPUL1 (36–38), to
VRC following Ad5 infection has been described previously.
However, it has been unclear whether this relocalization inhibits
DNA damage repair function or whether it is required for viral
replication (reviewed in 39)—in the case of BRCA2 and RAD51,
our data suggest the latter, as loss of either protein reduces Ad5
replication. In addition, using three different techniques to assess
HR function, our results suggest that the ability of cells to repair
DNA DSB damage via HR is not inhibited following Ad5 infec-
tion. This reinforces the idea that Ad5 utilizes components of the
HR pathway rather than degrading and inhibiting them, as is the
case with NHEJ.
Several key questions remain. First, how do cells retain the
apparent capacity to repair DSB damage by HR following the
proteasomal degradation of MRE11, which is critical for end
resection? Although MRE11 is clearly critical to end resection,
other molecules, in particular CtIP and Exo1, can also fulfill this
role (40, 41). Thus, it is possible that other proteins substitute for
the MRE11 end-resection function following Ad5 infection. Also,
degradation of MRE11 is not complete (see Fig. 2B and ref. 42);
thus, there may be a dosage effect whereby the remaining MRE11
retains sufficient end-resection capacity following adenovirus
infection. Nonetheless, whatever residual HR capacity remains
following infection is still unable to repair virus-induced genomic
DNA damage. This may result from both the cell-cycle and DNA
replication states induced by the virus. Adenovirus infection
drives infected cells into an S phase–like state, with endoredu-
plication of genomic DNA (43). However, genomic DNA repli-
cation is clearly disorganized, which may preclude reliable gen-
eration of intact sister chromatids. In addition, adenovirus infec-



























































































BRCA2 knockdown also decreases
adenovirus efficacy and replication. A,
24 hours following siRNA-mediated
BRCA2 knockdown, PEO4 cells were
infected with dl922-947 (MOI 30).
Survival was assessed 96 hours after
infection by the MTT assay. BRCA2
knockdown was confirmed by
quantitative RT-PCR, normalized to
18S RNA. % , P < 0.05; %%% , P < 0.001.
B and C, 24 hours following siRNA-
mediated BRCA2 knockdown, TOV21G
(B) and HeLa (C) cells were infected
with dl922-947 (MOI 1 and 2 for
TOV21G; MOI 8 for HeLa). Survival was
assessed 96 hours after infection by
the MTT assay. BRCA2 knockdown
was confirmed by quantitative
RT-PCR in TOV21G cells, normalized to
18S RNA. % , P < 0.05; %%% , P < 0.001.
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appearance of multiple abnormal mitoses (21). Thus, cells may
slip rapidly through S and G2 phases, thereby precluding HR
repair. This reemphasizes the challenge of investigating cellular
responses to adenovirus infection, where changes are dynamic
and evolve over a period of 48 to 72 hours.
A second key question is how doBRCA2 andRAD51 relocate to
VRCandwhich adenovirus proteins drive theprocess?And indeed
what is their precise function within these VRC? Ad5E4orf3 is
responsible for relocalization of PML protein into cytoplasmic
tracks, but whether it is also responsible for movement of cellular
proteins into VRC is unknown. Our immunoprecipitation sug-
gested a direct interaction between RAD51 and E2DBP; our
attempts at immunoblot and immunoprecipitation of BRCA2
were unsuccessful, so we do not know whether there is also a
similar direct interaction with E2DBP. Certainly, the RAD51 role
in viral efficacy appears independent of its function in HR as
knockdown in HR-incompetent cell lines also reduces viral effi-
cacy. Our data, however, show that the presence of BRCA2
together with RAD51 results in more efficient viral replication.
AdenovirusDNA replication generates a displaced single strand of
parental DNA in addition to a duplex formed of a newly synthe-
sized daughter strand plus the other parental strand, a structure
that could resemble a replication fork. Both RAD51 and BRCA2
have recently been shown toprotect newly replicatedDNA strands
at stalled replication forks fromdegradation (44, 45) and this role
is independent of their function in HR. It is possible that adeno-
virus utilizes this function of RAD51 andBRCA2 resulting inmore
accurate and efficient viral DNA replication, and that RAD51 can
execute this role alone. Certainly, no BRCA2 homolog has been
identified in lower eukaryotes, including Saccharomyces cerevisiae,
in which Rad51 alone can resolve replication stress. Clearly
adenoviral replication and cytotoxicity can still occur in the
absence of BRCA2 and RAD51, suggesting that these proteins are
supportive rather than critical to the adenoviral lifecycle.
Third, why are there differences between adenovirus species in
this effect? Here, we show that sensitivity to Ad11 and Ad35 does
not vary between BRCA2WT andmutant cells, and previous data
demonstrate that DDR proteins vary in their targeting by different
adenoviral serotypes (42). Nonetheless, it is clear that interaction
with DDRmachinery is a widespread phenomenon in DNA virus
infection. ATM is required for optimal replication of SV40 (46)
and HSV-1 requires ATM and the MRN complex for virus repli-
cation (47), while proteins involved in HR have been shown to
localize to EBV VRCs (48).
In summary, we show for the first time that adenovirus type 5
relocalizes components of the HR pathway to VRC and that viral
replication is enhanced in the presence of functional HR.We have
recently shown that oncolytic adenovirusesmay bemore effective
in ovarian cancers with paclitaxel resistance (30). Data here show









































































Adenovirus infection does not inhibit
homology-mediated DNA repair. A,
PEO4 cells were infected with dl922-
957 (MOI 10). 24 hours after infection,
cells were fixed. Expression of gH2AX
and RAD51 was assessed by confocal
microscopy. B, PEO1 and PEO4 cells
stably expressing DR-GFP plasmid
were transfected with a plasmid
encoding the rare cutting
endonuclease (pI-SceI) or control
plasmid. 24 hours thereafter,
expression of GFP was assessed by
flow cytometry. Data show fold
change in GFP-positive events
following pI-SceI transfection relative
to control plasmid (dotted line). Bars,
mean $SD. % , P < 0.05 compared with
control plasmid transfection. C, PEO1
and PEO4 cells stably expressing
DR-GFP plasmid were infected with
dl922-947 (MOI 50 and 500,
respectively). 24 hours later, they
were transfected with pI-SceI or
control plasmid. 24 hours thereafter,
expression of GFP was assessed by
flow cytometry. Data again show fold
change in GFP-positive events
following pI-SceI transfection relative
to control plasmid (dotted line). Bars,
mean $SD. %%% , P < 0.001 compared
with control plasmid transfection.
D, PEO4 cells were infected with
dl922-947 MOI 50 and 24 hours later
treated with rucaparib (0.01–300
mmol/L) for 72 hours.
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of poor prognosis ovarian cancers, namely those with platinum
and PARP inhibitor resistance through intact HR function. Given
the importance ofHR in thebiology ofHGSOC, anunderstanding
of the interaction between HR and any novel therapy is particu-
larly important in patient selection for clinical trials and identi-
fication of novel virus/drug combinations.
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Oncolytic adenoviruses replicate selectively within and lyse malignant cells. As such, they are being devel-
oped as anticancer therapeutics. However, the sensitivity of ovarian cancers to adenovirus cytotoxicity varies 
greatly, even in cells of similar infectivity. Using both the adenovirus E1A-CR2 deletion mutant dl922-947 
and WT adenovirus serotype 5 in a panel of human ovarian cancer cell lines that cover a 3-log range of sen-
sitivity, we observed profound overreplication of genomic DNA only in highly sensitive cell lines. This was 
associated with the presence of extensive genomic DNA damage. Inhibition of ataxia telangiectasia and Rad3-
related checkpoint kinase 1 (ATR-Chk1), but not ataxia telangiectasia mutated (ATM), promoted genomic 
DNA damage and overreplication in resistant and partially sensitive cells. This was accompanied by increased 
adenovirus cytotoxicity both in vitro and in vivo in tumor-bearing mice. We also demonstrated that Cdc25A 
was upregulated in highly sensitive ovarian cancer cell lines after adenovirus infection and was stabilized after 
loss of Chk1 activity. Knockdown of Cdc25A inhibited virus-induced DNA damage in highly sensitive cells 
and blocked the effects of Chk1 inhibition in resistant cells. Finally, inhibition of Chk1 decreased homolo-
gous recombination repair of virus-induced genomic DNA double-strand breaks. Thus, virus-induced host 
cell DNA damage signaling and repair are key determinants of oncolytic adenoviral activity, and promoting 
unscheduled DNA synthesis and/or impeding homologous recombination repair could potentiate the effects 
of oncolytic adenoviruses in the treatment of ovarian cancer.
Oncolytic viruses multiply selectively within infected cancer 
cells and cause death, with the release of mature viruses that 
infect neighboring cells. The adenovirus deletion mutant dl922-
947 contains a 24-bp deletion (amino acids 122–129) in the E1A-
CR2 region, which binds to E2F-pRb complexes, thereby disso-
ciating E2F to drive cells into an S phase–like state, allowing 
transactivation of genes necessary for viral DNA replication (1). 
We have previously shown that dl922-947 has considerable activ-
ity in ovarian cancer and is more potent than E1A WT adenovi-
ruses and the E1B-55K mutant dl1520 (Onyx-015, H101) (2, 3). 
dl922-947 replicates selectively in cells with abnormalities of 
the Rb pathway and consequent G1/S checkpoint, defects seen 
in over 90% of human cancers (4). Multiple different Rb path-
way abnormalities have been described in ovarian cancer (5, 6), 
and, even in ovarian cancer cells that are readily infected with 
adenovirus serotype 5 (Ad5) vectors, there is huge variability in 
sensitivity to dl922-947–mediated cell death. In addition, the 
mechanisms by which oncolytic adenoviruses induce cell death 
in cancer cells remain unclear (7).
We recently showed that early expression of E1A correlated well 
with cell sensitivity to dl922-947 (8). Upon infection, E1A is the 
first adenoviral protein to be expressed and is required for the 
efficient transcription of other viral early genes (9) as well as the 
disruption of pRb-E2F complexes (1). We have previously shown 
that dl922-947 activity is also associated with deregulation of 
multiple cell cycle checkpoints, which accelerates cell cycle pro-
gression and enhances efficacy (10).
However, one consequence of such deregulated cell cycle progres-
sion is unscheduled replication of cellular DNA, which will activate 
the DNA damage signaling pathways whose function is to preserve 
the integrity of the cellular genome (11). Two key kinases are central 
to DNA damage responses, ataxia telangiectasia mutated (ATM) 
and ataxia telangiectasia and Rad3-related (ATR). ATM is classi-
cally activated by double-strand breaks (DSBs), whereas ATR can 
be activated by a wide variety of DNA events, including replication-
associated DNA damage, resected DSB ends, and nucleotide exci-
sion repair. When activated, both trigger a series of signaling events 
and activate downstream cellular proteins, such as the checkpoint 
kinases 1 and 2 (Chk1 and Chk2). Both ATM and ATR can be acti-
vated by adenovirus infection (12, 13). However, the virus can evade 
some DNA damage responses: for example, E4orf3 causes immobi-
lization of the MRN complex, which can inhibit ATR signaling (14), 
while MRE11 is degraded in response to the activity of the E1B55K/
E4orf6 complex (15), which blocks signaling downstream of ATM. 
Nonetheless, infected cells still demonstrate some evidence of DNA 
damage signaling in the form of H2AX phosphorylation (13, 16).
We sought to explore the link between genomic DNA replica-
tion, DNA damage responses, and the overall efficacy of oncolytic 
adenoviruses in ovarian cancer. Our findings suggest that host cell 
DNA damage responses induced by aberrant genomic DNA replica-
tion strongly influence the potency of adenoviruses. Highly sensi-
tive cells displayed profound overreplication of genomic DNA with 
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associated DNA damage and downstream signaling after infection 
with dl922-947. Moreover, inhibition of the ATR-Chk1 pathway 
increased genomic DNA overreplication and damage by prevent-
ing Chk1-mediated degradation of the Cdc25A phosphatase. 
Furthermore, Chk1 inhibition increased the number of DSBs, the 
most cytotoxic form of DNA damage, by preventing homologous 
recombination (HR) and increased sensitivity to dl922-947 activity 
both in vitro and in vivo. Similar results were observed after WT 
adenovirus infection, demonstrating that our findings are not spe-
cific to E1A-CR2 deletion mutants. Importantly, inhibition of the 
ATR-Chk1 pathway augmented sensitivity to adenovirus in cancer 
cells without affecting nonmalignant cells. As clinical trials of E1A-
CR2–deleted adenoviruses have commenced (17), a better under-
standing of cellular responses to virus infection is vital and would 
open up the prospect of increased anticancer activity in patients.
Adenovirus-induced cytotoxicity is associated with overreplication of cel-
lular DNA in sensitive cells. The sensitivity of cancer cell lines to the 
oncolytic adenovirus dl922-947 varies considerably, even in cells 
with similar infectivity (8). TOV21G, IGROV1, and A2780CP are 3 
ovarian cancer cell lines that cover a range of sensitivities, with IC50 
values varying over 3 log scales (Figure 1A). The same wide range 
of sensitivity was seen with E1A WT adenoviruses (Figure 1A and 
Supplemental Figure 1A; supplemental material available online 
with this article; doi:10.1172/JCI43976DS1), although the WT 
viruses were consistently less potent in cancer cells than dl922-947, 
as seen before (3). The wide variation of sensitivity was not caused 
by differences in infectivity, as there were profound differences in 
cell survival at MOI that permitted 50% cells to be infected (Figure 
1B). E1A is the first adenovirus gene to be expressed (18). As before, 
we found that early E1A transcription and protein expression cor-
related with cellular sensitivity to adenovirus (Figure 1C).
Cell cycle analysis revealed a stark contrast between the pro-
files of sensitive and insensitive cells after infection. TOV21G 
cells readily accumulated DNA contents of more than 4 N after 
dl922-947 infection; by 72 hours, the proportion of TOV21G cells 
with a DNA content of more than 4 N exceeded 50%. In IGROV1 
cells, of intermediate sensitivity, the proportion reached 16.3% 
but only reached 7.0% in insensitive A2780CP cells, with little 
change throughout the course of infection (Figure 1D). Analysis 
of Hct116, another highly sensitive cancer line (dl922-947 IC50 ≈ 
0.04 PFU/cell; data not shown), yielded similar cell cycle profiles 
to those of TOV21G cells, with a DNA content of more than 4 N 
of 58% by 72 hours after infection (hpi) (Figure 1E), while another 
resistant line, SKOV3ip1, generated profiles very similar to those 
of A2780CP cells (data not shown). Ad5 WT infection caused over-
replication in TOV21G cells, although the proportion of cells with 
more than 4 N DNA was lower, reaching 34% 72 hpi (Supplemen-
tal Figure 1B). Thus, the effects seen with dl922-947 are not unique 
to ovarian cancer cells or to E1A-CR2 adenoviral deletion mutants, 
but they are greater than those seen with WT virus. The quantity of 
viral DNA generated in A2780CP cells was at least as great as that 
in the more sensitive TOV21G and IGROV1 cell lines (Figure 1F), 
indicating that the overreplication phenotype does not represent 
viral DNA but is a consequence of cellular DNA replication, con-
sistent with previous reports (19, 20). In addition, the differential 
sensitivity amongst the cell lines was uncoupled from infectious 
virion production, with no significant difference in the number 
of virions produced in the 3 cell lines (Figure 1G). Adenovirus-
induced cytotoxicity therefore appears not to depend upon the 
extent of virion production.
Oncolytic adenovirus cytotoxicity is associated extensive genomic DNA 
damage. Aberrant initiation of cellular DNA replication induces 
the accumulation of replication-associated DNA lesions (11, 21). 
To assess the extent of such DNA damage, cells were harvested up 
to 72 hpi with dl922-947, and phosphorylation of H2AX (ser 139; 
γH2AX) was analyzed immunocytochemically by flow cytometry 
with propidium iodide (PI) counterstaining to define cell cycle 
phase (22). Mock-infected cells displayed little γH2AX. In contrast, 
a huge increase in γH2AX was detectable in sensitive TOV21G cells 
after infection, and this increase occurred specifically in S and G2/
M cells and cells with more than 4 N DNA content (Figure 2A), 
indicating that DNA damage occurred after replication; at 48 hpi, 
over 90% of the overreplicated cells were γH2AX positive, compared 
with less than 10% γH2AX positivity in the G1 population. Even in 
the insensitive A2780CP cells, in which there was minimal over-
replication, the large majority of γH2AX positivity was seen in the 
S, G2/M, and more than 4 N DNA content populations; by 48 hpi, 
only 7.9% cells were overreplicated, but 83% of these were γH2AX 
positive, whereas 60% of cells remained in G1 phase, of which only 
1% were γH2AX positive (Figure 2A).
It is known that expression of E1A can induce chromosomal 
aberrations (23). To assess the relationship between E1A expres-
sion and γH2AX, cells were infected with dl922-947 or a nonrep-
licating E1-deleted Ad5 vector, and the intensity of γH2AX and 
E1A within individual cells was assessed by immunofluorescence 
(IF) intensity over 48 hours (Figure 2, B and C). Infection with the 
nonreplicating vector induced no increase in γH2AX (data not 
shown). After dl922-947 infection, E1A and γH2AX increased in 
both sensitive and insensitive cell lines over time, and there was 
a strong positive correlation between the 2 across both cell lines 
(r2 = 0.879, Pearson r = 0.937, P = 0.0006; Supplemental Figure 
2A). However, the increases in both E1A and γH2AX were signifi-
cantly greater in TOV21G cells than in A2780CP cells (Figure 2C 
and Supplemental Figure 2B). In addition, we identified a positive 
correlation between γH2AX and BrdU signals (r2 = 0.692, Pearson 
β
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r = 0.832, P < 0.0001, Supplemental Figure 3). BrdU-positive cells 
showed a pan-nuclear signal, distinct from virus replication cen-
ters, which are seen at discrete sites within the nucleus (24), sup-
porting the association of γH2AX with genomic DNA replication. 
γH2AX was also detected in TOV21G cells after infection with E1A 
WT adenovirus, although the damage occurred more slowly than 
that with dl922-947 (Supplemental Figure 4).
Since significantly greater H2AX phosphorylation was observed 
in S and G2/M cells and cells with more than 4 N DNA content, 
we investigated whether virus infection produced DSBs during 
genomic DNA replication. To analyze genomic DSBs, DNA from 
TOV21G and A2780CP cells was extracted up to 48 hpi, subjected 
to neutral pulsed-field gel electrophoresis (PFGE), and then labeled 
with anti-genomic DNA and anti-adenovirus type 5 DNA probes. 
X-irradiation (20 Gy) and TNF-related apoptosis-inducing ligand 
(TRAIL) (250 ng/ml) were used as positive controls for DSB and 
apoptotic DNA damage, respectively. dl922-947 induced genomic 
DSB damage in TOV21G cells, as indicated by the migration of 
genomic DNA out of the well (Figure 3A). DNA damage was initi-
ated 24 hpi but greatly increased at 48 hpi. The intensive damage 
signal at approximately 50 kb is likely to represent apoptotic DNA 
fragmentation (25) rather than adenoviral DNA, as there is a large 
increase in this signal between 24 and 48 hpi in TOV21G cells but 
little increase in adenovirus DNA. Thus, there were different kinet-
ics of genomic DNA damage and viral replication, which verified 
that infection with dl922-947 induces DNA damage in sensitive 
cells. In contrast, the resistant A2780CP cells had no genomic DNA 
damage compared with mock-infected controls, despite contain-
ing demonstrable adenoviral DNA. These results suggest strongly 
that cellular sensitivity to dl922-947 positively correlates with over-
replication of genomic DNA and associated DNA damage.
H2AX can be phosphorylated by ATR at replication collapse 
(26). To investigate whether overreplication could induce ATR 
to activate Chk1, phosphorylation of Chk1 was examined after 
infection with dl922-947 (Figure 3B). In highly sensitive TOV21G 
cells, Chk1 was activated earlier than in either of the other 2 cell 
lines, confirming that there is functional downstream signaling in 
response to virus-induced genomic DNA overreplication and dam-
age. Some later phosphorylation was seen in both IGROV1 and 
A2780CP cells, in keeping with the lower levels of overreplication 
and H2AX phosphorylation in these cells.
Chk1 inhibition augments dl922-947–induced overreplication and genomic 
DNA damage. To assess whether manipulation of the ATR-Chk1 path-
way could influence the efficacy of adenoviruses in insensitive ovar-
ian cancers, A2780CP cells were infected in the presence of the Chk1 
inhibitor UCN-01 (7-hydroxystaurosporine; ref. 27). First, cells were 
harvested for cell cycle analysis up to 72 hpi. Virus or UCN-01 alone 
exerted no effect upon cell cycle profile, but the combination of dl922-
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to greater accumulation of cells with more than 4 N DNA content 
(Figure 4A). This UCN-01 effect was also seen with intermediate-sen-
sitivity IGROV1 cells, indicating that these effects are not cell-type 
specific (Supplemental Figure 5). Similarly, inhibition of ATR-Chk1 
signaling by siRNA-mediated knockdown of ATR induced a small 
but significant increase in overreplication (Supplemental Figure 6). 
UCN-01 also greatly enhanced γH2AX, as detected by flow cytometry 
(Figure 4B). Furthermore, the increase in γH2AX was most marked in 
S/G2 and overreplicated cells; treatment of cells with UCN-01 alone 
in the absence of virus infection had no effect upon the proportion of 
overreplicated cells. However, the combination of dl922-947 and 300 
nM UCN-01 increased the proportion of overreplicated cells from 11% 
(UCN-01 alone) and 17% (dl922-947 alone) to 42.3% (combination), 
with over 89% of the cells with more than 4 N DNA content being 
γH2AX positive. By comparison, under 10% of G1 phase cells were 
γH2AX positive, despite receiving the same treatment. Importantly, 
UCN-01 did not induce overreplication in primary human fibroblast 
cells after infection with either dl922-947 or Ad5 WT, implying that 
the effects of Chk1 inhibition on viral function are specific to malig-
nant cells (Supplemental Figure 7).
IF analysis of γH2AX and E1A intensity in A2780CP cells after 
infection with dl922-947 indicated that 300 nM UCN-01 slightly 
increased the median intensity of E1A per cell from 11.5 to 15.6 
relative fluorescence units (RFU) (Figure 5A; P = 0.02) but induced 
a greater proportional increase in γH2AX: there was no difference 
in the median intensity of γH2AX staining after UCN-01 and 
dl922-947 given individually (9.9 and 9.5 RFU, respectively), but 
the combination caused a highly significant increase to 35.7 RFU 
(P < 0.0001). Thus, inhibition of Chk1 augmented the accumula-
tion of γH2AX following E1A expression, an effect that was also 
seen in IGROV cells (data not shown). To confirm that this effect 
was Chk1 specific, IGROV1 cells were transfected with siRNA to 
Chk1 prior to infection with dl922-947. IF demonstrated a signifi-
cant increase in γH2AX formation compared with that in control 
cells 24 hpi at 2 MOIs (Figure 5B).
To analyze directly the effect of Chk1 inhibition and associated 
overreplication upon genomic DNA damage, DNA was extracted 
from A2780CP cells after infection and subjected to neutral PFGE. 
Treatment with UCN-01 or dl922-947 alone induced modest DNA 
damage, but the combination of UCN-01 and dl922-947 induced 
large numbers of genomic DSBs in a UCN-01 concentration–
dependent manner (Figure 5C). Labeling with an adenovirus DNA 
probe confirmed that, as in Figure 3A, the large band at approxi-
mately 50 kb seen in the genomic DNA blot does not correspond 
to adenoviral DNA, despite the similar size, and also that UCN-01 
treatment does not compromise viral DNA replication.
Chk1 inhibition decreases HR repair in dl922-947–treated cells. Repli-
cation-associated DNA breaks are preferentially repaired via the 
HR pathway (28). In response to such breaks, activated Chk1 is 
responsible for recruitment of Rad51, which in turn catalyses the 
homology search and DNA strand exchange functions that are 
central to HR (reviewed in ref. 29). To examine how Chk1 inhi-
bition alters HR repair after dl922-947 infection, we quantified 
Rad51 focus formation by IF in A2780CP cells. dl922-947 infection 
alone caused a significant increase in the number of Rad51-posi-
tive cells, but there was a significant and dose-dependent reduc-
tion in Rad51 positivity in the presence of UCN-01 (Figure 6). Col-
lectively, the results in Figures 4–6 demonstrate that inhibition of 
Chk1 increases overreplication with extensive DNA damage and 
prevention of HR pathway activation.
Chk1 inhibition augments adenovirus activity in vitro and in vivo. The 
overreplication and genomic DNA damage effects induced by 
UCN-01 caused a dose-dependent increase in cytotoxicity of both 
dl922-947 and Ad5 WT in both A2780CP and IGROV1 cells (Fig-
ure 7A and data not shown). In addition, UCN-01 did not impede 
the production of intracellular infectious virions and caused an 
increase in virus release, possibly due to increased cell death and 
lysis (Figure 7B). siRNA-mediated Chk1 knockdown was highly 
toxic, such that it was not possible to maintain cells alive for the 
duration of a cytotoxicity assay. However, to demonstrate further 
that the effects were specific to Chk1, both A2780CP and IGROV1 
cells were infected with dl922-947 or Ad5 WT in the presence of the 
Chk1 inhibitor PF-00477736 (30). Sensitivity to both viruses was 
increased in both cell lines (Figure 7C).
To investigate whether these effects translated into increased 
antitumor activity in vivo, female nude mice bearing size-matched 
subcutaneous IGROV1 tumors received a single intratumoral injec-
tion of dl922-947 (1010 particles), with or without a single dose of 
UCN-01 (7.5 mg/kg) i.p. 24 hours later. Tumors were harvested 48 
hours after virus. Greater E1A was detected in tumors from mice 
treated with dl922-947 and UCN-01 compared with those treated 
with dl922-947 and vehicle (Figure 7D). Mice bearing established 
IGROV1-luciferase i.p. xenografts were then treated with dl922-947 
and UCN-01 alone and in combination. UCN-01 and dl922-947 
given individually caused tumor stasis, as monitored by biolumines-
cence imaging, whereas combination treatment caused significant 
tumor regression, which was sustained until the end of the experi-
ment (Figure 7E). In A2780CP xenografts, UCN-01 and dl922-947 
alone had no therapeutic effect, whereas the combination again 
caused regression, although this was temporary (data not shown).
Cdc25A is a key regulator of adenovirus cytotoxicity. To understand 
how Chk1 inhibition can promote overreplication, increase DNA 
damage, and augment viral activity, we investigated the Chk1 
target Cdc25A. Cdc25A is a target of E1A transactivation during 
adenovirus infection and promotes E1A-induced S phase entry 
(31). Deregulated Cdc25A phosphatase activity is sufficient to 
induce unscheduled genomic DNA replication through activation 
of cyclin-dependent kinases (32, 33). During an unperturbed inter-
phase, Cdc25A is subject to basal physiological turnover, which is 
accelerated in response to genotoxic damage (34), mediated by the 
ATR-Chk1 pathway (35, 36). To investigate a possible link between 
Chk1, Cdc25A, and cellular sensitivity, Cdc25A expression was 
assessed after infection with dl922-947. As with E1A, virus-induced 
Cdc25A expression was greater in TOV21G cells than in the 
insensitive cells (Figure 8A), which resulted predominantly from 
increased transcription (Supplemental Figure 8A). An increase in 
transcription was observed in both IGROV1 and A2780CP cells 
at higher MOIs (Supplemental Figure 8B), suggesting a possible 
threshold effect. A2780CP cells were then infected with dl922-947 
for 48 hours in the presence and absence of UCN-01. Cdc25A was 
degraded via a ubiquitin-proteasome-dependent pathway, and the 
combination of dl922-947 and the proteasome inhibitor MG132 
caused a very marked increase in Cdc25A levels (Figure 8B), indi-
cating that Cdc25A is targeted for proteasome-dependent degrada-
tion in insensitive A2780CP cells after dl922-947 infection. Chk1 
inhibition with UCN-01 stabilized Cdc25A, with a very marked 
increases in γH2AX (Figure 8B). There was also an increase in E1A 
(Figure 8C), which complemented the IF and overreplication data 
(Figures 4 and 5) and the immunohistochemistry from IGROV1 
tumors (Figure 7D) and substantiated Chk1 as a mediator of 
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Cdc25A degradation. The increase in Cdc25A with UCN-01 did 
not result from increased transcription (data not shown), con-
firming that Cdc25A stabilization occurs posttranscriptionally. 
MG132 did not increase virus-induced H2AX phosphorylation, 
because adenovirus function depends critically upon proteasomal 
degradation of key cellular proteins, including p53 (37).
siRNA-mediated ATR knockdown was also able to stabilize Cdc25A 
after dl922-947 infection (Figure 8D), in contrast to the ATM inhibi-
tor 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one (data not shown), 
confirming the involvement of the ATR-Chk1 pathway. Finally, over-
expression of Cdc25A significantly increased virus cytotoxicity in both 
A2780CP cells (Figure 8E) and IGROV1 cells (data not shown), with 
increased γH2AX formation (Figure 8E). Conversely, Cdc25A knock-
down reduced virus-induced DNA damage in 
TOV21G cells (Figure 8F) and also reversed both 
the DNA damage and overreplication seen in 
A2780CP cells treated with UCN-01 after virus 
infection (Figure 8G). These results substanti-
ate Cdc25A as an important mediator of virus-
induced DNA damage and as a key target for 
Chk1 activity after infection.
Overall, we propose a model whereby the 
sensitizing effects of Chk1 inhibition upon 
adenovirus-induced cell death in cancer cells 
are compound (Figure 9). These include (a) 
prevention of Chk1-mediated degradation of 
Cdc25A, which promotes unscheduled DNA 
synthesis with consequent induction of DNA 
damage, and (b) inhibition of Chk1-mediated 
recruitment of Rad51 to DSBs, which impairs 
HR repair. Together, these effects expedite the 
accumulation of cytotoxic lesions and cell 
death after infection.
The mode of adenovirus-induced cell death 
has remained obscure (7) and thereby difficult 
to manipulate for therapeutic gain. Unsched-
uled DNA synthesis induces the accumula-
tion of replication-associated DNA lesions 
(11, 21, 38), and our data support a correla-
tion between adenovirus-induced genomic 
DNA overreplication and cytotoxicity in ovar-
ian cancer. We demonstrate that the E1A-CR2 
mutant adenovirus dl922-947 induced massive 
accumulation of genomic DNA damage, spe-
cifically in cell lines sensitive to adenovirus-
induced cell death. Similar DNA damage 
was also induced in sensitive cells by the WT 
adenovirus, although this occurred more slowly. The damage, in 
the form of DSBs, occurred predominantly and specifically in rep-
licating cells and was most prominent in those cells harboring a 
more than 4 N DNA content, consistent with DNA damage being 
dependent upon aberrant overreplication of genomic DNA. As a 
consequence, DSBs were less abundant in resistant cells, in which 
there was minimal overreplication after infection.
Sensitive cells support greater transcription of E1A in the first 
hours after infection. Similarly, sensitive cells permit transcrip-
tion of Cdc25A early after infection, which promotes G1/S tran-
sition by dephosphorylating, and thereby activating, cyclin A- 
and cyclin E-cdk2 kinases, which are the rate limiting factors for 
firing of DNA replication origins. Transactivation of Cdc25A 
γ
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through 2 functional E2F-binding sites (E2F-A and E2F-C) 
within the Cdc25A promoter is essential for efficient induction 
of S phase by E2F1 and pRb family members (39). Cdc25A also 
promotes E1A-mediated S phase entry and DNA synthesis fol-
lowing after with adenovirus (31). Previously, it was reported 
that E1A expression was not responsible for γH2AX formation 
in HeLa cells after adenovirus infection: widespread γH2AX was 
seen only after infection with WT virus and not a nonreplicating 
pTP-deleted virus. In these experiments, E1A expression was seen 
with both viruses but at greater levels with the WT virus (16). 
However, we found a good correlation between E1A expression 
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there may be a threshold effect, whereby E1A expression must 
reach a threshold level to induce sufficient Cdc25A to promote 
genomic DNA overreplication (31). Thus, rapid genomic overrep-
lication and DNA damage are seen in TOV21G cells but at much 
lower levels in resistant and partially sensitive cells and only once 
E1A expression reaches a level sufficient to transactivate Cdc25A 
or after infection at much greater MOI.
Inhibition of ATR-Chk1-Cdc25A pathway augments dl922-947 
cytotoxicity via 2 mechanisms
In our model (Figure 9), we suggest that Chk1 inhibition increases 
virus cytotoxicity via 2 separate mechanisms.
Increase in overreplication via Cdc25A stabilization. Cdc25A is sub-
ject to proteasome-dependent degradation mediated by the ATR-
Chk1 pathway. This acts to modulate the pro-replicative activity of 
cyclin E-cdk2 during an unperturbed cell cycle (35). Replication-
associated DNA damage intensifies ATR-Chk1 signaling, which 
accelerates Cdc25A degradation to enact S phase checkpoint 
control (35, 40). As a consequence, downregulation of either ATR 
or Chk1 activity results in accumulation of Cdc25A and deregu-
lated DNA synthesis (40). The increase in overreplication was less 
marked with ATR knockdown than with UCN-01–mediated Chk1 
inhibition, which may simply reflect difficulty in achieving com-
plete knockdown. We failed to detect accumulation of Cdc25A 
in uninfected cells after either ATR siRNA (data not shown) or 
Chk1 inhibition with UCN-01 (Figure 8C) but did so only with 
dl922-947 infection. The increased Cdc25A levels seen with Chk1 
inhibition in infected cells were achieved despite no increase in 
Cdc25A transcription but were still sufficient to promote overrep-
lication. The overreplication promoted the formation and accu-
mulation of genotoxic DNA lesions to sensitize these otherwise 
resistant cells to dl922-947–induced cell death. Further evidence 
for a role for Cdc25A was provided by overexpression, which 
increased DNA damage and cytotoxicity in A2780CP cells, while, 
conversely, Cdc25A knockdown not only reduced virus-induced 
DNA damage in TOV21G cells but also reversed the overrepli-
cation promoted by UCN-01 in A2780CP cells. One question is 
how TOV21G cells can maintain Cdc25A expression (Figure 8A) 
in the presence of active phospho-Chk1 (Figure 3B). The levels 
of Cdc25A after infection will reflect the balance between virus-
induced expression and Chk1-mediated degradation. In TOV21G 
cells, E1A levels were sufficient to overcome the effects of Chk1 
— indeed, Chk1 inhibition in TOV21G cells increased their over-
replication even further (data not shown).
Augmentation of DNA damage by preventing HR repair. There is evi-
dence that adenovirus infection can inhibit certain forms of DNA 
damage repair: the E1B55K/E4orf6 complex promotes the degra-
dation of DNA ligase IV, which is vital to the process of nonho-
mologous end-joining (41). However, replication-associated DSBs 
are preferentially repaired by HR, in which Rad51 is a key mediator 
(reviewed in ref. 29). Phosphorylation of Rad51 by Chk1 promotes 
the chromatin association of Rad51 and is required for efficient 
HR repair and survival after replication stress-induced DNA dam-
age (36). Interestingly, we detected Rad51 foci as well as γH2AX 
signal after infection with dl922-947, indicating that dl922-947–
induced DSBs activate both DNA damage and DNA repair signal-
ing. We demonstrate that inhibition of Chk1 activity with UCN-01 
reduced the formation of Rad51 foci after infection, implying that 
UCN-01 also impacts on adenovirus-induced signaling to ATR-
Chk1-Rad51–directed HR repair.
Our data also suggest strongly that cell sensitivity to virus-
induced cytotoxicity is not a direct function of intracellular 
virion load: the number of viral genomes and functional virions 
was similar in all 3 cell lines examined here, despite their widely 
differing sensitivity to virus cytotoxicity. Moreover, UCN-01 treat-
ment increased cell death without any substantial increase in the 
number of intracellular virions.
The factors that determine cellular sensitivity to adenovirus-medi-
ated cytotoxicity are likely to be legion. We have recently demon-
strated that expression of p21 in ovarian cancer is a marker for a host 
cell environment conducive to the expression of E1A (8). E1A is the 
first viral gene to be expressed after infection, and its expression cor-
relates with cellular sensitivity. The data presented here indicate that 
the cellular environment can also impact on events downstream of 
E1A expression and, furthermore, can be instrumental in the ulti-
mate fate of a cell. In addition, the ease of virus spread between 
infected cells will contribute to overall cell sensitivity. Spread relies 
both upon release of virus from initially infected cells as well as upon 
subsequent infection of neighboring cells. Although adenovirus 
release is largely lytic, we have recently shown that a nonlytic mecha-
nism may exist, dependent upon stabilized microtubules (42). The 
in vitro experiments described here lasted for 5 days at most, which 
allowed approximately 2–3 rounds of replication (43). It will there-
fore be important to investigate the patterns of DNA damage and 
cytotoxicity in ovarian cancer cells after infection at a lower MOI, 
which will demand multiple rounds of replication and release.
Two major questions remain. First, why are the changes 
greater after dl922-947 infection compared with those after WT 
adenovirus infection? dl922-947 has greater cytotoxicity than Ad5 
WT in a variety of cancer models (2, 3), which has been demon-
strated again here. However, the molecular origin of this increased 
activity is uncertain. The data presented here indicate that the 
superior activity of dl922-947 mirrors the increased DNA damage 
and overreplication. The 24-bp deletion within E1A-CR2 region 
in dl922-947 greatly reduces binding to host cell p107, pRb, and 
cyclin A (1), effects that correlate with reinitiation of DNA syn-
thesis and host cell overreplication (44) as well as induction of 
cdk1 activity (45). Thus, the superior potency of dl922-947 may 
be caused by uncoordinated host cell DNA replication, with con-
sequent activation of DNA damage responses. Second, what is the 
role of HR competence in repairing virus-induced genomic DNA 
damage? There is much interest in the role of HR incompetence as 
a predictor of ovarian cancer responsiveness to PARP inhibition 
(38, 46, 47). Our data would suggest that HR incompetence would 
predispose cells to adenovirus-induced cell death, while inhibit-
ing HR in HR-proficient cells could convey sensitivity to otherwise 
resistant cells. We are currently exploring both questions further.
In summary, our data demonstrate that mechanisms to promote 
unscheduled DNA synthesis and/or impede HR repair will potenti-
ate the accumulation of cytotoxic lesions and increase death induced 
by the oncolytic adenovirus dl922-947. As UCN-01 has already 
shown itself to be safe in patients with advanced ovarian cancer (48), 
combination trials with oncolytic viruses should be explored.
Cell culture, adenoviruses, and cell viability assays. All cells were maintained at 37°C 
with 5% CO2, in Dulbecco’s modified Eagle’s medium supplemented with 
10% FCS, penicillin/streptomycin, and fungizone. dl922-947 is an adenovirus 
type 5 mutant containing a 24-bp deletion in E1A-CR2, which is also deleted 
in E3B. dl309 is identical to dl922-947 apart from a WT E1A region. Control 
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viruses adenovirus CMV GFP and adenovirus LM-X are both E1-deleted non-
replicating vectors as previously described (49). For viability assays, 2 × 104 
cells were infected in serum-free medium at MOI 0.001–1,000 PFU/cell. After 
2 hours, cells were refed with medium containing 5% FCS. Cell viability was 
assayed by MTT assay using a Victor3 Plate Reader (Perkin Elmer). All viability 
assays were done in triplicate, and experiments were repeated at least twice. 
For siRNA experiments, cells were transfected with ON-TARGETplus SMART-
pool siRNAs or scrambled siRNA control (Dharmacon) using DharmaFECT1. 
Virus infection took place 24 hours after knockdown. Cells were exposed to 
5 Gy X-irradiation using an Hs-X-Ray System (A.G.O. Installations Ltd.). ATM 
inhibitor 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one was obtained from 
Calbiochem. The plasmid pX-HA-cdc25a was donated by Ingrid Hoffman 
(German Cancer Research Center, Heidelberg, Germany) (33), and pGFP was 
obtained from Invitrogen. Plasmids (1 μg) were transfected into cells in 24-well 
plates using FuGene (Roche).
Quantitative PCR and TCID50 assays. Real-time PCR was performed on an 
ABI Prism 7700 (Applied Biosystems). Oligonucleotides and probes for E1A 
and β-actin are as follows: E1A, sense primer, 5′-CCACCTACCCTTCAC-
GAACTG; anti-sense primer, 5′-GCCTCCTCGTTGGGATCTTC; probe, 
ATGATTTAGACGTGACGGCC; and β-actin, sense primer, 5′-GCCAGCT-
CACCATGGATGAT; anti-sense primer, 5′-CACCTCCCCTGTGTGGACTT; 
probe, AGGCGGACTATGACTTAGTTGCGTACACCCT.
Those for 18S RNA and Cdc25A were purchased from Applied Biosystems 
(reference numbers 4310893E and Hs00947998_m1, respectively). PCR con-
ditions were as follows: 50°C for 2 minutes and 95°C for 10 minutes, followed 
by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. Where stated, a 
standard curve using 103–109 dl922-947 genomes was used for quantification. 
For tissue culture infectious dose 50% (TCID50) assays, 105 cells were infected 
at MOI 7.5 PFU/cell. Cells were harvested into 0.5 ml 0.1 M Tris, pH 8.0, and 
subjected to 3 rounds of freeze/thawing (liquid N2/37°C), after which they 
were centrifuged. The supernatant was titered on JH293 cells by serial dilu-
tion. To assay viral release from infected cells, culture medium was removed 
from cells every 24 hours and titered separately on JH293 cells.
Immunoblotting and IF. Protein lysates were electrophoresed on SDS-poly-
acrylamide gels and transferred onto nitrocellulose membranes by semi-
dry blotting. Antibody binding was visualized using enhanced chemilumi-
nescence (GE Healthcare). Antibodies used were anti-E1A, anti-Cdc25A, 
anti-ATR, anti-Actin, and anti-Ku70 (all Santa Cruz Biotechnology Inc.); 
anti-γH2AX (Upstate Biotechnology); anti-Ser 317 phospho-Chk1 (Cell 
Signaling Technology); anti-PARP (Serotec); and anti-Ku-80 (gifted from 
the lab of Penny Jeggo, University of Sussex). For IF, cells were grown on 
poly-L-lysine–coated coverslips, infected with dl922-947 (MOI 7.5), and fixed 
with 5% formaldehyde. Cells were permeabilized with 0.15% Triton X-100, 
and primary antibody binding was visualized with Texas Red– or Fluores-
cein-conjugated secondary antibodies (Vector Laboratories). For Rad51 
staining, cells were preextracted with 0.15% Triton X-100 and fixed with 5% 
formaldehyde. Coverslips were mounted in DAPI-containing Vectashield 
and imaged using either a Zeiss Axioplan2 or a Zeiss Axiovert 200M fluores-
cence microscope with a ×4 or ×10 objective lens and a digital camera (Orca-
ER, Hamamatsu) and Delta Vision Spectris software, with a ×100 objective 
lens for Rad51 foci (Applied Precision). Images taken at ×40 magnification 
were processed using Simple PCI software, and signal intensity per nucleus 
was analyzed using NIH ImageJ (http://rsbweb.nih.gov/ij/).
Flow cytometry. For cell cycle analyses, cells were trypsinized, washed twice 
in ice-cold PBS, and fixed in 70% ethanol. Cells were then washed with PBS 
and resuspended in 200 μl trypsinized PI and 100 μg/ml RNase A (MP 
Biomedicals). For γH2AX analysis, cells were harvested, washed, and fixed 
in ice-cold 70% ethanol. After incubation with primary anti-γH2AX mAb 
and FITC-conjugated anti-mouse secondary antibody for 20 minutes each 
at 37°C in the dark, cells were counterstained with PI. Cells were analyzed 
using a Fluorescence Activated Cell Sorter (FACSCanto, BD Biosciences), 
with FACS Diva software.
PFGE. Cells were infected with dl922-947 (MOI 7.5), with or without 
treatment with UCN-01. After trypsinization, cells were washed twice with 
PBS and were embedded in 0.75% low melting agarose gel plug (SeaPlaque 
agarose, Cambrex Bioproducts) at a concentration of 0.75 × 105 cells/plug. 
Plugs were then placed in buffer containing 20 mg/ml proteinase K, 0.5 M 
EDTA, and 1% sarkosyl (pH 9.0) and incubated at 50°C for 24 hours in the 
dark. Plugs were washed with 50 mM EDTA at room temperature for 1 hour 
and stored at 4°C in the same buffer. PFGE was carried out a CHEF Map-
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1% agarose gel (Pulsed Field Certified Agarose, Bio-Rad) in 0.5 × TBE. The 
forward voltage gradient was 5.4 V/cm for 5 to 60 seconds, and the reverse 
voltage gradient was 3.6 V/cm for 5 to 60 seconds, for a total of 20 hours 
at 14°C. After PFGE, gels were stained with ethidium bromide and photo-
graphed under UV transillumination. Southern blot hybridization was car-
ried out using standard procedures with HRP-conjugated genomic DNA or 
adenovirus type probes.
In vivo analyses and immunohistochemistry. Experiments were performed under 
suitable United Kingdom Home Office personal and project license author-
ity. All animal studies were also reviewed and approved by the ethical review 
board of the Biological Services Unit, Queen Mary University of London.
For analysis of E1A expression, 5 × 106 IGROV1 cells were inoculated sub-
cutaneously onto the flank of female nu/nu mice on day 1. Once tumors 
reached approximately 250 mm3, dl922-947 or vehicle was injected intra-
tumorally (single injection, 1 × 1010 particles in 50 μl PBS). A single dose 
of i.p. UCN-01 or vehicle (7.5 mg/kg in 20% icodextrin) was administered 
24 hours later. Mice were killed 24 hours thereafter. Tumors were excised 
and fixed in 10% formal-buffered saline (n = 2 per group) or snap frozen 
in dry ice (n = 3 per group). Fixed tumors were transferred to ice-cold 70% 
ethanol after 24 hours, and 4-μm sections were cut and processed. E1A 
expression was detected using a rabbit anti-Ad2 E1A antibody (Santa Cruz 
Biotechnology Inc.). Total RNA was extracted from snap-frozen tumors 
using TRIZOL. After DNAse digestion (Qiagen), 1 μg total RNA was reverse 
transcribed using random hexonucleotide primers (First-Strand Synthesis 
Kit, Roche) and analyzed by quantitative PCR. For assessment of antitu-
mor efficacy, 5 × 106 IGROV1-luciferase or A2780CP-luciferase cells were 
inoculated i.p. into female nu/nu mice on day 1. In IGROV1 experiments, 
dl922-947 or control adenovirus CMV-GFP (5 × 109 particles in 400 μl 20% 
icodextrin) were injected i.p. on days 9, 10, 15, and 16. UCN-01 (5 mg/kg) or 
vehicle (20% icodextrin) were administered i.p. on days 11, 12, 17, and 18. For 
A2780CP experiments, virus was administered on days 9, 11, 15, and 17, and 
UCN-01/vehicle were administered on days 10, 12, 16, and 18. Mice were 
injected i.p. with 125 mg/kg D-luciferin (Calliper Life Sciences) and then 
anesthetized (2% isoflurane by inhalation). Five minutes later, while still 
under anesthetic, they were placed in a light-tight chamber on a warmed 
stage (37°C), and light emission from a defined region of interest on the ven-
tral aspect was imaged on a Xenogen IVIS Imaging System 100 (Alameda). 
Data were analyzed using Living Image software (also Xenogen) and are pre-
sented as mean radiance (photons/s/cm2/steradian [photons/s/cm2/sr]).
Statistics. All statistical analyses were generated with GraphPad Prism 5.00. 
All analyses are unpaired, 2-tailed Student’s t-test unless otherwise stated. All 
experiments were performed in triplicate and error bars represent SD unless 
otherwise stated. P values of less than 0.05 were considered significant.
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a.2 results from screen
OVCAR4 screen 1 OVCAR4 screen 2 COV318 screen 1 COV318 screen 2
Gene ΔZ score ΔZ score ΔZ score ΔZ score
AHCY 0.71 0.91 1.39 0.75
AHCY -0.92 -4.72 0.34 0.72
ADPRT 1.32 0.91 0.96 1.15
ADPRT -2.42 -0.44 -2.26 -1.56
ADPRTL2 0.71 1.35 1.18 0.96
ADPRTL2 -2.72 -1.26 0.52 0.84
APEX2 -0.42 -2.32 0.42 0.33
APEX2 -0.80 -1.14 -1.75 0.68
ATR -0.35 0.79 0.32 1.04
ATR -2.08 -1.12 0.35 1.07
ARMET 1.28 0.80 1.13 1.84
ARMET 1.53 1.35 -0.01 0.89
BLM -0.01 1.49 0.01 0.52
BLM 0.47 -0.17 1.61 1.14
BRCA2 0.46 -0.08 0.28 0.58
BRCA2 0.71 0.00 -0.19 3.91
C18orf37 -2.98 -2.93 2.09 -0.69
C18orf37 0.11 1.36 1.19 0.25
CANX -1.07 0.44 -0.04 0.19
CANX -1.26 -0.23 0.72 -0.77
CARM1 -2.69 -0.72 0.22 1.60
CARM1 -0.92 -1.00 1.14 1.67
CCNH -0.58 -1.15 -0.63 -1.06
CCNH -0.77 -0.44 -0.29 0.69
CCT4 -0.91 -0.60 -0.66 0.10
CCT4 2.56 2.22 1.52 0.84
CCT5 1.44 1.60 1.44 1.21
CCT5 -3.47 -2.65 -0.72 -1.52
CDK7 0.23 1.04 1.26 0.93
CDK7 0.89 -0.45 0.66 -0.99
CKN1 -1.29 -1.46 -0.51 -0.92
CKN1 -0.03 0.67 -0.79 -2.70
CHEK1 -2.04 0.44 -0.45 -0.19
CHEK1 -0.04 1.45 0.16 -0.38
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CKS2 -0.39 1.28 -0.06 -0.84
CKS2 -0.73 0.08 -1.61 -2.09
CETN2 1.32 0.67 0.95 1.53
CETN2 -3.41 -2.38 -2.40 -3.13
CDKN3 0.87 -1.19 1.11 0.86
CDKN3 1.61 1.32 -0.20 -2.30
COL1A2 0.49 1.53 0.20 0.94
COL1A2 0.95 0.94 0.76 1.09
CRIP2 -0.63 -0.15 -2.95 -4.18
CRIP2 0.72 -0.15 -0.02 -2.05
COPB2 -0.20 0.16 -1.34 -5.09
COPB2 1.05 0.03 4.08 -5.93
DDB2 0.47 -1.60 -1.09 0.50
DDB2 2.71 0.72 -0.06 -5.39
DNMT1 -0.02 1.20 -1.45 0.99
DNMT1 1.11 1.37 -0.56 0.97
DDB1 -0.18 1.08 -0.73 2.10
DDB1 -0.06 0.89 -0.90 -0.02
DMC1 0.05 0.75 -1.57 0.04
DMC1 2.99 0.54 -0.42 -2.70
DDX48 3.85 2.07 0.19 -6.90
DDX48 3.76 2.70 1.24 -6.84
DCLRE1A 0.75 2.14 0.18 0.87
DCLRE1A 0.43 1.55 -0.51 0.22
DCLRE1C -0.17 2.48 0.66 1.12
DCLRE1C -0.64 0.76 -1.17 -0.63
DCLRE1B -2.24 -0.42 -0.17 0.46
DCLRE1B 0.81 1.82 0.88 -1.71
DEPC-1 -0.29 -0.79 -0.45 -1.37
DEPC-1 -1.30 -0.57 0.43 -2.23
DUT -0.28 2.28 0.49 1.19
DUT 0.02 0.44 -0.75 0.13
E2F5 -0.57 1.57 -0.24 0.58
E2F5 -0.34 0.84 0.47 0.00
DVL3 0.50 -1.59 -0.37 -2.34
DVL3 -1.57 1.44 0.86 0.44
DOT1L -2.40 -2.80 -1.18 -3.55
DOT1L -0.45 0.09 0.11 -0.55
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EHMT1 -0.14 1.70 -0.64 -2.25
EHMT1 -0.82 0.39 -1.00 0.27
ERCC3 -1.16 -0.13 -0.24 0.41
ERCC3 -0.09 0.24 -0.07 -0.52
ERCC2 0.30 0.16 -0.53 -0.22
ERCC2 0.27 1.14 0.55 1.18
ERCC4 -0.33 0.61 -1.00 -0.37
ERCC4 0.45 0.87 0.04 0.52
ERCC5 0.40 0.40 -0.89 -0.19
ERCC5 -0.15 -0.27 -0.56 -1.09
ERCC6 0.44 0.93 0.66 -0.46
ERCC6 -0.52 -1.32 0.47 -1.08
FANCA -0.63 -0.87 -1.53 -0.82
FANCA -0.13 0.06 1.51 0.43
FANCC -0.31 0.25 -1.07 -0.20
FANCC -0.40 -0.15 -0.47 0.21
FAP -0.01 -0.14 -0.27 -0.20
FAP 0.65 0.06 0.58 0.47
FANCG -0.53 -0.52 -1.02 -1.77
FANCG 0.63 0.77 -1.16 1.80
FANCE 0.06 0.30 -1.18 -0.32
FANCE 0.06 -0.27 0.13 0.85
FANCF 0.18 0.29 0.04 0.19
FANCF -0.58 -0.63 -0.23 -0.40
FANCD2 0.51 -0.26 0.98 0.70
FANCD2 1.34 -0.08 1.10 0.35
FEN1 0.89 -0.61 0.20 0.42
FEN1 -0.24 -1.24 -1.72 0.94
FLJ10858 0.23 1.67 -0.20 -1.08
FLJ10858 0.76 0.04 1.75 0.69
FLJ35220 0.48 0.11 1.53 0.90
FLJ35220 -0.10 -0.95 -0.38 -0.90
G22P1 0.23 -1.63 -0.58 -1.01
G22P1 -0.01 -1.37 0.47 -0.67
GTF2H2 -0.07 -2.49 -0.42 -1.78
GTF2H2 1.08 -1.01 -0.50 -0.03
GTF2H3 0.69 1.49 -0.65 0.43
GTF2H3 -1.19 -0.79 0.37 0.51
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H2AFZ -0.94 -0.08 -0.02 0.19
H2AFZ -0.05 -0.12 -0.01 0.23
GTF2H1 0.75 -0.31 0.95 0.44
GTF2H1 0.73 -0.46 0.98 0.08
HDAC2 0.57 -1.32 0.70 -1.52
HDAC2 0.83 0.07 -0.79 1.32
HDAC1 -0.06 0.45 0.20 0.85
HDAC1 -0.68 -0.21 0.45 -0.41
HDAC4 0.54 1.14 0.42 0.64
HDAC4 -0.47 -0.14 -0.38 -0.81
HDAC6 0.52 0.21 1.30 0.54
HDAC6 0.20 -0.50 0.48 -0.14
ZDHHC17 -0.21 -1.30 0.68 -0.04
ZDHHC17 -0.24 -0.07 2.24 -0.21
HDAC11 -1.07 -0.34 -1.45 -1.46
HDAC11 -1.52 0.02 1.45 0.84
HDAC10 -0.68 -0.27 -0.46 0.41
HDAC10 -0.06 -0.04 -0.67 -0.17
HSPE1 -0.46 -0.67 1.16 0.17
HSPE1 -2.45 -2.09 1.04 -0.47
HUS1 0.21 -1.61 0.79 -0.22
HUS1 0.84 -1.39 1.10 2.33
ILF2 0.86 1.23 1.29 1.22
ILF2 1.37 0.89 1.14 0.35
IFNGR2 0.20 1.18 0.79 0.48
IFNGR2 -0.50 0.48 -0.11 -0.46
HSU24186 -1.02 -0.75 -0.38 -0.40
HSU24186 1.65 0.92 -0.92 -0.88
KDELR2 0.27 0.44 -0.67 0.23
KDELR2 1.30 0.67 0.54 -1.43
KIAA0101 0.70 -2.16 -0.86 -0.27
KIAA0101 0.72 0.10 -0.26 0.34
LIG1 -0.44 -0.05 0.44 0.54
LIG1 -0.39 0.37 -1.85 -0.12
KPNA2 0.33 -0.83 -0.71 0.14
KPNA2 0.13 -0.71 -1.97 -1.68
LDHA 1.06 -0.18 -0.73 0.27
LDHA 1.34 1.62 0.32 0.68
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MAD2L2 -0.14 0.60 -0.57 -0.09
MAD2L2 0.15 -1.07 -3.34 -0.15
MCM3 -2.07 -1.40 -0.14 -0.15
MCM3 -0.04 1.59 -0.81 -0.07
MBD4 -0.44 1.75 0.17 0.00
MBD4 -1.56 -0.50 -0.59 -0.16
MBD3 -0.48 0.45 -0.85 -0.98
MBD3 0.11 0.59 -0.11 -0.26
MECP2 0.35 0.99 -1.50 0.37
MECP2 -0.30 -0.27 -0.09 0.98
MLH1 -0.96 -0.39 -1.25 1.61
MLH1 0.66 -2.53 0.09 -0.83
MGC90512 -1.87 0.01 0.25 0.07
MGC90512 1.58 1.20 0.85 -0.17
MNAT1 0.07 0.41 -0.48 -1.30
MNAT1 -0.89 0.50 -0.41 -0.77
MPG 1.32 0.33 0.11 0.64
MPG 0.12 1.50 0.39 0.26
MMP9 0.78 1.35 1.06 0.54
MMP9 -0.90 -2.74 -3.34 -2.27
MLL -0.07 1.11 0.78 0.55
MLL 0.54 0.47 0.32 0.17
MRPL3 0.39 1.33 0.06 -0.40
MRPL3 1.35 1.33 -1.07 -0.20
MLH3 -1.18 0.62 0.14 -1.01
MLH3 0.48 -0.12 0.37 0.17
MMS19L -0.17 -0.38 0.91 1.13
MMS19L 1.13 -1.50 1.20 0.46
MSH6 1.16 1.01 0.84 1.20
MSH6 0.49 -0.22 -0.95 -0.55
MSH2 0.21 0.89 -1.07 0.50
MSH2 1.85 0.75 1.33 0.87
MSH3 0.66 0.57 1.66 2.03
MSH3 1.14 -0.28 0.58 1.41
MSH4 -0.62 -0.85 1.84 0.81
MSH4 -0.35 -1.34 -2.10 1.86
MTHFD2 -0.30 0.67 0.69 0.86
MTHFD2 0.32 0.80 0.21 1.70
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MUTYH 0.40 0.07 0.87 0.94
MUTYH 0.05 -0.58 -0.77 -0.01
NBS1 0.57 -0.08 0.53 -0.14
NBS1 1.55 -0.67 0.86 0.40
NCBP2 -1.64 -1.14 1.26 -0.73
NCBP2 0.34 -1.50 -0.46 -0.67
NONO 1.34 1.04 0.04 0.05
NONO -3.60 -2.74 -4.15 -3.05
NEIL1 1.01 0.40 -0.93 0.06
NEIL1 1.25 -0.39 -1.02 -0.10
NEIL2 0.48 -0.72 0.04 -0.95
NEIL2 0.55 -0.37 0.66 0.09
NTHL1 0.39 0.15 1.49 1.00
NTHL1 2.55 -0.63 0.81 1.41
OK/SW-cl.56 0.33 0.05 -0.97 0.42
OK/SW-cl.56 1.01 -0.28 -0.18 -0.50
PAFAH1B3 -0.20 0.21 0.23 -0.41
PAFAH1B3 -1.24 -1.39 -0.69 -0.35
PAICS -0.24 -0.46 0.47 0.22
PAICS 0.37 -1.03 0.60 0.70
PLK1 -0.88 -2.63 0.78 -0.22
PLK1 0.81 -2.64 0.27 0.30
PMS1 0.39 0.73 -0.67 0.48
PMS1 -0.76 0.14 -0.76 0.21
PMS2 -0.61 -0.71 -0.63 0.28
PMS2 -2.15 -1.65 -0.69 0.19
POLB 0.27 -0.92 0.06 0.09
POLB 0.28 -0.99 1.32 0.91
POLD1 0.44 -0.33 1.81 0.80
POLD1 0.73 -0.70 1.05 0.30
POLG 0.77 1.40 -0.20 0.96
POLG -3.29 -1.55 0.44 -0.38
POLE -0.49 0.78 0.78 1.01
POLE -0.59 -0.03 0.14 0.69
POLH 0.56 -0.84 0.97 0.07
POLH -0.57 -1.30 1.04 0.30
POLI 0.41 0.32 0.55 0.28
POLI -0.62 -1.31 0.86 0.46
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PNKP 0.12 0.60 -0.20 -0.48
PNKP -0.56 0.02 1.19 -0.52
POLL 0.34 0.77 0.12 0.24
POLL -2.65 0.23 -0.70 0.62
POLM 1.63 0.02 0.08 0.70
POLM 2.13 1.18 -2.51 1.29
POLK -0.55 1.58 -0.03 0.84
POLK -1.32 -0.30 -1.53 0.27
POLN 2.17 0.29 -1.54 0.26
POLN -4.82 -0.90 -0.63 -0.27
PRDX4 -0.70 -0.71 -0.55 -1.67
PRDX4 0.05 0.02 0.94 2.46
PRKDC -0.20 0.27 -1.83 0.26
PRKDC -2.46 0.09 -1.56 0.21
RAD23B -1.44 0.61 -1.31 0.27
RAD23B 3.39 0.80 0.44 0.33
RAD54L 2.07 -0.51 -1.11 -0.18
RAD54L 1.61 0.28 0.15 1.23
RAD9A 0.59 0.02 -0.19 -0.33
RAD9A 2.75 1.16 1.42 4.83
RAD23A -2.15 -1.73 -0.41 0.11
RAD23A 4.15 1.30 -1.13 0.47
RAD18 -0.05 0.93 0.03 0.54
RAD18 1.87 -1.34 -1.70 -1.02
RBM4 -2.02 -3.02 -2.72 -1.87
RBM4 0.50 -1.47 -0.15 -1.71
RECQL4 1.26 -0.70 1.28 -0.18
RECQL4 1.64 0.95 1.37 3.97
REV3L -3.08 1.72 -0.01 1.60
REV3L 2.79 -0.43 -0.98 -0.19
RPA1 8.38 1.82 2.41 1.98
RPA1 -1.20 2.88 2.04 1.54
RPA2 -0.14 -4.10 -1.32 -0.07
RPA2 4.14 -0.77 0.34 1.04
RPA3 3.16 -3.09 -0.22 -1.69
RPA3 2.81 -0.52 1.74 3.47
REV1L -4.11 -0.58 -1.77 -0.07
REV1L -1.09 -0.96 -0.62 0.40
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SDHC -1.44 -0.56 -0.48 -0.07
SDHC -4.13 0.66 -1.57 0.42
RRM2B -1.86 0.56 -1.44 1.26
RRM2B -2.48 -0.32 0.40 -0.16
SET8 5.41 -1.81 1.00 -2.39
SET8 3.14 -0.03 2.28 3.04
SET7 -2.38 0.28 3.29 0.88
SET7 0.47 -0.21 -0.07 0.87
SMARCA4 -2.49 -0.30 0.51 1.15
SMARCA4 -0.47 0.36 0.07 -0.47
SNRPF -4.06 0.57 -0.09 1.52
SNRPF -5.00 1.64 -0.11 0.81
SOX4 3.01 -1.16 2.19 0.19
SOX4 -3.90 0.33 0.29 1.04
SMUG1 0.72 -0.42 0.08 0.05
SMUG1 1.45 0.06 -0.59 0.92
SND1 -1.75 1.53 -1.03 0.34
SND1 -0.85 0.99 -0.04 1.06
SSBP1 2.54 -0.04 -0.17 -0.43
SSBP1 5.37 2.34 1.11 0.88
SSR1 -11.80 1.23 -0.08 -3.17
SSR1 -10.91 2.90 1.60 0.63
SUV39H1 1.52 0.16 -2.05 -0.13
SUV39H1 0.01 -0.32 -1.78 0.44
SUV39H2 -0.95 0.30 -1.41 0.21
SUV39H2 -2.97 -1.28 -0.74 0.73
TDG -1.05 1.11 0.42 0.93
TDG -4.58 -1.09 0.81 0.38
TDP1 -3.66 -0.04 -1.71 -0.83
TDP1 -1.61 -0.73 1.21 -1.38
TARS -1.76 0.49 -1.12 0.03
TARS 0.00 -1.25 -1.87 -0.37
TMEM30A 4.11 -3.86 -4.25 -3.53
TMEM30A -1.09 -0.69 -1.29 -0.79
TOP2A -5.18 0.52 0.10 0.43
TOP2A -2.39 -0.03 1.30 0.31
TRA1 -1.98 -0.42 0.90 -1.51
TRA1 0.34 2.07 0.66 -0.05
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TP53BP1 -4.95 0.93 -1.54 -0.16
TP53BP1 1.63 0.08 -0.19 0.56
TPX2 2.84 0.81 -0.25 0.00
TPX2 -0.18 0.63 1.12 0.72
TSTA3 -0.43 0.29 -1.13 0.00
TSTA3 -0.75 -0.25 0.09 0.54
UBE2B 0.62 0.98 1.86 1.63
UBE2B 1.45 0.26 0.64 1.74
UBE2N 0.55 -0.50 -0.13 0.34
UBE2N -0.84 -2.61 0.21 0.76
UBE2V2 -0.25 -2.31 0.91 0.27
UBE2V2 1.16 -0.23 3.29 2.09
XPA -1.89 -0.28 -0.76 -0.83
XPA -0.72 -0.84 0.62 -0.11
WRN -1.78 0.27 -0.29 -1.20
WRN 0.58 1.13 0.78 0.21
XPC -0.09 0.45 0.48 -0.22
XPC -0.60 -0.35 0.38 -0.62
XRCC2 0.17 -0.81 0.40 0.29
XRCC2 1.34 1.36 1.88 1.16
XRCC3 -1.46 -0.60 -1.03 -1.63
XRCC3 0.30 1.39 0.39 1.19
XRCC1 -0.76 0.10 1.21 -0.27
XRCC1 1.06 2.29 0.49 -0.45
XAB2 3.06 2.52 1.43 1.61
XAB2 1.61 1.04 1.22 0.34
XRCC5 0.73 -0.42 0.84 -0.59
XRCC5 1.57 -0.52 2.12 1.58
PMS2L4 -0.53 0.37 -0.54 0.73
PMS2L4 -1.27 0.15 -1.51 -0.27
H2AFX -0.90 -0.24 -0.60 -0.35
H2AFX 0.24 0.70 -0.26 -0.26
MGMT 0.32 0.17 0.75 0.79
MGMT -1.25 -2.54 -0.12 -0.13
PTMA 3.17 1.18 2.06 1.64
PTMA -0.38 -2.00 0.87 0.91
RPL27 0.94 1.16 0.75 0.75
RPL27 0.40 2.04 -0.33 -0.16
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PSME2 0.51 0.57 0.47 -0.77
PSME2 0.54 0.16 1.19 1.21
SNRPE 2.99 1.96 0.67 1.50
SNRPE 0.74 0.67 0.19 0.93
UBE2S 1.54 0.17 2.28 -0.55
UBE2S 0.42 -0.62 2.71 1.65
RPL35 1.05 1.78 -1.58 -0.39
RPL35 0.62 2.22 -1.89 0.16
GTF2H4 -1.29 1.52 0.34 -0.34
GTF2H4 0.62 1.44 2.19 2.11
ATM -0.18 0.40 0.03 0.05
ATM 0.39 0.47 1.39 0.84
NME1 0.41 0.04 2.47 -0.67
NME1 0.12 0.71 2.74 0.83
RPL13 -0.35 1.56 -0.05 0.62
RPL13 -2.21 1.05 -3.16 -0.38
ACLY -1.87 0.59 -1.67 -1.21
ACLY -0.06 0.82 0.75 1.65
HRMT1L2 3.17 1.79 1.09 1.61
HRMT1L2 3.60 0.44 2.24 2.39
APEX1 -0.35 -0.01 0.21 -0.37
APEX1 2.18 -0.14 3.02 2.60
CDC2 -0.66 0.60 -0.55 -0.26
CDC2 -0.45 1.04 -2.25 -0.91
ERCC1 -1.05 -0.32 -1.17 -0.66
ERCC1 -1.77 -1.50 0.36 0.52
HNRPA2B1 -0.81 -1.14 -1.09 1.96
HNRPA2B1 -0.68 -1.82 -0.54 -1.17
HSPD1 1.15 -1.31 0.63 -2.38
HSPD1 1.71 -0.26 2.07 -1.18
IARS 1.20 1.44 -0.53 1.14
IARS 0.17 1.81 0.37 0.63
LIG3 0.61 1.28 -1.50 -0.40
LIG3 -2.05 -0.19 -1.47 0.11
LIG4 3.84 2.19 -1.46 0.28
LIG4 -1.46 -1.42 -0.82 -1.39
MBD1 -2.18 -1.76 -0.25 -3.67
MBD1 0.57 -0.88 0.97 -3.14
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MSH5 -0.39 2.00 -0.73 0.96
MSH5 1.16 1.53 0.71 1.57
NUDT1 1.47 1.97 -2.05 0.85
NUDT1 0.78 0.89 -0.61 1.50
OGG1 0.83 0.00 0.18 1.21
OGG1 0.48 -1.03 -0.60 -1.48
PCNA 1.31 1.06 -0.32 0.46
PCNA 1.33 1.47 1.04 0.79
PPP2R5C -2.29 -1.04 -1.00 -0.13
PPP2R5C -0.46 0.82 0.24 -0.04
PSMA1 1.07 1.58 -0.33 0.77
PSMA1 0.45 1.80 2.69 1.78
RAD1 0.46 0.54 0.16 1.06
RAD1 1.16 -0.05 0.34 0.95
RAD17 1.47 1.00 -0.20 1.04
RAD17 -0.90 -0.54 -1.18 -0.80
RAD51 -0.08 0.89 0.68 1.34
RAD51 0.58 0.59 -0.34 -1.21
RAD51C 0.93 2.07 -0.44 0.02
RAD51C -2.05 0.76 -0.69 -1.45
RAD51L1 1.15 0.45 -0.11 1.02
RAD51L1 2.67 -0.27 1.16 0.77
RAD51L3 -2.65 -2.47 -0.73 -0.84
RAD51L3 -1.52 -1.71 1.10 0.11
RAD52 -0.50 -0.46 1.40 -0.11
RAD52 0.32 -1.17 0.99 0.08
RFC4 0.10 0.23 1.90 -0.66
RFC4 -0.50 1.38 3.15 1.56
SMARCA3 1.97 0.60 0.85 1.04
SMARCA3 1.89 0.48 0.26 0.94
TGIF 0.21 -0.70 -1.39 0.73
TGIF 1.26 0.44 -0.10 0.91
UBE2A 1.40 0.97 -0.59 -0.39
UBE2A 0.27 0.76 0.52 -0.66
UNG 0.03 -0.08 -0.91 -0.48
UNG -1.55 0.16 0.32 0.02
XRCC4 -0.70 -0.63 -0.65 -0.57
XRCC4 0.55 0.66 -0.45 2.19
A.2 results from screen 291
OGT -0.40 0.13 -0.86 0.39
OGT 1.99 1.44 0.76 0.34
EXO1 1.34 1.51 -0.46 0.23
EXO1 0.02 0.58 0.69 -0.59
MBD2 -0.41 -2.18 0.73 0.45
MBD2 -1.34 -0.27 1.49 -0.42
TRAF4 2.15 0.03 -0.02 1.50
TRAF4 1.17 -0.16 0.47 0.49
DNMT2 0.48 -0.16 0.09 0.49
DNMT2 0.72 -0.41 -0.09 0.29
EZH2 1.15 0.32 0.41 0.08
EZH2 1.28 1.29 1.13 0.85
MRE11A 1.09 -0.56 0.00 0.61
MRE11A -0.79 -0.47 3.25 0.38
RAD50 1.83 0.62 -0.11 1.02
RAD50 2.72 0.27 -0.37 -0.13
G3BP 1.93 1.68 -0.88 0.52
G3BP 1.30 0.04 1.28 0.32
PRDX2 0.26 -0.48 0.92 0.52
PRDX2 1.77 0.62 0.99 1.14
PSMC4 1.62 0.89 -0.56 -1.30
PSMC4 0.99 1.38 2.61 0.01
POLQ 2.15 0.42 0.52 1.43
POLQ 1.58 -0.03 0.23 -0.33
DNMT3B -0.98 -0.75 -0.32 -0.25
DNMT3B 0.67 0.52 -0.21 0.14
CHEK2 -3.07 -1.88 0.06 -0.06
CHEK2 0.10 -0.76 -0.55 -0.09
CBX3 0.32 -1.63 -0.36 -1.43
CBX3 -0.16 2.36 0.87 -2.37
BRCA1 1.12 0.48 -0.49 1.75
BRCA1 1.77 -0.32 0.48 -0.11
RAD54B -0.03 0.15 -0.34 -0.62
RAD54B -0.59 -0.22 0.19 0.23
SPO11 1.15 0.69 0.45 2.21
SPO11 -3.46 -1.81 -2.30 -0.50
TREX1 -1.74 -2.06 -0.98 -0.35
TREX1 -1.77 -1.55 2.17 0.64
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MRPS12 2.12 1.07 -0.09 0.78
MRPS12 0.28 -0.77 0.94 -0.81
NUP205 2.34 1.09 0.93 0.87
NUP205 2.30 1.10 1.21 0.33
DNMT3A -0.61 0.68 0.23 0.47
DNMT3A 0.08 -0.83 -0.52 -0.31
DNMT3A -4.56 -3.11 -0.41 -0.91
DNMT3A 0.52 -0.12 0.13 -0.03
TREX2 -1.55 -2.00 0.76 -0.33
TREX2 -0.39 -1.72 2.03 0.72
TREX2 1.14 -0.19 0.25 -0.46
TREX2 0.51 1.30 0.99 -1.62
TREX2 -0.38 0.83 -0.08 -0.41
TREX2 -0.25 0.16 -0.08 -1.54
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